GT,Diagnosis 1
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and death in childhood. The patient does not have in common: death in infancy.

\n\n+2. Propionic acidemia: This is another rare genetic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase. Symptoms include metabolic acidosis, decreased propionyl-CoA carboxylase activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, death in childhood. The patient does not have in common: decreased propionyl-CoA carboxylase activity, death in infancy.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder caused by a deficiency of multiple enzymes involved in the metabolism of amino acids and fatty acids. Symptoms include metabolic acidosis, decreased enzyme activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, death in childhood. The patient does not have in common: decreased enzyme activity, death in infancy.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders caused by a deficiency of enzymes involved in the metabolism of amino acids and fatty acids. Symptoms include metabolic acidosis, decreased enzyme activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, death in childhood. The patient does not have in common: decreased enzyme activity, death in infancy.

Note that these are just a few potential diseases that may be related to the symptoms provided, and a more comprehensive diagnosis would require further testing and evaluation."
['Succinic semialdehyde dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Motor delay, Generalized hypotonia, and Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Pneumonia.

\n\n+2. Propionic Acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Motor delay, Generalized hypotonia, and Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Pneumonia.

\n\n+3. Multiple Carboxylase Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Motor delay, Generalized hypotonia, and Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Pneumonia.

\n\n+4. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. The patient has in common: Motor delay, Generalized hypotonia, and Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Pneumonia.

\n\n+5. Pompe Disease: This is a rare genetic disorder that affects the body's ability to break down glycogen. The patient does not have in common: Motor delay, Generalized hypotonia, Elevated urinary carboxylic acid. The patient has in common: Death in infancy, Pneumonia.

Note: The patient's symptoms are more consistent with a diagnosis of Methylmalonic Acidemia, Propionic Acidemia, or Multiple Carboxylase Deficiency, but further testing and evaluation would be necessary to confirm the diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia', 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Muscular Dystrophy:
The patient has symptoms of Motor delay, Abnormal muscle physiology, and Cerebellar atrophy in common with this disease. However, the patient does not have symptoms of Congenital diaphragmatic hernia, Hiatus hernia, or Lipodystrophy.

\n\n+2. Spinal Muscular Atrophy:
The patient has symptoms of Motor delay, Abnormal muscle physiology, and Cerebellar atrophy in common with this disease. However, the patient does not have symptoms of Congenital diaphragmatic hernia, Hiatus hernia, or Lipodystrophy.

\n\n+3. Cerebellar Ataxia:
The patient has symptoms of Cerebellar atrophy and Cerebellar agenesis in common with this disease. However, the patient does not have symptoms of Congenital diaphragmatic hernia, Motor delay, Abnormal muscle physiology, or Hiatus hernia.

\n\n+4. Prader-Willi Syndrome:
The patient has symptoms of Failure to thrive and Lipodystrophy in common with this disease. However, the patient does not have symptoms of Congenital diaphragmatic hernia, Motor delay, Abnormal muscle physiology, Cerebellar atrophy, or Cerebellar agenesis.

\n\n+5. Rett Syndrome:
The patient has symptoms of Motor delay, Abnormal muscle physiology, and Cerebellar atrophy in common with this disease. However, the patient does not have symptoms of Congenital diaphragmatic hernia, Hiatus hernia, or Lipodystrophy.

\n\n+6. Mucopolysaccharidosis:
The patient does not have any symptoms in common with this disease.

\n\n+7. Pompe Disease:
The patient does not have any symptoms in common with this disease.

\n\n+8. Charcot-Marie-Tooth Disease:
The patient has symptoms of Motor delay and Abnormal muscle physiology in common with this disease. However, the patient does not have symptoms of Congenital diaphragmatic hernia, Cerebellar atrophy, or Cerebellar agenesis.

Note: This is not an exhaustive list, and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, and motor delay. The patient has in common: Delayed speech and language development, Motor delay, Intellectual disability. The patient does not have in common: Hydronephrosis, Abnormality of prenatal development or birth, Generalized hypotonia, Death in infancy, Fever, Opisthotonus, Athetosis, Kyphoscoliosis, Neonatal death, Death in childhood, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Death in adolescence, Feeding difficulties, Elevated urinary carboxylic acid.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, and motor delay. The patient has in common: Delayed speech and language development, Motor delay, Intellectual disability. The patient does not have in common: Hydronephrosis, Abnormality of prenatal development or birth, Generalized hypotonia, Death in infancy, Fever, Opisthotonus, Athetosis, Kyphoscoliosis, Neonatal death, Death in childhood, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Death in adolescence, Feeding difficulties, Elevated urinary carboxylic acid.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include intellectual disability, delayed speech and language development, and motor delay. The patient has in common: Delayed speech and language development, Motor delay, Intellectual disability. The patient does not have in common: Hydronephrosis, Abnormality of prenatal development or birth, Generalized hypotonia, Death in infancy, Fever, Opisthotonus, Athetosis, Kyphoscoliosis, Neonatal death, Death in childhood, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Death in adolescence, Feeding difficulties, Elevated urinary carboxylic acid.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. Symptoms include intellectual disability, delayed speech and language development, and motor delay. The patient has in common: Delayed speech and language development, Motor delay, Intellectual disability. The patient does not have in common: Hydronephrosis, Abnormality of prenatal development or birth, Generalized hypotonia, Death in infancy, Fever, Opisthotonus, Athetosis, Kyphoscoliosis, Neonatal death, Death in childhood, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Death in adolescence, Feeding difficulties, Elevated urinary carboxylic acid.

\n\n+5. Urea cycle disorder: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. Symptoms include intellectual disability, delayed speech and language development, and motor delay. The patient has in common: Delayed speech and language development, Motor delay, Intellectual disability. The patient does not have in common: Hydronephrosis, Abnormality of prenatal development or birth, Generalized hypotonia, Death in infancy, Fever, Opisthotonus, Athetosis, Kyphoscoliosis, Neonatal death, Death in childhood, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Death in adolescence, Feeding difficulties, Elevated urinary carboxylic acid.

Note: These are just a few potential diseases that the patient may have, and a more thorough diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Tyrosinemia: This is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. The patient has symptoms of Hypertyrosinemia and Hyperphenylalaninemia in common with this disease. However, the patient does not have symptoms of skin rash, abnormality of prenatal development or birth, obesity, diarrhea, gastrointestinal inflammation, recurrent viral infections, erythematous plaque, erythematous macule, erythematous papule, or hernia.

\n\n+2. Congenital Tyrosinemia: This is a severe form of tyrosinemia that is present at birth. The patient has symptoms of Hypertyrosinemia and Hyperphenylalaninemia in common with this disease. However, the patient does not have symptoms of skin rash, abnormality of prenatal development or birth, obesity, diarrhea, gastrointestinal inflammation, recurrent viral infections, erythematous plaque, erythematous macule, erythematous papule, or hernia.

\n\n+3. Phenylketonuria (PKU): This is a genetic disorder that affects the breakdown of the amino acid phenylalanine. The patient has symptoms of Hyperphenylalaninemia in common with this disease. However, the patient does not have symptoms of skin rash, abnormality of prenatal development or birth, obesity, diarrhea, gastrointestinal inflammation, recurrent viral infections, erythematous plaque, erythematous macule, erythematous papule, or hernia.

\n\n+4. Gastrointestinal Inflammatory Disease: This is a broad term that encompasses various conditions that cause inflammation in the gastrointestinal tract. The patient has symptoms of diarrhea, gastrointestinal inflammation in common with this disease. However, the patient does not have symptoms of skin rash, abnormality of prenatal development or birth, obesity, death in infancy, neonatal death, death in childhood, recurrent viral infections, hypertyrosinemia, hyperphenylalaninemia, erythematous plaque, erythematous macule, erythematous papule, or hernia.

\n\n+5. Viral Gastroenteritis: This is a common condition caused by a viral infection that affects the stomach and intestines. The patient has symptoms of diarrhea in common with this disease. However, the patient does not have symptoms of skin rash, abnormality of prenatal development or birth, obesity, death in infancy, neonatal death, death in childhood, gastrointestinal inflammation, recurrent viral infections, hypertyrosinemia, hyperphenylalaninemia, erythematous plaque, erythematous macule, erythematous papule, or hernia.

Note: These are just a few potential diseases that the patient may have based on the symptoms provided. A proper diagnosis would require a comprehensive medical evaluation and testing."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with each disease and which symptoms they do not have in common:

\n\n+1. Mucopolysaccharidosis: This is a group of genetic disorders caused by a deficiency of enzymes that break down mucopolysaccharides, leading to the accumulation of these substances in various tissues. The patient has in common: Skin rash, Alopecia, Increased circulating lactate concentration. The patient does not have in common: Death in infancy (most cases of Mucopolysaccharidosis do not result in death in infancy).

\n\n+2. Congenital Ichthyosis: This is a group of rare genetic disorders characterized by dry, scaly skin from birth. The patient has in common: Skin rash, Alopecia. The patient does not have in common: Death in infancy, Increased circulating lactate concentration, Increased CSF lactate.

\n\n+3. Epidermolysis Bullosa: This is a group of rare genetic disorders characterized by skin fragility and blistering. The patient has in common: Skin rash, Alopecia. The patient does not have in common: Death in infancy, Increased circulating lactate concentration, Increased CSF lactate.

\n\n+4. Lactic Acidosis: This is a condition characterized by an accumulation of lactic acid in the blood, which can be caused by a variety of factors such as mitochondrial disorders, infections, or certain medications. The patient has in common: Increased circulating lactate concentration, Increased CSF lactate. The patient does not have in common: Skin rash, Alopecia, Death in infancy.

\n\n+5. Neonatal Sepsis: This is a life-threatening condition caused by a bacterial infection in newborns. The patient has in common: Death in infancy. The patient does not have in common: Skin rash, Alopecia, Increased circulating lactate concentration, Increased CSF lactate.

\n\n+6. Mitochondrial Disorders: This is a group of genetic disorders caused by mutations in mitochondrial DNA, leading to impaired energy production in cells. The patient has in common: Increased circulating lactate concentration, Increased CSF lactate. The patient does not have in common: Skin rash, Alopecia, Death in infancy.

Note: This is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Leber Congenital Amaurosis: This is a rare inherited disorder that causes severe visual impairment or blindness at birth. The patient has symptoms in common with this disease, such as 'Rod-cone dystrophy', but does not have symptoms like 'Intellectual disability', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Lipodystrophy', 'Cerebellar agenesis', 'Acute hepatitis', and 'Chronic hepatitis'.

\n\n+2. Joubert Syndrome: This is a rare genetic disorder that affects the development of the brain and spinal cord. The patient has symptoms in common with this disease, such as 'Cerebellar atrophy', 'Cerebellar agenesis', and 'Abnormal facial shape', but does not have symptoms like 'Rod-cone dystrophy', 'Intellectual disability', 'Death in infancy', 'Thromboembolism', 'Abnormal calvaria morphology', 'Lipodystrophy', 'Acute hepatitis', and 'Chronic hepatitis'.

\n\n+3. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder that affects the development of multiple organs and tissues. The patient has symptoms in common with this disease, such as 'Abnormal facial shape', 'Abnormal calvaria morphology', and 'Lipodystrophy', but does not have symptoms like 'Rod-cone dystrophy', 'Intellectual disability', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Cerebellar agenesis', 'Acute hepatitis', and 'Chronic hepatitis'.

\n\n+4. Alagille Syndrome: This is a rare genetic disorder that affects the development of the liver, heart, and other organs. The patient has symptoms in common with this disease, such as 'Chronic hepatitis', but does not have symptoms like 'Rod-cone dystrophy', 'Intellectual disability', 'Cerebellar atrophy', 'Death in infancy', 'Thromboembolism', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Lipodystrophy', 'Cerebellar agenesis', and 'Acute hepatitis'.

\n\n+5. Zellweger Syndrome: This is a rare genetic disorder that affects the development of the brain, liver, and other organs. The patient has symptoms in common with this disease, such as 'Cerebellar atrophy', 'Cerebellar agenesis', and 'Chronic hepatitis', but does not have symptoms like 'Rod-cone dystrophy', 'Intellectual disability', 'Death in infancy', 'Thromboembolism', 'Abnormal facial shape', 'Abnormal calvaria morphology', 'Lipodystrophy', and 'Acute hepatitis'.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, Dystonia, and Decreased plasma free carnitine in common with this disease. The patient does not have symptoms of Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, and Neonatal death, which are not typical of Glutaric Acidemia Type 1.

\n\n+2. Mucopolysaccharidosis Type III:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, and Dystonia in common with this disease. The patient does not have symptoms of Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, and Decreased plasma free carnitine, which are not typical of Mucopolysaccharidosis Type III.

\n\n+3. Congenital Muscular Dystrophy:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, and Dystonia in common with this disease. The patient does not have symptoms of Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, and Decreased plasma free carnitine, which are not typical of Congenital Muscular Dystrophy.

\n\n+4. Prader-Willi Syndrome:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, and Dystonia in common with this disease. The patient does not have symptoms of Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, and Decreased plasma free carnitine, which are not typical of Prader-Willi Syndrome.

\n\n+5. Mitochondrial Disease:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, Dystonia, and Decreased plasma free carnitine in common with this disease. The patient does not have symptoms of Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, and Neonatal death, which are not typical of Mitochondrial Disease.

Note: The above list is not exhaustive and is based on the symptoms provided. A thorough medical evaluation and diagnostic testing would be necessary to confirm a specific diagnosis."
['Isovaleric acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the body. The patient has symptoms in common with MSUD, such as hyperammonemia, abnormal circulating glycine concentration, and feeding difficulties. However, the patient does not have symptoms such as seizures, muscle weakness, or intellectual disability, which are common in MSUD.

\n\n+2. Propionic Acidemia: Propionic acidemia is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of propionic acid in the body. The patient has symptoms in common with propionic acidemia, such as hyperammonemia, abnormal circulating glycine concentration, and feeding difficulties. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in propionic acidemia.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of methylmalonic acid in the body. The patient has symptoms in common with methylmalonic acidemia, such as hyperammonemia, abnormal circulating glycine concentration, and feeding difficulties. However, the patient does not have symptoms such as muscle weakness, fatigue, or skin rash, which are common in methylmalonic acidemia.

\n\n+4. Urea Cycle Disorders: Urea cycle disorders are a group of rare genetic disorders that affect the breakdown of ammonia in the body. The patient has symptoms in common with urea cycle disorders, such as hyperammonemia, abnormal circulating glycine concentration, and feeding difficulties. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in urea cycle disorders.

\n\n+5. Organic Acidemias: Organic acidemias are a group of rare genetic disorders that affect the breakdown of organic acids in the body. The patient has symptoms in common with organic acidemias, such as hyperammonemia, abnormal circulating glycine concentration, and feeding difficulties. However, the patient does not have symptoms such as seizures, muscle weakness, or intellectual disability, which are common in organic acidemias.

Note: These are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further testing and evaluation."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Aicardi-Goutières Syndrome: A rare genetic disorder characterized by microcephaly, intellectual disability, and ataxia. The patient has microcephaly, intellectual disability, and ataxia in common with this disease. However, the patient does not have seizures, which are a common symptom of Aicardi-Goutières Syndrome.

\n\n+2. Joubert Syndrome: A rare genetic disorder characterized by cerebellar atrophy, ataxia, and hypotonia. The patient has ataxia, hypotonia, and cerebellar atrophy in common with this disease. However, the patient does not have the characteristic ""molar tooth"" sign on MRI, which is a common feature of Joubert Syndrome.

\n\n+3. Mowat-Wilson Syndrome: A rare genetic disorder characterized by intellectual disability, ataxia, and hypotonia. The patient has intellectual disability, ataxia, and hypotonia in common with this disease. However, the patient does not have the characteristic facial features, such as a small nose and thin upper lip, which are common in Mowat-Wilson Syndrome.

\n\n+4. Pontocerebellar Hypoplasia: A rare genetic disorder characterized by cerebellar atrophy, ataxia, and hypotonia. The patient has ataxia, hypotonia, and cerebellar atrophy in common with this disease. However, the patient does not have the characteristic pontine hypoplasia, which is a common feature of Pontocerebellar Hypoplasia.

\n\n+5. Rett Syndrome: A rare genetic disorder characterized by intellectual disability, ataxia, and hypotonia. The patient has intellectual disability, ataxia, and hypotonia in common with this disease. However, the patient does not have the characteristic hand wringing and loss of purposeful hand movements, which are common in Rett Syndrome.

\n\n+6. Smith-Magenis Syndrome: A rare genetic disorder characterized by intellectual disability, ataxia, and hypotonia. The patient has intellectual disability, ataxia, and hypotonia in common with this disease. However, the patient does not have the characteristic facial features, such as a prominent forehead and a short nose, which are common in Smith-Magenis Syndrome.

\n\n+7. Tuberous Sclerosis Complex: A rare genetic disorder characterized by seizures, ataxia, and hypotonia. The patient does not have seizures, which are a common symptom of Tuberous Sclerosis Complex. However, the patient has ataxia and hypotonia in common with this disease.

\n\n+8. Zellweger Syndrome: A rare genetic disorder characterized by intellectual disability, ataxia, and hypotonia. The patient has intellectual disability, ataxia, and hypotonia in common with this disease. However, the patient does not have the characteristic liver dysfunction and dysmorphic features, which are common in Zellweger Syndrome.

Please note that this is not an exhaustive list, and a definitive diagnosis can only be made through further testing and evaluation."
"['Methylmalonic acidemia with homocystinuria, type cblC']","Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as hyperammonemia, hyperhomocystinemia, and hyperalaninemia. However, the patient does not have symptoms such as seizures, intellectual disability, or liver dysfunction, which are common in Methylmalonic aciduria.

\n\n+2. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. The patient has symptoms in common with this disease, such as abnormal circulating carnitine concentration and hyperammonemia. However, the patient does not have symptoms such as muscle weakness, fatigue, or cardiomyopathy, which are common in Carnitine deficiency.

\n\n+3. Hyperammonemia: This is a condition characterized by elevated levels of ammonia in the blood, which can be caused by a variety of factors, including liver disease, kidney disease, or genetic disorders. The patient has symptoms in common with this disease, such as hyperammonemia and vomiting. However, the patient does not have symptoms such as altered mental status, seizures, or coma, which are common in severe cases of Hyperammonemia.

\n\n+4. Congenital heart defect: This is a condition characterized by a defect in the structure of the heart, which can be present at birth. The patient has symptoms in common with this disease, such as ventricular septal defect. However, the patient does not have symptoms such as cyanosis, congestive heart failure, or arrhythmias, which are common in Congenital heart defect.

\n\n+5. Neurodegenerative disorder: This is a broad term that encompasses a range of disorders that affect the brain and nervous system, such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. The patient has symptoms in common with this disease, such as motor delay and generalized hypotonia. However, the patient does not have symptoms such as cognitive decline, speech difficulties, or muscle weakness, which are common in Neurodegenerative disorder.

\n\n+6. Genetic disorder: This is a broad term that encompasses a range of disorders that are caused by genetic mutations, such as Down syndrome, Turner syndrome, and cystic fibrosis. The patient has symptoms in common with this disease, such as abnormality of prenatal development or birth and neonatal death. However, the patient does not have symptoms such as intellectual disability, short stature, or respiratory problems, which are common in Genetic disorder.

Please note that this is not an exhaustive list and further evaluation and testing may be necessary to determine the underlying cause of the patient's symptoms."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Reye's Syndrome: Reye's Syndrome is a rare but potentially life-threatening condition that affects the brain and liver. It is often caused by a viral infection, such as a cold or flu. Symptoms include vomiting, diarrhea, and altered mental status. The patient has in common: Vomiting, Diarrhea. The patient does not have in common: Death in infancy, Hypoglycemia, Elevated circulating hepatic transaminase concentration, Abnormal circulating carnitine concentration.

\n\n+2. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. It can cause a range of symptoms, including vomiting, diarrhea, and altered mental status. The patient has in common: Vomiting, Diarrhea. The patient does not have in common: Death in infancy, Hypoglycemia, Elevated circulating hepatic transaminase concentration, Abnormal circulating carnitine concentration.

\n\n+3. Carnitine Deficiency: Carnitine deficiency is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms can include vomiting, diarrhea, and altered mental status. The patient has in common: Vomiting, Diarrhea. The patient does not have in common: Death in infancy, Hypoglycemia, Elevated circulating hepatic transaminase concentration.

\n\n+4. Hepatic Encephalopathy: Hepatic encephalopathy is a condition that occurs when the liver is unable to remove toxins from the blood, leading to altered mental status and other symptoms. The patient has in common: Elevated circulating hepatic transaminase concentration. The patient does not have in common: Death in infancy, Hypoglycemia, Vomiting, Diarrhea, Abnormal circulating carnitine concentration.

\n\n+5. Hypoglycemia due to Inborn Errors of Metabolism: Hypoglycemia can be caused by a range of inborn errors of metabolism, including defects in glucose metabolism. Symptoms can include hypoglycemia, vomiting, and altered mental status. The patient has in common: Hypoglycemia. The patient does not have in common: Death in infancy, Diarrhea, Elevated circulating hepatic transaminase concentration, Abnormal circulating carnitine concentration.

\n\n+6. Neonatal Hepatitis: Neonatal hepatitis is a condition that occurs when the liver is inflamed or damaged in newborns. Symptoms can include vomiting, diarrhea, and elevated liver enzymes. The patient has in common: Vomiting, Diarrhea, Elevated circulating hepatic transaminase concentration. The patient does not have in common: Death in infancy, Hypoglycemia, Abnormal circulating carnitine concentration.

Note: This is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Succinic semialdehyde dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include hyperkalemia, hyponatremia, and respiratory acidosis, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or skin rashes, which are common in Methylmalonic Acidemia.

\n\n+2. Propionic Acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include hyperkalemia, hyponatremia, and respiratory acidosis, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in Propionic Acidemia.

\n\n+3. Carnitine Deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms include hyperkalemia, hyponatremia, and respiratory acidosis, which the patient has in common. However, the patient does not have symptoms such as muscle weakness, fatigue, or heart problems, which are common in Carnitine Deficiency.

\n\n+4. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms include hyperkalemia, hyponatremia, and respiratory acidosis, which the patient has in common. However, the patient does not have symptoms such as developmental delays, seizures, or skin rashes, which are common in Organic Acidemia.

\n\n+5. Neonatal Sepsis: This is a serious infection that occurs in newborns, often caused by bacteria such as E. coli or Group B strep. Symptoms include hyperkalemia, hyponatremia, and respiratory acidosis, which the patient has in common. However, the patient does not have symptoms such as fever, irritability, or poor feeding, which are common in Neonatal Sepsis.

\n\n+6. Congenital Heart Disease: This is a group of rare genetic disorders that affect the development of the heart. Symptoms include hyperkalemia, hyponatremia, and respiratory acidosis, which the patient has in common. However, the patient does not have symptoms such as cyanosis, heart murmur, or poor circulation, which are common in Congenital Heart Disease.

Note: The above list is not exhaustive and is based on the symptoms provided. A thorough medical evaluation and testing would be necessary to confirm a diagnosis."
['Classic homocystinuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Mucopolysaccharidosis type VII (MPS VII): This is a rare genetic disorder caused by a deficiency of the enzyme beta-glucuronidase, leading to the accumulation of glycosaminoglycans in various tissues. The patient has in common: Ptosis, Intellectual disability, Motor delay, and Death in childhood. The patient does not have in common: Ectopia lentis, Large hands, Long foot, Hyperhomocystinemia, Hypermethioninemia, Fatigue.

\n\n+2. Smith-Lemli-Opitz syndrome: This is a rare genetic disorder caused by a deficiency of the enzyme 7-dehydrocholesterol reductase, leading to impaired cholesterol synthesis. The patient has in common: Ptosis, Intellectual disability, Motor delay, and Death in childhood. The patient does not have in common: Ectopia lentis, Large hands, Long foot, Hyperhomocystinemia, Hypermethionemia, Fatigue.

\n\n+3. Aicardi-Goutières syndrome: This is a rare genetic disorder caused by mutations in genes involved in the processing of DNA, leading to the accumulation of DNA in the brain and other tissues. The patient has in common: Ptosis, Intellectual disability, Motor delay, and Death in childhood. The patient does not have in common: Ectopia lentis, Large hands, Long foot, Hyperhomocystinemia, Hypermethionemia, Fatigue.

\n\n+4. Homocystinuria: This is a rare genetic disorder caused by a deficiency of the enzyme cystathionine beta-synthase, leading to the accumulation of homocysteine in the blood. The patient has in common: Hyperhomocystinemia. The patient does not have in common: Ectopia lentis, Large hands, Long foot, Intellectual disability, Motor delay, Death in childhood, Death in adolescence, Fatigue.

\n\n+5. Methionine adenosyltransferase deficiency: This is a rare genetic disorder caused by a deficiency of the enzyme methionine adenosyltransferase, leading to the accumulation of methionine in the blood. The patient has in common: Hypermethioninemia. The patient does not have in common: Ectopia lentis, Large hands, Long foot, Intellectual disability, Motor delay, Death in childhood, Death in adolescence, Fatigue.

Please note that these are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Insulin Deficiency Syndrome (CIDS): 
The patient has symptoms of hyperinsulinemia, hypoglycemia, and neonatal death, which are common in CIDS. However, the patient does not have symptoms of diabetes or ketoacidosis, which are typically seen in CIDS.

\n\n+2. Mucopolysaccharidosis Type VII (MPS VII): 
The patient has symptoms of sparse hair, abnormal hemoglobin, and feeding difficulties, which are common in MPS VII. However, the patient does not have symptoms of joint stiffness, corneal clouding, or intellectual disability, which are typically seen in MPS VII.

\n\n+3. Prader-Willi Syndrome (PWS): 
The patient has symptoms of hyperinsulinemia, hypoglycemia, and feeding difficulties, which are common in PWS. However, the patient does not have symptoms of short stature, obesity, or intellectual disability, which are typically seen in PWS.

\n\n+4. Smith-Magenis Syndrome (SMS): 
The patient has symptoms of sparse hair, abnormal hemoglobin, and feeding difficulties, which are common in SMS. However, the patient does not have symptoms of intellectual disability, sleep disturbances, or behavioral problems, which are typically seen in SMS.

\n\n+5. Trisomy 13 (Patau Syndrome): 
The patient has symptoms of wide mouth, epicanthus, and sparse hair, which are common in Trisomy 13. However, the patient does not have symptoms of intellectual disability, microcephaly, or heart defects, which are typically seen in Trisomy 13.

\n\n+6. Williams Syndrome: 
The patient does not have symptoms of hyperinsulinemia, hypoglycemia, or feeding difficulties, which are not typically seen in Williams Syndrome. However, the patient has symptoms of wide mouth, epicanthus, and sparse hair, which are common in Williams Syndrome.

Note: This is not an exhaustive list, and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Propionic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Urea Cycle Disorders: Urea cycle disorders are a group of genetic disorders that affect the body's ability to break down protein and produce energy. Symptoms may include intellectual disability, seizures, and hyperammonemia. The patient has in common: intellectual disability, seizure, hyperammonemia. The patient does not have in common: abnormality of prenatal development or birth, motor delay, death in infancy, anemia, hepatomegaly, neonatal death, death in childhood, abnormal circulating carnitine concentration, hypoglycinemia.

\n\n+2. Organic Acidemias: Organic acidemias are a group of genetic disorders that affect the body's ability to break down certain compounds. Symptoms may include intellectual disability, seizures, and hyperammonemia. The patient has in common: intellectual disability, seizure, hyperammonemia. The patient does not have in common: abnormality of prenatal development or birth, motor delay, death in infancy, anemia, hepatomegaly, neonatal death, death in childhood, abnormal circulating carnitine concentration, hypoglycinemia.

\n\n+3. Maple Syrup Urine Disease: Maple syrup urine disease is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms may include intellectual disability, seizures, and hyperammonemia. The patient has in common: intellectual disability, seizure, hyperammonemia. The patient does not have in common: abnormality of prenatal development or birth, motor delay, death in infancy, anemia, hepatomegaly, neonatal death, death in childhood, abnormal circulating carnitine concentration, hypoglycinemia.

\n\n+4. Glutaric Acidemia Type I: Glutaric acidemia type I is a rare genetic disorder that affects the body's ability to break down certain compounds. Symptoms may include intellectual disability, seizures, and hyperammonemia. The patient has in common: intellectual disability, seizure, hyperammonemia. The patient does not have in common: abnormality of prenatal development or birth, motor delay, death in infancy, anemia, hepatomegaly, neonatal death, death in childhood, abnormal circulating carnitine concentration, hypoglycinemia.

\n\n+5. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the body's ability to break down certain compounds. Symptoms may include intellectual disability, seizures, and hyperammonemia. The patient has in common: intellectual disability, seizure, hyperammonemia. The patient does not have in common: abnormality of prenatal development or birth, motor delay, death in infancy, anemia, hepatomegaly, neonatal death, death in childhood, abnormal circulating carnitine concentration, hypoglycinemia.

Note: These are just a few potential diseases that may be related to the symptoms provided. A more comprehensive diagnosis would require further testing and evaluation."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, including metabolic acidosis, apnea, and methylmalonic aciduria. However, the patient does not have symptoms such as seizures, developmental delay, or intellectual disability, which are common in methylmalonic acidemia.

\n\n+2. Methylmalonyl-CoA mutase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, including decreased methylmalonyl-CoA mutase activity, metabolic acidosis, and methylmalonic aciduria. However, the patient does not have symptoms such as muscle weakness, fatigue, or joint pain, which are common in methylmalonyl-CoA mutase deficiency.

\n\n+3. Thrombocytopenia-absent radius syndrome: This is a rare genetic disorder that affects the development of the bones and blood cells. The patient has symptoms in common with this disease, including thrombocytopenia and radial aplasia (absence of the radius bone). However, the patient does not have symptoms such as intellectual disability, developmental delay, or heart defects, which are common in thrombocytopenia-absent radius syndrome.

\n\n+4. Leukopenia: This is a condition characterized by a low white blood cell count. The patient has symptoms in common with this disease, including leukopenia. However, the patient does not have symptoms such as fever, chills, or increased susceptibility to infection, which are common in leukopenia.

\n\n+5. Metabolic acidosis: This is a condition characterized by a buildup of acid in the body. The patient has symptoms in common with this disease, including metabolic acidosis. However, the patient does not have symptoms such as nausea, vomiting, or abdominal pain, which are common in metabolic acidosis.

\n\n+6. Apnea: This is a condition characterized by the temporary cessation of breathing. The patient has symptoms in common with this disease, including apnea. However, the patient does not have symptoms such as cyanosis (blue discoloration of the skin), which is common in apnea.

\n\n+7. Methylmalonic aciduria: This is a condition characterized by the accumulation of methylmalonic acid in the body. The patient has symptoms in common with this disease, including methylmalonic aciduria. However, the patient does not have symptoms such as developmental delay, intellectual disability, or seizures, which are common in methylmalonic aciduria.

\n\n+8. Neonatal death: This is a condition characterized by the death of a newborn baby. The patient has symptoms in common with this disease, including neonatal death. However, the patient does not have symptoms such as prenatal diagnosis, which is common in neonatal death.

\n\n+9. Feeding difficulties: This is a condition characterized by difficulty eating or swallowing. The patient has symptoms in common with this disease, including feeding difficulties. However, the patient does not have symptoms such as gagging, choking, or coughing, which are common in feeding difficulties.

\n\n+10. Abnormal nervous system physiology: This is a condition characterized by abnormal functioning of the nervous system. The patient has symptoms in common with this disease, including abnormal nervous system physiology. However, the patient does not have symptoms such as muscle weakness, fatigue, or numbness, which are common in abnormal nervous system physiology.

Based on the symptoms provided, the most likely diagnosis is Methylmalonic acidemia or Methylmalonyl-CoA mutase deficiency. Further testing and evaluation are needed to confirm the diagnosis and determine the best course of treatment."
['Systemic primary carnitine deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Reye's Syndrome: Reye's Syndrome is a rare and potentially life-threatening condition that affects the brain and liver. Symptoms include vomiting, hypoglycemia, and elevated liver enzymes. The patient has in common: Vomiting, Hypoglycemia. The patient does not have in common: Coma, Death in infancy, Sudden death, Elevated circulating alkaline phosphatase concentration, Decreased plasma free carnitine, Abnormal circulating aspartate family amino acid concentration, Abnormal circulating alanine concentration, Increased circulating lactate dehydrogenase concentration.

\n\n+2. Carnitine Deficiency: Carnitine Deficiency is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms include hypoglycemia, vomiting, and decreased plasma free carnitine. The patient has in common: Hypoglycemia, Vomiting, Decreased plasma free carnitine. The patient does not have in common: Coma, Death in infancy, Sudden death, Elevated circulating alkaline phosphatase concentration, Abnormal circulating aspartate family amino acid concentration, Abnormal circulating alanine concentration, Increased circulating lactate dehydrogenase concentration.

\n\n+3. Mitochondrial Myopathy: Mitochondrial Myopathy is a group of disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include muscle weakness, fatigue, and elevated lactate levels. The patient does not have in common: Coma, Death in infancy, Sudden death, Hypoglycemia, Vomiting, Elevated circulating alkaline phosphatase concentration, Decreased plasma free carnitine, Abnormal circulating aspartate family amino acid concentration, Abnormal circulating alanine concentration.

\n\n+4. Acute Liver Failure: Acute Liver Failure is a rare and life-threatening condition that occurs when the liver suddenly stops functioning. Symptoms include jaundice, vomiting, and elevated liver enzymes. The patient has in common: Vomiting, Elevated circulating alkaline phosphatase concentration. The patient does not have in common: Coma, Death in infancy, Sudden death, Hypoglycemia, Decreased plasma free carnitine, Abnormal circulating aspartate family amino acid concentration, Abnormal circulating alanine concentration, Increased circulating lactate dehydrogenase concentration.

\n\n+5. Inborn Errors of Metabolism: Inborn Errors of Metabolism are a group of rare genetic disorders that affect the body's ability to break down certain nutrients. Symptoms include vomiting, hypoglycemia, and elevated liver enzymes. The patient has in common: Vomiting, Hypoglycemia. The patient does not have in common: Coma, Death in infancy, Sudden death, Elevated circulating alkaline phosphatase concentration, Decreased plasma free carnitine, Abnormal circulating aspartate family amino acid concentration, Abnormal circulating alanine concentration, Increased circulating lactate dehydrogenase concentration.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['3-methylcrotonyl-CoA carboxylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Carnitine Deficiency Disorder: This is a group of rare genetic disorders that affect the body's ability to use fat as a source of energy. Symptoms include decreased plasma free carnitine, feeding difficulties, and poor coordination. The patient has decreased plasma free carnitine and poor coordination in common with this disease, but does not have lethargy, drowsiness, or sleep abnormality.

\n\n+2. Prader-Willi Syndrome: This is a genetic disorder that affects the brain and causes a range of physical and behavioral symptoms. Symptoms include poor coordination, feeding difficulties, and sleep abnormalities. The patient has poor coordination and feeding difficulties in common with this disease, but does not have decreased plasma free carnitine.

\n\n+3. Mitochondrial Disease: This is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms can include lethargy, drowsiness, sleep abnormalities, and poor coordination. The patient has lethargy, drowsiness, and poor coordination in common with this disease, but does not have decreased plasma free carnitine or feeding difficulties.

\n\n+4. Krabbe Disease: This is a rare genetic disorder that affects the brain and spinal cord. Symptoms include lethargy, drowsiness, and poor coordination. The patient has lethargy, drowsiness, and poor coordination in common with this disease, but does not have decreased plasma free carnitine or feeding difficulties.

\n\n+5. Pompe Disease: This is a rare genetic disorder that affects the muscles. Symptoms include lethargy, drowsiness, and poor coordination. The patient has lethargy, drowsiness, and poor coordination in common with this disease, but does not have decreased plasma free carnitine or feeding difficulties.

Note that this is not an exhaustive list, and there may be other potential diseases that could be causing the patient's symptoms. Further testing and evaluation would be necessary to determine the most likely diagnosis."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Rett Syndrome: Rett Syndrome is a rare genetic disorder that affects brain development and function. It is characterized by delayed speech and language development, hypothyroidism, and dysarthria. The patient has common symptoms with Rett Syndrome, including delayed speech and language development, hypothyroidism, and dysarthria. However, the patient does not have common symptoms such as hand wringing, loss of purposeful hand movements, and seizures.

\n\n+2. Leigh Syndrome: Leigh Syndrome is a rare genetic disorder that affects the development and function of the brain and spinal cord. It is characterized by delayed speech and language development, encephalopathy, and hyperreflexia. The patient has common symptoms with Leigh Syndrome, including delayed speech and language development, encephalopathy, and hyperreflexia. However, the patient does not have common symptoms such as seizures, ataxia, and optic atrophy.

\n\n+3. Methylmalonic Acidemia: Methylmalonic Acidemia is a rare genetic disorder that affects the breakdown of certain amino acids. It is characterized by delayed speech and language development, encephalopathy, and recurrent viral infections. The patient has common symptoms with Methylmalonic Acidemia, including delayed speech and language development, encephalopathy, and recurrent viral infections. However, the patient does not have common symptoms such as vomiting, diarrhea, and lethargy.

\n\n+4. Glycine Encephalopathy: Glycine Encephalopathy is a rare genetic disorder that affects the breakdown of glycine, an amino acid. It is characterized by delayed speech and language development, encephalopathy, and abnormal circulating glycine concentration. The patient has common symptoms with Glycine Encephalopathy, including delayed speech and language development, encephalopathy, and abnormal circulating glycine concentration. However, the patient does not have common symptoms such as seizures, ataxia, and muscle weakness.

\n\n+5. Ethylmalonic Aciduria: Ethylmalonic Aciduria is a rare genetic disorder that affects the breakdown of certain amino acids. It is characterized by delayed speech and language development, encephalopathy, and recurrent viral infections. The patient has common symptoms with Ethylmalonic Aciduria, including delayed speech and language development, encephalopathy, and recurrent viral infections. However, the patient does not have common symptoms such as vomiting, diarrhea, and lethargy.

Note: The patient's symptoms do not match exactly with any of the proposed diseases, but they share some common symptoms. Further testing and evaluation are needed to confirm the diagnosis."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Syndrome: This is a rare genetic disorder that affects the body's ability to use carnitine, an amino acid that plays a crucial role in energy production. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Trisomy 13 (Patau Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 13. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+3. Trisomy 18 (Edwards Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 18. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+4. Mitochondrial Disorders: These are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. They can cause a range of symptoms, including muscle weakness, seizures, and developmental delays. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+5. Fetal Alcohol Syndrome: This is a condition caused by prenatal exposure to alcohol, characterized by physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of Macrocephaly, Cystic hygroma, Lethargy, Generalized hypotonia, Dystonia, Metabolic acidosis, Vomiting, Diarrhea, Dyspnea, Drowsiness, and Sleep abnormality in common with this disease. The patient does not have symptoms of Hyperhidrosis, Fever, and Death in infancy.

\n\n+2. Mucopolysaccharidosis:
The patient has symptoms of Macrocephaly, Cystic hygroma, Lethargy, Generalized hypotonia, Dystonia, and Metabolic acidosis in common with this disease. The patient does not have symptoms of Hyperhidrosis, Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, Glutaric aciduria, Elevated circulating glutaric acid concentration, Neonatal death, Death in childhood, Decreased plasma free carnitine, and Dyskinesia.

\n\n+3. Congenital Muscular Dystrophy:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, Dystonia, and Metabolic acidosis in common with this disease. The patient does not have symptoms of Cystic hygroma, Hyperhidrosis, Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, Glutaric aciduria, Elevated circulating glutaric acid concentration, Neonatal death, Death in childhood, Decreased plasma free carnitine, and Dyskinesia.

\n\n+4. Mitochondrial Disease:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, Dystonia, Metabolic acidosis, Vomiting, Diarrhea, Dyspnea, Drowsiness, and Sleep abnormality in common with this disease. The patient does not have symptoms of Cystic hygroma, Hyperhidrosis, Fever, Death in infancy, Glutaric aciduria, Elevated circulating glutaric acid concentration, Neonatal death, Death in childhood, Decreased plasma free carnitine, and Dyskinesia.

\n\n+5. Prader-Willi Syndrome:
The patient has symptoms of Macrocephaly, Lethargy, Generalized hypotonia, Dystonia, and Metabolic acidosis in common with this disease. The patient does not have symptoms of Cystic hygroma, Hyperhidrosis, Fever, Vomiting, Diarrhea, Dyspnea, Drowsiness, Sleep abnormality, Glutaric aciduria, Elevated circulating glutaric acid concentration, Neonatal death, Death in childhood, Decreased plasma free carnitine, and Dyskinesia.

Please note that this is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia', 'Death in childhood', 'Death in adolescence'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia', 'Death in childhood', 'Death in adolescence'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Death in adolescence'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Death in adolescence', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Death in adolescence', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
['L-2-hydroxyglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Leukodystrophy: Leukodystrophies are a group of rare genetic disorders that affect the development and maintenance of the white matter in the brain. The patient has symptoms in common with Leukodystrophy such as 'Abnormal cerebral white matter morphology' and 'Difficulty walking', 'Difficulty climbing stairs', 'Difficulty running'. The patient does not have symptoms in common with Leukodystrophy such as 'Delayed speech and language development', 'Intellectual disability', 'Death in infancy', 'Death in childhood'.

\n\n+2. Spinal Muscular Atrophy (SMA): SMA is a genetic disorder that affects the nerve cells responsible for controlling voluntary muscle movement. The patient has symptoms in common with SMA such as 'Difficulty walking', 'Difficulty climbing stairs', 'Difficulty running', 'Hyperreflexia'. The patient does not have symptoms in common with SMA such as 'Delayed speech and language development', 'Intellectual disability', 'Death in infancy', 'Death in childhood', 'Abnormal cerebral white matter morphology'.

\n\n+3. Rett Syndrome: Rett Syndrome is a rare genetic disorder that affects brain development and function. The patient has symptoms in common with Rett Syndrome such as 'Delayed speech and language development', 'Intellectual disability', 'Difficulty walking', 'Difficulty climbing stairs', 'Difficulty running'. The patient does not have symptoms in common with Rett Syndrome such as 'Hyperreflexia', 'Death in infancy', 'Death in childhood', 'Abnormal cerebral white matter morphology'.

\n\n+4. Meningitis: Meningitis is an infection that causes inflammation of the protective membranes (meninges) surrounding the brain and spinal cord. The patient does not have symptoms in common with Meningitis such as 'Delayed speech and language development', 'Intellectual disability', 'Hyperreflexia', 'Difficulty walking', 'Difficulty climbing stairs', 'Difficulty running', 'Abnormal cerebral white matter morphology'.

\n\n+5. Cerebral Palsy: Cerebral Palsy is a group of permanent disorders that appear in early childhood, affecting movement, posture, and muscle tone. The patient has symptoms in common with Cerebral Palsy such as 'Difficulty walking', 'Difficulty climbing stairs', 'Difficulty running', 'Hyperreflexia'. The patient does not have symptoms in common with Cerebral Palsy such as 'Delayed speech and language development', 'Intellectual disability', 'Death in infancy', 'Death in childhood', 'Abnormal cerebral white matter morphology'.

Please note that this is not an exhaustive list and a proper diagnosis would require a thorough medical examination and additional testing."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Mucopolysaccharidosis Type II (MPS II): This is a genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of glycosaminoglycans in the body. The patient has apathy, spasticity, and hypotonia in common with this disease, but does not have obesity, hypoglycemia, or neonatal death.

\n\n+2. Leukodystrophy: This is a group of genetic disorders that affect the development and maintenance of the white matter in the brain. The patient has spasticity, hypotonia, and hypoglycemia in common with this disease, but does not have apathy, obesity, or neonatal death.

\n\n+3. Congenital Muscular Dystrophy: This is a group of genetic disorders that affect the development and maintenance of muscle tissue. The patient has spasticity, hypotonia, and death in infancy in common with this disease, but does not have apathy, obesity, or hypoglycemia.

\n\n+4. Mitochondrial Disease: This is a group of genetic disorders that affect the mitochondria, the energy-producing structures within cells. The patient has hypoglycemia, hypotonia, and death in early adulthood in common with this disease, but does not have apathy, spasticity, or obesity.

\n\n+5. Prader-Willi Syndrome: This is a genetic disorder caused by a deletion or mutation in the Prader-Willi syndrome critical region on chromosome 15. The patient has obesity, hypotonia, and hypoglycemia in common with this disease, but does not have apathy, spasticity, or neonatal death.

\n\n+6. Zellweger Syndrome: This is a rare genetic disorder caused by a deficiency of peroxisomes, which are organelles found in cells. The patient has hypotonia, hypoglycemia, and death in infancy in common with this disease, but does not have apathy, spasticity, or obesity.

Note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Classic galactosemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Galactosemia: Galactosemia is a rare genetic disorder that affects the breakdown of galactose, a sugar found in milk and other dairy products. Symptoms include delayed speech and language development, hypergalactosemia, and abnormality of galactoside metabolism. The patient has in common: delayed speech and language development, hypergalactosemia, and abnormality of galactoside metabolism. The patient does not have in common: obesity, death in infancy, increased total bilirubin, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration, death in adolescence.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of tyrosine, an amino acid found in many foods. Symptoms include delayed speech and language development, abnormal circulating tyrosine concentration, and increased risk of liver disease. The patient has in common: delayed speech and language development, abnormal circulating tyrosine concentration. The patient does not have in common: obesity, death in infancy, hyperalaninemia, aminoaciduria, increased total bilirubin, abnormality of galactoside metabolism, abnormal circulating aspartate family amino acid concentration, death in adolescence.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids, including leucine, isoleucine, and valine. Symptoms include delayed speech and language development, increased risk of seizures, and increased risk of brain damage. The patient does not have in common: obesity, death in infancy, hyperalaninemia, aminoaciduria, increased total bilirubin, abnormality of galactoside metabolism, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration, death in adolescence.

\n\n+4. Phenylketonuria (PKU): PKU is a rare genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include delayed speech and language development, increased risk of seizures, and increased risk of brain damage. The patient does not have in common: obesity, death in infancy, hyperalaninemia, aminoaciduria, increased total bilirubin, abnormality of galactoside metabolism, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration, death in adolescence.

\n\n+5. Mucopolysaccharidosis (MPS): MPS is a group of rare genetic disorders that affect the breakdown of certain sugars. Symptoms include delayed speech and language development, increased risk of joint pain, and increased risk of respiratory problems. The patient does not have in common: obesity, death in infancy, hyperalaninemia, aminoaciduria, increased total bilirubin, abnormality of galactoside metabolism, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration, death in adolescence.

Note: The above list is not exhaustive, and a definitive diagnosis can only be made after a thorough medical examination and testing."
['3-hydroxy-3-methylglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and dicarboxylic aciduria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, fever, vomiting, and abnormal circulating glycine concentration.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and dicarboxylic aciduria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, fever, vomiting, and abnormal circulating glycine concentration.

\n\n+3. 3-Methylglutaconic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and dicarboxylic aciduria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, fever, vomiting, and abnormal circulating glycine concentration.

\n\n+4. Glycine encephalopathy: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include metabolic acidosis, hyperammonemia, and abnormal circulating glycine concentration, which the patient has in common. The patient does not have in common the symptoms of death in infancy, fever, vomiting, and dicarboxylic aciduria.

\n\n+5. Organic acidemia: This is a broad term that refers to a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and dicarboxylic aciduria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, fever, vomiting, and abnormal circulating glycine concentration.

Note that these are just a few potential diseases that the patient may have, and a more thorough diagnosis would require further testing and evaluation."
['Classic homocystinuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Hypertrophic Pyloric Stenosis: This is a condition where the muscle at the bottom of the stomach is thicker than normal, causing blockage of the stomach. The patient has in common: None. The patient does not have in common: Jaundice, Generalized hypotonia, Anemia, Hyperhomocystinemia, Progressive neurologic deterioration, Hypomethioninemia, Death in childhood, Recurrent viral infections, Abnormal circulating porphyrin concentration, Abnormality of folate metabolism.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Anemia, Hyperhomocystinemia, Hypomethioninemia. The patient does not have in common: Jaundice, Generalized hypotonia, Progressive neurologic deterioration, Death in childhood, Recurrent viral infections, Abnormal circulating porphyrin concentration, Abnormality of folate metabolism.

\n\n+3. Porphyrinuria: This is a condition where the body produces too much porphyrin, a chemical that is normally produced in small amounts. The patient has in common: Abnormal circulating porphyrin concentration. The patient does not have in common: Jaundice, Generalized hypotonia, Anemia, Hyperhomocystinemia, Progressive neurologic deterioration, Hypomethioninemia, Death in childhood, Recurrent viral infections, Abnormality of folate metabolism.

\n\n+4. Folate-Responsive Homocystinuria: This is a genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Hyperhomocystinemia, Abnormality of folate metabolism. The patient does not have in common: Jaundice, Generalized hypotonia, Anemia, Progressive neurologic deterioration, Hypomethioninemia, Death in childhood, Recurrent viral infections, Abnormal circulating porphyrin concentration.

\n\n+5. Mitochondrial Disorders: This is a group of disorders that affect the mitochondria, the energy-producing structures within cells. The patient has in common: Generalized hypotonia, Progressive neurologic deterioration, Recurrent viral infections. The patient does not have in common: Jaundice, Anemia, Hyperhomocystinemia, Hypomethioninemia, Death in childhood, Abnormal circulating porphyrin concentration, Abnormality of folate metabolism.

\n\n+6. Acute Intermittent Porphyria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Abnormal circulating porphyrin concentration. The patient does not have in common: Jaundice, Generalized hypotonia, Anemia, Hyperhomocystinemia, Progressive neurologic deterioration, Hypomethioninemia, Death in childhood, Recurrent viral infections, Abnormality of folate metabolism.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common and which symptoms they do not have in common:

\n\n+1. Congenital Adrenal Hyperplasia: This is a rare genetic disorder that affects the adrenal glands and can cause abnormal development, upper airway obstruction, and death in infancy or childhood. The patient has symptoms in common with this disease: 'Abnormality of prenatal development or birth', 'Upper airway obstruction', 'Death in infancy', 'Death in childhood'. The patient does not have symptoms in common with this disease: 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood'.

\n\n+2. Phenylketonuria (PKU): This is a genetic disorder that affects the breakdown of the amino acid phenylalanine and can cause intellectual disability, seizures, and death if left untreated. The patient has symptoms in common with this disease: 'Hypertyrosinemia', 'Hyperphenylalaninemia'. The patient does not have symptoms in common with this disease: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood'.

\n\n+3. Tracheomalacia: This is a condition where the trachea is weak and collapses, causing upper airway obstruction. The patient has symptoms in common with this disease: 'Upper airway obstruction'. The patient does not have symptoms in common with this disease: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood'.

\n\n+4. Cystic Fibrosis: This is a genetic disorder that affects the respiratory, digestive, and reproductive systems and can cause chronic pulmonary obstruction and death in early adulthood. The patient does not have symptoms in common with this disease: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Death in childhood', 'Death in adolescence'.

\n\n+5. Rett Syndrome: This is a rare genetic disorder that affects brain development and can cause abnormal development, intellectual disability, and death in early childhood. The patient does not have symptoms in common with this disease: 'Upper airway obstruction', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Chronic pulmonary obstruction', 'Death in adolescence', 'Death in early adulthood'.

Note: This is not an exhaustive list and the patient may have a different diagnosis. A thorough medical examination and further testing would be necessary to confirm a diagnosis."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, developmental delays, and muscle weakness. The patient has in common: Seizure, Spasticity. The patient does not have in common: Apathy, Death in infancy, Alopecia, Dyspnea, Fatigue, Elevated urinary carboxylic acid.

\n\n+2. Propionic Acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, developmental delays, and muscle weakness. The patient has in common: Seizure, Spasticity. The patient does not have in common: Apathy, Death in infancy, Alopecia, Dyspnea, Fatigue, Elevated urinary carboxylic acid.

\n\n+3. Glutaric Acidemia Type I: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, developmental delays, and muscle weakness. The patient has in common: Seizure, Spasticity. The patient does not have in common: Apathy, Death in infancy, Alopecia, Dyspnea, Fatigue, Elevated urinary carboxylic acid.

\n\n+4. Multiple Carboxylase Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, developmental delays, and muscle weakness. The patient has in common: Seizure, Spasticity. The patient does not have in common: Apathy, Death in infancy, Alopecia, Dyspnea, Fatigue, Elevated urinary carboxylic acid.

\n\n+5. Leigh Syndrome: This is a rare genetic disorder that affects the brain and spinal cord. Symptoms include seizures, developmental delays, and muscle weakness. The patient has in common: Seizure, Spasticity. The patient does not have in common: Apathy, Death in infancy, Alopecia, Dyspnea, Fatigue, Elevated urinary carboxylic acid.

Note: The patient's symptoms of apathy, alopecia, and dyspnea are not typically associated with these diseases, and further testing would be needed to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Hypertyrosinemia, Hyperphenylalaninemia. The patient does not have in common: Obesity, Death in infancy, Neonatal death, Death in childhood, Death in adolescence, Gastrointestinal inflammation.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Hypertyrosinemia. The patient does not have in common: Obesity, Death in infancy, Neonatal death, Death in childhood, Death in adolescence, Gastrointestinal inflammation, Hyperphenylalaninemia.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: Hypertyrosinemia. The patient does not have in common: Obesity, Death in infancy, Neonatal death, Death in childhood, Death in adolescence, Gastrointestinal inflammation, Hyperphenylalaninemia.

\n\n+4. Gastrointestinal Inflammatory Disease: This is a broad term that encompasses various inflammatory conditions affecting the gastrointestinal tract. Symptoms include abdominal pain, diarrhea, and weight loss. The patient has in common: Gastrointestinal inflammation. The patient does not have in common: Obesity, Death in infancy, Neonatal death, Death in childhood, Death in adolescence, Hypertyrosinemia, Hyperphenylalaninemia.

\n\n+5. Inborn Errors of Metabolism: This is a broad term that encompasses various genetic disorders that affect the breakdown of nutrients. Symptoms vary depending on the specific disorder. The patient has in common: Hypertyrosinemia, Hyperphenylalaninemia. The patient does not have in common: Obesity, Death in infancy, Neonatal death, Death in childhood, Death in adolescence, Gastrointestinal inflammation.

Please note that this is not an exhaustive list, and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the body. The patient has in common: Skin rash, Alopecia, Metabolic acidosis, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Increased CSF lactate, Aminoaciduria, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine, leading to the accumulation of toxic compounds in the body. The patient has in common: Skin rash, Alopecia, Metabolic acidosis, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Increased CSF lactate, Aminoaciduria, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body. The patient has in common: Skin rash, Alopecia, Metabolic acidosis, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Increased CSF lactate, Aminoaciduria, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+4. Organic Acidemia: Organic acidemia is a group of rare genetic disorders that affect the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body. The patient has in common: Skin rash, Alopecia, Metabolic acidosis, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Increased CSF lactate, Aminoaciduria, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+5. Glycine Encephalopathy: Glycine encephalopathy is a rare genetic disorder that affects the breakdown of the amino acid glycine, leading to the accumulation of toxic compounds in the body. The patient has in common: Skin rash, Alopecia, Metabolic acidosis, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Increased CSF lactate, Aminoaciduria, Erythematous plaque, Erythematous macule, Erythematous papule.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include decreased methylmalonyl-CoA mutase activity, feeding difficulties, and dehydration. The patient has these symptoms in common with Methylmalonic Acidemia. However, the patient does not have symptoms such as seizures, intellectual disability, or skin rashes, which are common in this disease.

\n\n+2. Propionic Acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include decreased methylmalonyl-CoA mutase activity, feeding difficulties, and dehydration. The patient has these symptoms in common with Propionic Acidemia. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in this disease.

\n\n+3. Multiple Carboxylase Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include decreased methylmalonyl-CoA mutase activity, feeding difficulties, and dehydration. The patient has these symptoms in common with Multiple Carboxylase Deficiency. However, the patient does not have symptoms such as seizures, intellectual disability, or skin rashes, which are common in this disease.

\n\n+4. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms include decreased methylmalonyl-CoA mutase activity, feeding difficulties, and dehydration. The patient has these symptoms in common with Organic Acidemia. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in this disease.

\n\n+5. Mitochondrial Disease: This is a group of rare genetic disorders that affect the body's energy-producing structures called mitochondria. Symptoms include decreased methylmalonyl-CoA mutase activity, feeding difficulties, and dehydration. The patient has these symptoms in common with Mitochondrial Disease. However, the patient does not have symptoms such as muscle weakness, seizures, or vision loss, which are common in this disease.

Note: The patient's symptoms of ""Death in infancy"" and ""Neonatal death"" are concerning and may indicate a more severe or life-threatening condition. Further evaluation and testing are needed to determine the underlying cause of these symptoms."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as metabolic acidosis, increased circulating lactate concentration, and elevated urinary carboxylic acid. However, the patient does not have symptoms such as seizures, vomiting, or developmental delays, which are common in methylmalonic acidemia.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as metabolic acidosis, increased circulating lactate concentration, and elevated urinary carboxylic acid. The patient also has symptoms such as lethargy, generalized hypotonia, and death in infancy, which are common in propionic acidemia.

\n\n+3. Glycine encephalopathy: This is a rare genetic disorder that affects the body's ability to break down the amino acid glycine. The patient has symptoms in common with this disease, such as metabolic acidosis, increased circulating lactate concentration, and abnormal circulating glycine concentration. The patient also has symptoms such as lethargy, generalized hypotonia, and death in infancy, which are common in glycine encephalopathy.

\n\n+4. Organic acidemia: This is a general term that refers to a group of rare genetic disorders that affect the body's ability to break down certain organic compounds. The patient has symptoms in common with this disease, such as metabolic acidosis, increased circulating lactate concentration, and elevated urinary carboxylic acid. The patient also has symptoms such as lethargy, generalized hypotonia, and death in infancy, which are common in some types of organic acidemia.

\n\n+5. Mitochondrial disease: This is a general term that refers to a group of rare genetic disorders that affect the body's ability to generate energy. The patient has symptoms in common with this disease, such as metabolic acidosis, increased circulating lactate concentration, and fatigue. The patient also has symptoms such as lethargy, generalized hypotonia, and death in infancy, which are common in some types of mitochondrial disease.

Note that these are just a few potential diseases that the patient may have, and a more thorough evaluation and testing would be necessary to make a definitive diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['3-hydroxy-3-methylglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include developmental delays, seizures, and vomiting. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Dicarboxylic aciduria, 3-Methylglutaric aciduria.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include developmental delays, seizures, and vomiting. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Dicarboxylic aciduria, 3-Methylglutaric aciduria.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and vomiting. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Dicarboxylic aciduria, 3-Methylglutaric aciduria.

\n\n+4. Dicarboxylic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and vomiting. The patient has in common: Dicarboxylic aciduria. The patient does not have in common: Death in infancy, 3-Methylglutaric aciduria, Elevated urinary carboxylic acid.

\n\n+5. 3-Methylglutaric aciduria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and vomiting. The patient has in common: 3-Methylglutaric aciduria. The patient does not have in common: Death in infancy, Dicarboxylic aciduria, Elevated urinary carboxylic acid.

\n\n+6. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms include muscle weakness, fatigue, and seizures. The patient has in common: None. The patient does not have in common: Death in infancy, Dicarboxylic aciduria, 3-Methylglutaric aciduria, Elevated urinary carboxylic acid.

Note: The patient's symptoms are not a perfect match for any of the potential diseases listed, but they do share some commonalities. Further testing and evaluation would be necessary to determine the exact diagnosis."
['Wilson disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Wilson's Disease: Wilson's Disease is a rare genetic disorder that affects the body's ability to remove excess copper from the body. Symptoms include elevated circulating hepatic transaminase concentration, increased urinary copper concentration, and decreased circulating copper concentration. The patient has in common: elevated circulating hepatic transaminase concentration, increased urinary copper concentration, and decreased circulating copper concentration. The patient does not have in common: carious teeth, obesity, death in childhood, abnormal circulating porphyrin concentration, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, decreased circulating ceruloplasmin concentration.

\n\n+2. Porphyrinuria: Porphyrinuria is a rare genetic disorder that affects the production of heme, a protein found in red blood cells. Symptoms include abnormal circulating porphyrin concentration and elevated circulating hepatic transaminase concentration. The patient has in common: abnormal circulating porphyrin concentration and elevated circulating hepatic transaminase concentration. The patient does not have in common: carious teeth, obesity, death in childhood, increased urinary copper concentration, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, decreased circulating ceruloplasmin concentration, decreased circulating copper concentration.

\n\n+3. Ceruloplasmin Deficiency: Ceruloplasmin Deficiency is a rare genetic disorder that affects the production of ceruloplasmin, a protein that helps to remove excess copper from the body. Symptoms include decreased circulating ceruloplasmin concentration and elevated circulating hepatic transaminase concentration. The patient has in common: elevated circulating hepatic transaminase concentration. The patient does not have in common: carious teeth, obesity, death in childhood, abnormal circulating porphyrin concentration, increased urinary copper concentration, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, decreased circulating copper concentration.

\n\n+4. Hepatocellular Carcinoma: Hepatocellular Carcinoma is a type of liver cancer that can cause elevated circulating hepatic transaminase concentration. Symptoms include elevated circulating hepatic transaminase concentration, abnormal circulating aspartate family amino acid concentration, and abnormal circulating alanine concentration. The patient has in common: elevated circulating hepatic transaminase concentration. The patient does not have in common: carious teeth, obesity, death in childhood, abnormal circulating porphyrin concentration, increased urinary copper concentration, decreased circulating ceruloplasmin concentration, decreased circulating copper concentration.

\n\n+5. Iron Deficiency Anemia: Iron Deficiency Anemia is a condition where the body does not have enough iron to produce hemoglobin, a protein found in red blood cells. Symptoms include decreased serum iron and abnormal circulating aspartate family amino acid concentration. The patient has in common: abnormal circulating aspartate family amino acid concentration. The patient does not have in common: carious teeth, obesity, death in childhood, abnormal circulating porphyrin concentration, increased urinary copper concentration, elevated circulating hepatic transaminase concentration, decreased circulating ceruloplasmin concentration, decreased circulating copper concentration.

Please note that this is not an exhaustive list and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Syndrome: This is a rare genetic disorder that affects the body's ability to use carnitine, an amino acid that plays a crucial role in energy production. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Trisomy 13 (Patau Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 13. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+3. Trisomy 18 (Edwards Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 18. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+4. Mitochondrial Disorders: These are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. They can cause a range of symptoms, including muscle weakness, seizures, and developmental delays. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+5. Fetal Alcohol Syndrome: This is a condition caused by prenatal exposure to alcohol, characterized by physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia', 'Death in childhood'. The patient does not have in common: 'Death in infancy', 'Hypertyrosinemia', 'Recurrent viral infections'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia', 'Death in childhood'. The patient does not have in common: 'Death in infancy', 'Hyperphenylalaninemia', 'Recurrent viral infections'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Death in infancy', 'Hypertyrosinemia', 'Recurrent viral infections'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Death in infancy', 'Hyperphenylalaninemia', 'Hypertyrosinemia', 'Recurrent viral infections'.

\n\n+5. Mitochondrial Disorders: Mitochondrial disorders are a group of genetic disorders that affect the energy-producing structures within cells. Symptoms include muscle weakness, seizures, and developmental delays. The patient does not have in common: 'Death in infancy', 'Hyperphenylalaninemia', 'Hypertyrosinemia', 'Recurrent viral infections'.

Note: These are just a few potential diseases that may be related to the symptoms provided. A more comprehensive diagnosis would require a thorough medical examination and additional testing."
['3-methylcrotonyl-CoA carboxylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Glycine Encephalopathy: This is a rare genetic disorder that affects the brain and spinal cord. Symptoms include seizures, developmental delay, and intellectual disability. The patient has in common: Abnormal circulating glycine concentration. The patient does not have in common: Aminoaciduria, Abnormal circulating carnitine concentration, Elevated urinary carboxylic acid.

\n\n+2. Carnitine Deficiency: This is a rare genetic disorder that affects the body's ability to use fat for energy. Symptoms include muscle weakness, fatigue, and heart problems. The patient has in common: Abnormal circulating carnitine concentration. The patient does not have in common: Aminoaciduria, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid.

\n\n+3. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. Symptoms include vomiting, diarrhea, and lethargy. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Aminoaciduria, Abnormal circulating glycine concentration, Abnormal circulating carnitine concentration.

\n\n+4. Aminoaciduria: This is a rare genetic disorder that affects the kidneys' ability to reabsorb certain amino acids. Symptoms include proteinuria, hematuria, and kidney stones. The patient has in common: Aminoaciduria. The patient does not have in common: Abnormal circulating glycine concentration, Abnormal circulating carnitine concentration, Elevated urinary carboxylic acid.

\n\n+5. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include vomiting, diarrhea, and lethargy. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Aminoaciduria, Abnormal circulating glycine concentration, Abnormal circulating carnitine concentration.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Carbamoyl-phosphate synthetase 1 deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. 3-Methylglutaconic Aciduria Type IV: This is a rare genetic disorder that affects the metabolism of fatty acids and can cause muscle weakness, feeding difficulties, and liver enlargement. The patient has in common: '3-Methylglutaconic aciduria', 'Feeding difficulties', 'Hepatomegaly'. The patient does not have in common: 'Generalized hypotonia', 'Death in infancy', 'Tachypnea', 'Neonatal death'.

\n\n+2. Pompe Disease: This is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase, which breaks down glycogen in the body. It can cause muscle weakness, feeding difficulties, and liver enlargement. The patient has in common: 'Generalized hypotonia', 'Feeding difficulties', 'Hepatomegaly'. The patient does not have in common: '3-Methylglutaconic aciduria', 'Tachypnea', 'Neonatal death'.

\n\n+3. Mucopolysaccharidosis Type VI: This is a rare genetic disorder caused by a deficiency of the enzyme arylsulfatase B, which breaks down mucopolysaccharides in the body. It can cause muscle weakness, feeding difficulties, and liver enlargement. The patient has in common: 'Generalized hypotonia', 'Feeding difficulties', 'Hepatomegaly'. The patient does not have in common: '3-Methylglutaconic aciduria', 'Tachypnea', 'Neonatal death'.

\n\n+4. Mitochondrial Myopathy: This is a rare genetic disorder caused by a defect in the mitochondria, which can cause muscle weakness, feeding difficulties, and liver enlargement. The patient has in common: 'Generalized hypotonia', 'Feeding difficulties', 'Hepatomegaly'. The patient does not have in common: '3-Methylglutaconic aciduria', 'Tachypnea', 'Neonatal death'.

\n\n+5. Congenital Myasthenic Syndrome: This is a rare genetic disorder caused by a defect in the transmission of nerve impulses to muscles, which can cause muscle weakness, feeding difficulties, and respiratory problems. The patient has in common: 'Generalized hypotonia', 'Feeding difficulties', 'Tachypnea'. The patient does not have in common: '3-Methylglutaconic aciduria', 'Hepatomegaly', 'Neonatal death'.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Citrullinemia type I'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Zellweger Syndrome: Zellweger syndrome is a rare genetic disorder that affects the development of the brain and other organs. Symptoms include delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient has common symptoms with Zellweger syndrome: delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient does not have common symptoms with Zellweger syndrome: hyperhidrosis, lethargy, obesity, hypoglycemia, respiratory alkalosis, hyperammonemia, hypothermia, drowsiness, sleep abnormality, tachypnea, oroticaciduria, neonatal death, death in childhood, elevated plasma citrulline, pustule, acute hepatitis, or chronic hepatitis.

\n\n+2. Leigh Syndrome: Leigh syndrome is a rare genetic disorder that affects the development of the brain and other organs. Symptoms include delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient has common symptoms with Leigh syndrome: delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient does not have common symptoms with Leigh syndrome: hyperhidrosis, lethargy, obesity, hypoglycemia, respiratory alkalosis, hyperammonemia, hypothermia, drowsiness, sleep abnormality, tachypnea, oroticaciduria, neonatal death, death in childhood, elevated plasma citrulline, pustule, acute hepatitis, or chronic hepatitis.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient has common symptoms with Methylmalonic acidemia: delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient does not have common symptoms with Methylmalonic acidemia: hyperhidrosis, lethargy, obesity, hypoglycemia, respiratory alkalosis, hyperammonemia, hypothermia, drowsiness, sleep abnormality, tachypnea, oroticaciduria, neonatal death, death in childhood, elevated plasma citrulline, pustule, acute hepatitis, or chronic hepatitis.

\n\n+4. Pyruvate Dehydrogenase Deficiency: Pyruvate dehydrogenase deficiency is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient has common symptoms with Pyruvate dehydrogenase deficiency: delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient does not have common symptoms with Pyruvate dehydrogenase deficiency: hyperhidrosis, lethargy, obesity, hypoglycemia, respiratory alkalosis, hyperammonemia, hypothermia, drowsiness, sleep abnormality, tachypnea, oroticaciduria, neonatal death, death in childhood, elevated plasma citrulline, pustule, acute hepatitis, or chronic hepatitis.

\n\n+5. Mitochondrial Disease: Mitochondrial disease is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient has common symptoms with Mitochondrial disease: delayed speech and language development, motor delay, and abnormality of prenatal development or birth. The patient does not have common symptoms with Mitochondrial disease: hyperhidrosis, lethargy, obesity, hypoglycemia, respiratory alkalosis, hyperammonemia, hypothermia, drowsiness, sleep abnormality, tachypnea, oroticaciduria, neonatal death, death in childhood, elevated plasma citrulline, pustule, acute hepatitis, or chronic hepatitis.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and testing."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of Macrocephaly, Abnormality of visual evoked potentials, Seizure, Generalized hypotonia, and Athetosis in common with this disease. The patient does not have symptoms of Irritability, Death in infancy, and Neonatal death, which are not typical of Glutaric Acidemia Type 1.

\n\n+2. Methylmalonic Acidemia:
The patient has symptoms of Macrocephaly, Abnormality of visual evoked potentials, Seizure, and Generalized hypotonia in common with this disease. The patient does not have symptoms of Irritability, Athetosis, Glutaric aciduria, Death in infancy, and Neonatal death, which are not typical of Methylmalonic Acidemia.

\n\n+3. Pyruvate Dehydrogenase Deficiency:
The patient has symptoms of Macrocephaly, Abnormality of visual evoked potentials, Seizure, and Generalized hypotonia in common with this disease. The patient does not have symptoms of Irritability, Athetosis, Glutaric aciduria, Death in infancy, and Neonatal death, which are not typical of Pyruvate Dehydrogenase Deficiency.

\n\n+4. Leigh Syndrome:
The patient has symptoms of Macrocephaly, Abnormality of visual evoked potentials, Seizure, and Generalized hypotonia in common with this disease. The patient does not have symptoms of Irritability, Athetosis, Glutaric aciduria, Death in infancy, and Neonatal death, which are not typical of Leigh Syndrome.

\n\n+5. Canavan Disease:
The patient has symptoms of Macrocephaly, Abnormality of visual evoked potentials, and Generalized hypotonia in common with this disease. The patient does not have symptoms of Seizure, Irritability, Athetosis, Glutaric aciduria, Death in infancy, and Neonatal death, which are not typical of Canavan Disease.

Note: The patient's symptoms are more consistent with Glutaric Acidemia Type 1, but further testing and evaluation are necessary to confirm the diagnosis."
['Tyrosinemia type 1'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include delayed speech and language development, intellectual disability, and seizures. The patient has delayed speech and language development in common with PKU, but does not have intellectual disability or seizures.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include delayed speech and language development, liver disease, and increased risk of liver cancer. The patient has delayed speech and language development in common with tyrosinemia, but does not have liver disease or increased risk of liver cancer.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include delayed speech and language development, intellectual disability, and seizures. The patient has delayed speech and language development in common with MSUD, but does not have intellectual disability or seizures.

\n\n+4. Alkaptonuria: Alkaptonuria is a rare genetic disorder that affects the breakdown of the amino acid homogentisic acid. Symptoms include delayed speech and language development, joint pain, and dark urine. The patient has delayed speech and language development in common with alkaptonuria, but does not have joint pain or dark urine.

\n\n+5. Hyperphenylalaninemia: Hyperphenylalaninemia is a condition characterized by elevated levels of the amino acid phenylalanine in the blood. Symptoms include delayed speech and language development, intellectual disability, and seizures. The patient has delayed speech and language development in common with hyperphenylalaninemia, but does not have intellectual disability or seizures.

Note that the patient's symptoms are consistent with several genetic disorders that affect amino acid metabolism. Further testing and evaluation would be necessary to confirm a specific diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia', 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+4. Organic Acidemia: Organic acidemia is a group of rare genetic disorders that affect the breakdown of certain organic acids. Symptoms include intellectual disability, seizures, and a range of physical and neurological problems. The patient has in common: 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+5. Fatty Acid Oxidation Disorders: Fatty acid oxidation disorders are a group of rare genetic disorders that affect the breakdown of fatty acids. Symptoms include intellectual disability, seizures, and a range of physical and neurological problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Obesity', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid'.

Note: These are just a few potential diseases that may be related to the symptoms provided. A definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and elevated levels of phenylalanine in the blood. The patient has in common: intellectual disability, seizure, and elevated urinary carboxylic acid. The patient does not have in common: hyperactivity, obesity, severe short stature, death in childhood, death in adolescence, and death in early adulthood.

\n\n+2. Hyperphenylalaninemia: This is a condition characterized by elevated levels of phenylalanine in the blood, which can lead to intellectual disability, seizures, and other symptoms. The patient has in common: intellectual disability, seizure, and elevated urinary carboxylic acid. The patient does not have in common: hyperactivity, obesity, severe short stature, death in childhood, death in adolescence, and death in early adulthood.

\n\n+3. Tyrosinemia type I: This is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include intellectual disability, seizures, and liver damage. The patient has in common: intellectual disability, seizure, and elevated urinary carboxylic acid. The patient does not have in common: hyperactivity, obesity, severe short stature, death in childhood, death in adolescence, and death in early adulthood.

\n\n+4. Prader-Willi syndrome: This is a genetic disorder that affects appetite regulation, leading to obesity and other symptoms. The patient has in common: obesity. The patient does not have in common: intellectual disability, seizure, hyperactivity, severe short stature, death in childhood, death in adolescence, and death in early adulthood.

\n\n+5. Smith-Magenis syndrome: This is a rare genetic disorder that affects the development of the brain and other organs. Symptoms include intellectual disability, hyperactivity, and sleep disturbances. The patient has in common: intellectual disability and hyperactivity. The patient does not have in common: seizure, obesity, severe short stature, death in childhood, death in adolescence, and death in early adulthood.

Note: These are just a few potential diseases that may be related to the symptoms provided. A definitive diagnosis would require further testing and evaluation."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and vomiting, which the patient has in common. The patient also has thrombocytopenia and leukopenia, which are common symptoms of methylmalonic acidemia. However, the patient does not have seizures, generalized hypotonia, or death in infancy, which are not typical symptoms of this disease.

\n\n+2. Methylmalonic aciduria: This is a milder form of methylmalonic acidemia, characterized by a buildup of methylmalonic acid in the urine. The patient has metabolic acidosis, hyperammonemia, and vomiting in common with this disease. However, the patient does not have thrombocytopenia or leukopenia, which are not typical symptoms of methylmalonic aciduria. The patient also does not have seizures, generalized hypotonia, or death in infancy, which are not typical symptoms of this disease.

\n\n+3. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms can include metabolic acidosis, hyperammonemia, and vomiting, which the patient has in common. However, the patient does not have thrombocytopenia or leukopenia, which are not typical symptoms of organic acidemia. The patient also does not have seizures, generalized hypotonia, or death in infancy, which are not typical symptoms of this disease.

\n\n+4. Leukodystrophy: This is a group of rare genetic disorders that affect the development and maintenance of the brain and spinal cord. Symptoms can include seizures, generalized hypotonia, and death in infancy, which the patient has in common. However, the patient does not have metabolic acidosis, hyperammonemia, or vomiting, which are not typical symptoms of leukodystrophy. The patient also does not have thrombocytopenia or leukopenia, which are not typical symptoms of this disease.

\n\n+5. Thrombocytopenia-absent radius (TAR) syndrome: This is a rare genetic disorder that affects the development of the bones and blood platelets. Symptoms can include thrombocytopenia and leukopenia, which the patient has in common. However, the patient does not have metabolic acidosis, hyperammonemia, or vomiting, which are not typical symptoms of TAR syndrome. The patient also does not have seizures, generalized hypotonia, or death in infancy, which are not typical symptoms of this disease.

Note: These are just a few potential diseases that the patient may have based on the symptoms provided. A definitive diagnosis would require further testing and evaluation."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Syndrome: This is a rare genetic disorder that affects the body's ability to use carnitine, an amino acid that plays a crucial role in energy production. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Trisomy 13 (Patau Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 13. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+3. Trisomy 18 (Edwards Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 18. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+4. Mitochondrial Disorders: These are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. They can cause a range of symptoms, including muscle weakness, seizures, and developmental delays. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+5. Fetal Alcohol Syndrome: This is a condition caused by prenatal exposure to alcohol, characterized by physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and vomiting. The patient has in common: metabolic acidosis, hyperammonemia, and vomiting. The patient does not have in common: death in infancy.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, hyperammonemia, and vomiting. The patient has in common: metabolic acidosis, hyperammonemia, and vomiting. The patient does not have in common: death in infancy.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include metabolic acidosis, hyperammonemia, and vomiting. The patient has in common: metabolic acidosis, hyperammonemia, and vomiting. The patient does not have in common: death in infancy.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain organic compounds. Symptoms include metabolic acidosis, hyperammonemia, and vomiting. The patient has in common: metabolic acidosis, hyperammonemia, and vomiting. The patient does not have in common: death in infancy.

\n\n+5. Neonatal-onset multisystem inflammatory disease (NOMID): This is a rare genetic disorder that affects the body's immune system. Symptoms include metabolic acidosis, hyperammonemia, and vomiting. The patient has in common: metabolic acidosis and hyperammonemia. The patient does not have in common: death in infancy, vomiting.

Note: The patient's symptoms of death in infancy and methylmalonic aciduria are specific to methylmalonic acidemia, which is a rare genetic disorder that affects the body's ability to break down certain proteins and fats."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Citrullinemia: Citrullinemia is a rare genetic disorder that affects the metabolism of amino acids. The patient has symptoms in common with citrullinemia, such as hyperammonemia, cerebral edema, and orotic aciduria. However, the patient does not have symptoms such as intellectual disability, developmental delay, or skin lesions, which are common in citrullinemia.

\n\n+2. Argininosuccinic Aciduria: Argininosuccinic aciduria is another rare genetic disorder that affects the metabolism of amino acids. The patient has symptoms in common with argininosuccinic aciduria, such as hyperammonemia, cerebral edema, and orotic aciduria. However, the patient does not have symptoms such as intellectual disability, developmental delay, or skin lesions, which are common in argininosuccinic aciduria.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the metabolism of fatty acids and amino acids. The patient has symptoms in common with methylmalonic acidemia, such as hyperammonemia, cerebral edema, and orotic aciduria. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in methylmalonic acidemia.

\n\n+4. Glutaric Acidemia Type I: Glutaric acidemia type I is a rare genetic disorder that affects the metabolism of fatty acids and amino acids. The patient has symptoms in common with glutaric acidemia type I, such as hyperammonemia, cerebral edema, and orotic aciduria. However, the patient does not have symptoms such as developmental delay, intellectual disability, or seizures, which are common in glutaric acidemia type I.

\n\n+5. Urea Cycle Disorders: Urea cycle disorders are a group of rare genetic disorders that affect the metabolism of amino acids. The patient has symptoms in common with urea cycle disorders, such as hyperammonemia, cerebral edema, and orotic aciduria. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in urea cycle disorders.

\n\n+6. Neonatal Adrenoleukodystrophy: Neonatal adrenoleukodystrophy is a rare genetic disorder that affects the metabolism of fatty acids. The patient has symptoms in common with neonatal adrenoleukodystrophy, such as hyperammonemia, cerebral edema, and orotic aciduria. However, the patient does not have symptoms such as adrenal insufficiency, developmental delay, or seizures, which are common in neonatal adrenoleukodystrophy.

Based on the symptoms provided, citrullinemia, argininosuccinic aciduria, and urea cycle disorders are the most likely potential diseases. However, further testing and evaluation are needed to confirm the diagnosis."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, hypotonia, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, hypotonia, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include seizures, hypotonia, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

\n\n+4. Mitochondrial myopathy: This is a rare genetic disorder that affects the mitochondria, the energy-producing structures within cells. Symptoms include muscle weakness, seizures, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

\n\n+5. Congenital myasthenic syndrome: This is a rare genetic disorder that affects the nerve-muscle connection. Symptoms include muscle weakness, seizures, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

\n\n+6. Krabbe disease: This is a rare genetic disorder that affects the breakdown of fatty substances in the brain. Symptoms include seizures, hypotonia, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

\n\n+7. Tay-Sachs disease: This is a rare genetic disorder that affects the breakdown of fatty substances in the brain. Symptoms include seizures, hypotonia, and developmental delays. The patient has in common: Seizure, Generalized hypotonia, Growth delay. The patient does not have in common: Alopecia, Fasciculations, Elevated urinary carboxylic acid.

Note: The patient's symptoms are consistent with several rare genetic disorders that affect the breakdown of proteins and fats, as well as mitochondrial function. Further testing and evaluation would be necessary to determine the specific diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a rare genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and skin problems. The patient has in common: Hyperphenylalaninemia. The patient does not have in common: Obesity, Hypercholesterolemia, Hypertyrosinemia, Death in early adulthood.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and skin problems. The patient has in common: Hypertyrosinemia. The patient does not have in common: Obesity, Hypercholesterolemia, Hyperphenylalaninemia, Death in early adulthood.

\n\n+3. Familial Hypercholesterolemia: Familial Hypercholesterolemia is a genetic disorder that affects the body's ability to remove low-density lipoprotein (LDL) cholesterol from the bloodstream. Symptoms include high cholesterol levels, heart disease, and premature death. The patient has in common: Hypercholesterolemia. The patient does not have in common: Obesity, Hypertyrosinemia, Hyperphenylalaninemia, Death in early adulthood.

\n\n+4. Prader-Willi Syndrome: Prader-Willi Syndrome is a rare genetic disorder that affects appetite regulation and metabolism. Symptoms include obesity, short stature, and intellectual disability. The patient has in common: Obesity. The patient does not have in common: Hypercholesterolemia, Hypertyrosinemia, Hyperphenylalaninemia, Death in early adulthood.

\n\n+5. Atherosclerosis: Atherosclerosis is a condition in which plaque builds up in the arteries, leading to heart disease and stroke. Symptoms include high cholesterol levels, high blood pressure, and chest pain. The patient has in common: Hypercholesterolemia. The patient does not have in common: Obesity, Hypertyrosinemia, Hyperphenylalaninemia, Death in early adulthood.

Note: The patient's symptoms of death in early adulthood are not a common symptom of any of the diseases listed above. Further investigation and testing would be necessary to determine the underlying cause of this symptom."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Hypothyroidism:
The patient has symptoms of Premature birth, Severe short stature, and Hypertyrosinemia in common with Congenital Hypothyroidism. However, the patient does not have symptoms of Hypospadias, Death in infancy, Neonatal death, Hyperphenylalaninemia, or Hernia.

\n\n+2. Phenylketonuria (PKU):
The patient has symptoms of Hyperphenylalaninemia in common with PKU. However, the patient does not have symptoms of Hypospadias, Death in infancy, Premature birth, Severe short stature, Neonatal death, or Hernia.

\n\n+3. Turner Syndrome:
The patient has symptoms of Severe short stature in common with Turner Syndrome. However, the patient does not have symptoms of Hypospadias, Death in infancy, Premature birth, Hypertyrosinemia, Neonatal death, Hyperphenylalaninemia, or Hernia.

\n\n+4. Prader-Willi Syndrome:
The patient does not have any symptoms in common with Prader-Willi Syndrome.

\n\n+5. Smith-Lemli-Opitz Syndrome:
The patient has symptoms of Premature birth and Severe short stature in common with Smith-Lemli-Opitz Syndrome. However, the patient does not have symptoms of Hypospadias, Death in infancy, Hypertyrosinemia, Neonatal death, Hyperphenylalaninemia, or Hernia.

\n\n+6. Trisomy 18:
The patient has symptoms of Premature birth, Severe short stature, and Neonatal death in common with Trisomy 18. However, the patient does not have symptoms of Hypospadias, Death in infancy, Hypertyrosinemia, Hyperphenylalaninemia, or Hernia.

Note: These are just potential diseases based on the symptoms provided, and a proper diagnosis would require a comprehensive medical evaluation and testing."
['Smith-Lemli-Opitz syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder caused by a defect in the cholesterol biosynthesis pathway. Common symptoms include microcephaly, delayed speech and language development, intellectual disability, and short stature. The patient's symptoms of strabismus, syndactyly, and severe hearing impairment are also consistent with this disorder. However, the patient's symptoms of low-set ears, wide nasal bridge, and motor delay are not typical of Smith-Lemli-Opitz Syndrome.

\n\n+2. RSH (Smith-Lemli-Opitz) Syndrome: This is a rare genetic disorder caused by a defect in the cholesterol biosynthesis pathway. Common symptoms include microcephaly, delayed speech and language development, intellectual disability, and short stature. The patient's symptoms of strabismus, syndactyly, and severe hearing impairment are also consistent with this disorder. However, the patient's symptoms of low-set ears, wide nasal bridge, and motor delay are not typical of RSH Syndrome.

\n\n+3. 7-Dehydrocholesterol Reductase Deficiency: This is a rare genetic disorder caused by a defect in the cholesterol biosynthesis pathway. Common symptoms include microcephaly, delayed speech and language development, intellectual disability, and short stature. The patient's symptoms of strabismus, syndactyly, and severe hearing impairment are also consistent with this disorder. However, the patient's symptoms of low-set ears, wide nasal bridge, and motor delay are not typical of 7-Dehydrocholesterol Reductase Deficiency.

\n\n+4. 8-Dehydrocholesterol Reductase Deficiency: This is a rare genetic disorder caused by a defect in the cholesterol biosynthesis pathway. Common symptoms include microcephaly, delayed speech and language development, intellectual disability, and short stature. The patient's symptoms of strabismus, syndactyly, and severe hearing impairment are also consistent with this disorder. However, the patient's symptoms of low-set ears, wide nasal bridge, and motor delay are not typical of 8-Dehydrocholesterol Reductase Deficiency.

\n\n+5. Congenital Microcephaly: This is a rare genetic disorder characterized by a small head size at birth. Common symptoms include microcephaly, delayed speech and language development, and intellectual disability. The patient's symptoms of strabismus, syndactyly, and severe hearing impairment are not typical of Congenital Microcephaly.

\n\n+6. Syndactyly: This is a rare genetic disorder characterized by webbing or fusion of fingers or toes. Common symptoms include syndactyly, delayed speech and language development, and intellectual disability. The patient's symptoms of microcephaly, strabismus, and severe hearing impairment are not typical of Syndactyly.

\n\n+7. Intellectual Disability: This is a rare genetic disorder characterized by intellectual disability. Common symptoms include delayed speech and language development, intellectual disability, and short stature. The patient's symptoms of microcephaly, strabismus, and severe hearing impairment are not typical of Intellectual Disability.

\n\n+8. Motor Delay: This is a rare genetic disorder characterized by delayed motor development. Common symptoms include motor delay, delayed speech and language development, and intellectual disability. The patient's symptoms of microcephaly, strabismus, and severe hearing impairment are not typical of Motor Delay.

Please note that these are just potential diseases and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of ataxia, opisthotonus, athetosis, progressive neurologic deterioration, elevated circulating glutaric acid concentration, and decreased plasma free carnitine. The patient does not have symptoms of death in infancy or death in childhood. Glutaric Acidemia Type 1 is a rare genetic disorder that affects the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body.

\n\n+2. Methylmalonic Acidemia:
The patient has symptoms of ataxia, opisthotonus, athetosis, progressive neurologic deterioration, and elevated circulating glutaric acid concentration. The patient does not have symptoms of death in infancy, death in childhood, or decreased plasma free carnitine. Methylmalonic Acidemia is a rare genetic disorder that affects the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body.

\n\n+3. Carnitine Deficiency Disorders:
The patient has symptoms of ataxia, opisthotonus, athetosis, progressive neurologic deterioration, and decreased plasma free carnitine. The patient does not have symptoms of death in infancy, death in childhood, or elevated circulating glutaric acid concentration. Carnitine Deficiency Disorders are a group of rare genetic disorders that affect the transport of fatty acids into the mitochondria, leading to the accumulation of toxic compounds in the body.

\n\n+4. Organic Acidemias:
The patient has symptoms of ataxia, opisthotonus, athetosis, progressive neurologic deterioration, and elevated circulating glutaric acid concentration. The patient does not have symptoms of death in infancy, death in childhood, or decreased plasma free carnitine. Organic Acidemias are a group of rare genetic disorders that affect the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body.

\n\n+5. Mitochondrial Disorders:
The patient has symptoms of ataxia, opisthotonus, athetosis, progressive neurologic deterioration, and decreased plasma free carnitine. The patient does not have symptoms of death in infancy, death in childhood, or elevated circulating glutaric acid concentration. Mitochondrial Disorders are a group of rare genetic disorders that affect the function of the mitochondria, leading to the accumulation of toxic compounds in the body.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and laboratory tests."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Prader-Willi Syndrome: Prader-Willi syndrome is a rare genetic disorder that affects the development of the brain and body. It is characterized by short stature, obesity, and intellectual disability. The patient has in common with Prader-Willi syndrome: Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, and Death in infancy. The patient does not have in common with Prader-Willi syndrome: Hip dysplasia, Hypertyrosinemia, Neonatal death, and Hyperphenylalaninemia.

\n\n+2. Phenylketonuria (PKU): Phenylketonuria is a genetic disorder that affects the body's ability to break down the amino acid phenylalanine. It is characterized by intellectual disability, seizures, and behavioral problems. The patient has in common with PKU: Hypertyrosinemia, Hyperphenylalaninemia. The patient does not have in common with PKU: Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Hip dysplasia, Death in infancy, Neonatal death.

\n\n+3. Congenital Muscular Dystrophy: Congenital muscular dystrophy is a group of genetic disorders that affect the development of muscles. It is characterized by muscle weakness, muscle wasting, and intellectual disability. The patient has in common with Congenital Muscular Dystrophy: Motor delay, Generalized hypotonia. The patient does not have in common with Congenital Muscular Dystrophy: Abnormality of prenatal development or birth, Hip dysplasia, Death in infancy, Hypertyrosinemia, Neonatal death, Hyperphenylalaninemia.

\n\n+4. Osteogenesis Imperfecta: Osteogenesis imperfecta is a genetic disorder that affects the development of bones. It is characterized by brittle bones, blue sclera, and hearing loss. The patient does not have in common with Osteogenesis Imperfecta: Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Hip dysplasia, Death in infancy, Hypertyrosinemia, Neonatal death, Hyperphenylalaninemia.

\n\n+5. Congenital Hip Dysplasia: Congenital hip dysplasia is a condition where the hip joint does not form properly. It is characterized by hip pain, limited mobility, and arthritis. The patient has in common with Congenital Hip Dysplasia: Hip dysplasia. The patient does not have in common with Congenital Hip Dysplasia: Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Death in infancy, Hypertyrosinemia, Neonatal death, Hyperphenylalaninemia.

Please note that this is not an exhaustive list, and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and hypotonia. The patient has in common: Seizure, Generalized hypotonia. The patient does not have in common: Retrognathia, Abnormality of prenatal development or birth, Death in infancy, Apnea, Opisthotonus, Hypertyrosinemia, Neonatal death, Death in childhood, Hyperphenylalaninemia.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Hypertyrosinemia. The patient does not have in common: Retrognathia, Abnormality of prenatal development or birth, Seizure, Generalized hypotonia, Death in infancy, Apnea, Opisthotonus, Neonatal death, Death in childhood, Hyperphenylalaninemia.

\n\n+3. Congenital hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include delayed development, short stature, and intellectual disability. The patient does not have in common: Retrognathia, Abnormality of prenatal development or birth, Seizure, Generalized hypotonia, Death in infancy, Apnea, Opisthotonus, Hypertyrosinemia, Neonatal death, Death in childhood, Hyperphenylalaninemia.

\n\n+4. Prader-Willi syndrome: Prader-Willi syndrome is a genetic disorder that affects the development of the brain and body. Symptoms include short stature, obesity, and intellectual disability. The patient does not have in common: Retrognathia, Abnormality of prenatal development or birth, Seizure, Generalized hypotonia, Death in infancy, Apnea, Opisthotonus, Hypertyrosinemia, Neonatal death, Death in childhood, Hyperphenylalaninemia.

\n\n+5. Rett syndrome: Rett syndrome is a genetic disorder that affects the development of the brain and body. Symptoms include intellectual disability, seizures, and loss of purposeful hand movements. The patient has in common: Seizure, Generalized hypotonia. The patient does not have in common: Retrognathia, Abnormality of prenatal development or birth, Death in infancy, Apnea, Opisthotonus, Hypertyrosinemia, Neonatal death, Death in childhood, Hyperphenylalaninemia.

Note: The above list is not exhaustive and is based on the symptoms provided. A thorough medical evaluation and diagnostic testing would be necessary to confirm a diagnosis."
['Tyrosinemia type 1'],"Based on the symptoms provided, here are some potential diseases that the patient may have:

\n\n+1. Phenylketonuria (PKU): The patient has symptoms in common with PKU such as hyperphenylalaninemia, intellectual disability, and elevated circulating alpha-fetoprotein concentration. However, the patient does not have symptoms such as seizures, motor delay, or obesity, which are not typically associated with PKU.

\n\n+2. Hypophosphatasia: The patient has symptoms in common with hypophosphatasia such as elevated circulating alkaline phosphatase concentration, hypertyrosinemia, and decreased serum iron. However, the patient does not have symptoms such as autistic behavior, self-mutilation, or hyperactivity, which are not typically associated with hypophosphatasia.

\n\n+3. Rett syndrome: The patient has symptoms in common with Rett syndrome such as autistic behavior, intellectual disability, and motor delay. However, the patient does not have symptoms such as seizures, obesity, or elevated circulating alpha-fetoprotein concentration, which are not typically associated with Rett syndrome.

\n\n+4. Prader-Willi syndrome: The patient has symptoms in common with Prader-Willi syndrome such as obesity, hyperactivity, and intellectual disability. However, the patient does not have symptoms such as seizures, motor delay, or elevated circulating alkaline phosphatase concentration, which are not typically associated with Prader-Willi syndrome.

\n\n+5. Smith-Magenis syndrome: The patient has symptoms in common with Smith-Magenis syndrome such as autistic behavior, intellectual disability, and hyperactivity. However, the patient does not have symptoms such as seizures, motor delay, or elevated circulating alpha-fetoprotein concentration, which are not typically associated with Smith-Magenis syndrome.

\n\n+6. Fragile X syndrome: The patient has symptoms in common with Fragile X syndrome such as intellectual disability and hyperactivity. However, the patient does not have symptoms such as seizures, motor delay, or elevated circulating alkaline phosphatase concentration, which are not typically associated with Fragile X syndrome.

\n\n+7. Mucopolysaccharidosis type VII: The patient has symptoms in common with Mucopolysaccharidosis type VII such as intellectual disability and elevated circulating alpha-fetoprotein concentration. However, the patient does not have symptoms such as seizures, motor delay, or obesity, which are not typically associated with Mucopolysaccharidosis type VII.

Note: This is not an exhaustive list and the patient may have a different diagnosis. A thorough medical evaluation and testing would be necessary to determine the correct diagnosis."
['Classic galactosemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Galactosemia: Galactosemia is a rare genetic disorder that affects the body's ability to process galactose, a sugar found in milk and other dairy products. Symptoms include vomiting, increased total bilirubin, and hypergalactosemia. The patient has in common: Vomiting, Increased total bilirubin, Hypergalactosemia. The patient does not have in common: Death in infancy, Neonatal death.

\n\n+2. Kernicterus: Kernicterus is a condition that occurs when high levels of bilirubin in the blood cause damage to the brain. Symptoms include increased total bilirubin, vomiting, and in severe cases, death in infancy. The patient has in common: Increased total bilirubin, Vomiting. The patient does not have in common: Hypergalactosemia, Neonatal death.

\n\n+3. Hypoglycemia: Hypoglycemia is a condition characterized by abnormally low blood sugar levels. Symptoms include vomiting, lethargy, and in severe cases, death in infancy. The patient has in common: Vomiting. The patient does not have in common: Increased total bilirubin, Hypergalactosemia, Neonatal death.

\n\n+4. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone, leading to developmental delays and other symptoms. Symptoms include vomiting, lethargy, and in severe cases, death in infancy. The patient has in common: Vomiting. The patient does not have in common: Increased total bilirubin, Hypergalactosemia, Neonatal death.

\n\n+5. Neonatal Sepsis: Neonatal sepsis is a life-threatening condition that occurs when bacteria infect the bloodstream of a newborn. Symptoms include vomiting, lethargy, and in severe cases, death in infancy. The patient has in common: Vomiting. The patient does not have in common: Increased total bilirubin, Hypergalactosemia.

Please note that this is not an exhaustive list, and a proper diagnosis would require a thorough medical examination and additional testing."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death.

\n\n+4. Tyrosinemia type II: Tyrosinemia type II is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death.

\n\n+5. Tyrosinemia type III: Tyrosinemia type III is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death.

Please note that these are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Carnitine Deficiency Disorder: This is a group of rare genetic disorders that affect the body's ability to use carnitine, an amino acid that plays a crucial role in energy production. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Obesity', 'Death in childhood', 'Death in adolescence'.

\n\n+2. Prader-Willi Syndrome: This is a rare genetic disorder that affects the hypothalamus, leading to a range of physical and behavioral symptoms. The patient has in common: 'Obesity', 'Death in childhood'. The patient does not have in common: 'Abnormal circulating carnitine concentration', 'Death in adolescence'.

\n\n+3. Mitochondrial Disease: This is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Obesity', 'Death in childhood', 'Death in adolescence'.

\n\n+4. Reye's Syndrome: This is a rare and potentially life-threatening condition that affects the brain and liver. The patient has in common: 'Death in childhood'. The patient does not have in common: 'Obesity', 'Abnormal circulating carnitine concentration', 'Death in adolescence'.

\n\n+5. Other Genetic Disorders: There may be other genetic disorders that could be causing the patient's symptoms, such as fatty acid oxidation disorders or other rare genetic conditions. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Obesity', 'Death in childhood', 'Death in adolescence'.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, hyperphenylalaninemia, and hypertyrosinemia. The patient has in common: Intellectual disability, Hyperphenylalaninemia, Hypertyrosinemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in adolescence.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include intellectual disability, hypertyrosinemia, and liver damage. The patient has in common: Intellectual disability, Hypertyrosinemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in adolescence, Hyperphenylalaninemia.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, hyperphenylalaninemia, and maple syrup-like urine odor. The patient has in common: Intellectual disability, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in adolescence, Hypertyrosinemia.

\n\n+4. Mucopolysaccharidosis: Mucopolysaccharidosis is a group of genetic disorders that affect the breakdown of mucopolysaccharides. Symptoms include intellectual disability, joint pain, and skin problems. The patient has in common: Intellectual disability. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in adolescence, Hyperphenylalaninemia, Hypertyrosinemia.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient has in common: Intellectual disability. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in adolescence, Hyperphenylalaninemia, Hypertyrosinemia.

Note: These are just a few potential diseases that may be related to the symptoms provided. A proper diagnosis would require a comprehensive medical evaluation and testing."
['Smith-Lemli-Opitz syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder caused by a defect in the DHCR7 gene, which is responsible for the production of cholesterol. Symptoms include intellectual disability, microcephaly, and facial dysmorphism. The patient has in common: Microcephaly, Intellectual disability, and Skin rash. The patient does not have in common: Cryptorchidism, Hypospadias, Strabismus, Ptosis, Hypermetropia, obsolete Eczematoid dermatitis, Syndactyly, Lethargy, Motor delay, Generalized hypotonia, Dystonia, Death in infancy, Vomiting, Constipation, Drowsiness, Sleep abnormality, Hypocholesterolemia, Elevated 8-dehydrocholesterol, Neonatal death, Death in childhood, Recurrent viral infections, Elevated circulating 7-dehydrocholesterol concentration, Feeding difficulties, Hypoxemia, Severe hearing impairment.

\n\n+2. CHARGE Syndrome: This is a rare genetic disorder caused by a mutation in the CHD7 gene, which is responsible for the development of the heart, face, and other organs. Symptoms include coloboma, heart defects, and intellectual disability. The patient has in common: Intellectual disability, and Skin rash. The patient does not have in common: Cryptorchidism, Hypospadias, Microcephaly, Low-set ears, Strabismus, Ptosis, Hypermetropia, obsolete Eczematoid dermatitis, Syndactyly, Lethargy, Motor delay, Generalized hypotonia, Dystonia, Death in infancy, Vomiting, Constipation, Drowsiness, Sleep abnormality, Hypocholesterolemia, Elevated 8-dehydrocholesterol, Neonatal death, Death in childhood, Recurrent viral infections, Elevated circulating 7-dehydrocholesterol concentration, Feeding difficulties, Hypoxemia, Severe hearing impairment.

\n\n+3. Mowat-Wilson Syndrome: This is a rare genetic disorder caused by a deletion of the ZBTB20 gene, which is responsible for the development of the brain and other organs. Symptoms include intellectual disability, facial dysmorphism, and seizures. The patient has in common: Intellectual disability, and Skin rash. The patient does not have in common: Cryptorchidism, Hypospadias, Microcephaly, Low-set ears, Strabismus, Ptosis, Hypermetropia, obsolete Eczematoid dermatitis, Syndactyly, Lethargy, Motor delay, Generalized hypotonia, Dystonia, Death in infancy, Vomiting, Constipation, Drowsiness, Sleep abnormality, Hypocholesterolemia, Elevated 8-dehydrocholesterol, Neonatal death, Death in childhood, Recurrent viral infections, Elevated circulating 7-dehydrocholesterol concentration, Feeding difficulties, Hypoxemia, Severe hearing impairment.

\n\n+4. RSH Syndrome: This is a rare genetic disorder caused by a mutation in the RSH gene, which is responsible for the development of the brain and other organs. Symptoms include intellectual disability, facial dysmorphism, and seizures. The patient has in common: Intellectual disability, and Skin rash. The patient does not have in common: Cryptorchidism, Hypospadias, Microcephaly, Low-set ears, Strabismus, Ptosis, Hypermetropia, obsolete Eczematoid dermatitis, Syndactyly, Lethargy, Motor delay, Generalized hypotonia, Dystonia, Death in infancy, Vomiting, Constipation, Drowsiness, Sleep abnormality, Hypocholesterolemia, Elevated 8-dehydrocholesterol, Neonatal death, Death in childhood, Recurrent viral infections, Elevated circulating 7-dehydrocholesterol concentration, Feeding difficulties, Hypoxemia, Severe hearing impairment.

\n\n+5. Smith-Magenis Syndrome: This is a rare genetic disorder caused by a deletion of the RAI1 gene, which is responsible for the development of the brain and other organs. Symptoms include intellectual disability, facial dysmorphism, and sleep disturbances. The patient has in common: Intellectual disability, and Skin rash. The patient does not have in common: Cryptorchidism, Hypospadias, Microcephaly, Low-set ears, Strabismus, Ptosis, Hypermetropia, obsolete Eczematoid dermatitis, Syndactyly, Lethargy, Motor delay, Generalized hypotonia, Dystonia, Death in infancy, Vomiting, Constipation, Drowsiness, Sleep abnormality, Hypocholesterolemia, Elevated 8-dehydrocholesterol, Neonatal death, Death in childhood, Recurrent viral infections, Elevated circulating 7-dehydrocholesterol concentration, Feeding difficulties, Hypoxemia, Severe hearing impairment.

Please note that these are just potential diseases and a definitive diagnosis can only be made after further testing and evaluation."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Molybdenum Cofactor Deficiency Type A: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms of hyporeflexia, generalized hypotonia, and abnormal circulating aspartate family amino acid concentration in common with this disease. The patient does not have symptoms of strabismus, obesity, or death in infancy.

\n\n+2. Molybdenum Cofactor Deficiency Type B: Similar to Type A, this is also a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms of hyporeflexia, generalized hypotonia, and abnormal circulating aspartate family amino acid concentration in common with this disease. The patient does not have symptoms of strabismus, obesity, or death in infancy.

\n\n+3. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms of hyporeflexia, generalized hypotonia, and abnormal circulating aspartate family amino acid concentration in common with this disease. The patient does not have symptoms of strabismus, obesity, or death in infancy.

\n\n+4. Cerebral Palsy: This is a neurological disorder that affects movement, muscle tone, and posture. The patient has symptoms of generalized hypotonia and abnormal circulating aspartate family amino acid concentration in common with this disease. The patient does not have symptoms of strabismus, hyporeflexia, obesity, or death in infancy.

\n\n+5. Prader-Willi Syndrome: This is a rare genetic disorder that affects growth, development, and behavior. The patient has symptoms of obesity in common with this disease. The patient does not have symptoms of strabismus, hyporeflexia, generalized hypotonia, or death in infancy.

\n\n+6. Leigh Syndrome: This is a rare genetic disorder that affects the brain and nervous system. The patient has symptoms of cerebral atrophy and abnormal circulating aspartate family amino acid concentration in common with this disease. The patient does not have symptoms of strabismus, hyporeflexia, generalized hypotonia, obesity, or death in infancy.

\n\n+7. Krabbe Disease: This is a rare genetic disorder that affects the brain and nervous system. The patient has symptoms of cerebral atrophy and abnormal circulating aspartate family amino acid concentration in common with this disease. The patient does not have symptoms of strabismus, hyporeflexia, generalized hypotonia, obesity, or death in infancy.

Note: The patient's symptoms of fever and death in infancy are not specific to any of the proposed diseases, and further testing would be needed to determine the underlying cause of these symptoms."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and skin problems. The patient has in common: Obesity, Pneumonia, Death in infancy, Death in childhood, Death in adolescence, Death in early adulthood. The patient does not have in common: Coarctation of aorta, Fever, Hypertyrosinemia, Hyperphenylalaninemia.

\n\n+2. Congenital Heart Disease: Congenital heart disease refers to heart defects that are present at birth. Symptoms include shortness of breath, fatigue, and swelling in the legs. The patient has in common: Coarctation of aorta, Death in infancy, Death in childhood, Death in adolescence, Death in early adulthood. The patient does not have in common: Obesity, Fever, Pneumonia, Hypertyrosinemia, Hyperphenylalaninemia.

\n\n+3. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and skin problems. The patient has in common: Hypertyrosinemia, Death in infancy, Death in childhood, Death in adolescence, Death in early adulthood. The patient does not have in common: Obesity, Coarctation of aorta, Fever, Pneumonia, Hyperphenylalaninemia.

\n\n+4. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizures, and skin problems. The patient has in common: Hypertyrosinemia, Death in infancy, Death in childhood, Death in adolescence, Death in early adulthood. The patient does not have in common: Obesity, Coarctation of aorta, Fever, Pneumonia, Hyperphenylalaninemia.

\n\n+5. Hyperphenylalaninemia: Hyperphenylalaninemia is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and skin problems. The patient has in common: Hyperphenylalaninemia, Death in infancy, Death in childhood, Death in adolescence, Death in early adulthood. The patient does not have in common: Obesity, Coarctation of aorta, Fever, Pneumonia, Hypertyrosinemia.

Note: The patient's symptoms are quite severe and suggest a genetic disorder. Further testing and evaluation would be necessary to confirm a diagnosis."
['Classic homocystinuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Homocystinuria: Homocystinuria is a rare genetic disorder caused by a deficiency of the enzyme cystathionine beta-synthase. Symptoms include hyperhomocystinemia, hypermethioninemia, and aminoaciduria. The patient has hyperhomocystinemia and aminoaciduria in common with this disease, but does not have hypermethioninemia.

\n\n+2. Methylmalonic acidemia: Methylmalonic acidemia is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include hyperhomocystinemia, hypermethioninemia, and aminoaciduria. The patient has hyperhomocystinemia and aminoaciduria in common with this disease, but does not have hypermethioninemia.

\n\n+3. Maple syrup urine disease: Maple syrup urine disease is a rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex. Symptoms include aminoaciduria and hyperhomocystinemia. The patient has aminoaciduria in common with this disease, but does not have hyperhomocystinemia.

\n\n+4. Phenylketonuria (PKU): Phenylketonuria is a rare genetic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase. Symptoms include aminoaciduria and hyperhomocystinemia. The patient has aminoaciduria in common with this disease, but does not have hyperhomocystinemia.

\n\n+5. Cystinuria: Cystinuria is a rare genetic disorder caused by a defect in the transport of cystine and other amino acids in the kidneys. Symptoms include aminoaciduria and hyperhomocystinemia. The patient has aminoaciduria in common with this disease, but does not have hyperhomocystinemia.

Note that these are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further testing and evaluation."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with each disease and which symptoms they do not have in common:

\n\n+1. Lesch-Nyhan Syndrome: Lesch-Nyhan Syndrome is a rare genetic disorder that affects the body's ability to produce the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Symptoms include ataxia, generalized hypotonia, and abnormal circulating pyrimidine concentration. The patient does not have in common the symptoms of uraciluria and death in childhood, as Lesch-Nyhan Syndrome typically does not present with these symptoms.

\n\n+2. Molybdenum Cofactor Deficiency Type A: Molybdenum Cofactor Deficiency Type A is a rare genetic disorder that affects the body's ability to produce the enzyme sulfite oxidase. Symptoms include ataxia, generalized hypotonia, and abnormal circulating pyrimidine concentration. The patient does not have in common the symptoms of uraciluria and death in childhood, as Molybdenum Cofactor Deficiency Type A typically does not present with these symptoms.

\n\n+3. Molybdenum Cofactor Deficiency Type B: Molybdenum Cofactor Deficiency Type B is a rare genetic disorder that affects the body's ability to produce the enzyme xanthine dehydrogenase. Symptoms include ataxia, generalized hypotonia, and abnormal circulating pyrimidine concentration. The patient does not have in common the symptoms of uraciluria and death in childhood, as Molybdenum Cofactor Deficiency Type B typically does not present with these symptoms.

\n\n+4. Urea Cycle Disorders: Urea cycle disorders are a group of rare genetic disorders that affect the body's ability to produce urea, a waste product that is excreted in the urine. Symptoms include ataxia, generalized hypotonia, and abnormal circulating pyrimidine concentration. The patient has in common the symptoms of uraciluria, as some urea cycle disorders can present with this symptom. However, the patient does not have in common the symptom of death in childhood, as most urea cycle disorders do not typically present with this symptom.

\n\n+5. Pyrimidine Metabolism Disorders: Pyrimidine metabolism disorders are a group of rare genetic disorders that affect the body's ability to produce and break down pyrimidines, which are building blocks of DNA and RNA. Symptoms include ataxia, generalized hypotonia, and abnormal circulating pyrimidine concentration. The patient has in common the symptoms of uraciluria, as some pyrimidine metabolism disorders can present with this symptom. However, the patient does not have in common the symptom of death in childhood, as most pyrimidine metabolism disorders do not typically present with this symptom.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Tyrosinemia Type 1:
Symptoms in common: Hypertyrosinemia
Symptoms not in common: Hyperphenylalaninemia, Death in early adulthood

Tyrosinemia Type 1 is a rare genetic disorder caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. It is characterized by liver damage, liver failure, and an increased risk of liver cancer.

\n\n+2. Phenylketonuria (PKU):
Symptoms in common: Hyperphenylalaninemia
Symptoms not in common: Hypertyrosinemia, Death in early adulthood

PKU is a genetic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase. It is characterized by elevated levels of phenylalanine in the blood, which can lead to intellectual disability, seizures, and behavioral problems.

\n\n+3. Maple Syrup Urine Disease (MSUD):
Symptoms in common: None
Symptoms not in common: Hypertyrosinemia, Hyperphenylalaninemia, Death in early adulthood

MSUD is a rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex. It is characterized by the accumulation of toxic compounds in the blood, which can lead to seizures, developmental delays, and intellectual disability.

\n\n+4. Alkaptonuria:
Symptoms in common: None
Symptoms not in common: Hypertyrosinemia, Hyperphenylalaninemia, Death in early adulthood

Alkaptonuria is a rare genetic disorder caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase. It is characterized by the accumulation of homogentisic acid in the urine, which can lead to dark-colored urine, joint pain, and kidney stones.

\n\n+5. Mucopolysaccharidosis Type VII (Sly Syndrome):
Symptoms in common: None
Symptoms not in common: Hypertyrosinemia, Hyperphenylalaninemia, Death in early adulthood

Mucopolysaccharidosis Type VII is a rare genetic disorder caused by a deficiency of the enzyme beta-glucuronidase. It is characterized by the accumulation of glycosaminoglycans in the body, which can lead to a range of symptoms including joint pain, developmental delays, and intellectual disability.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Pyrimidine Metabolism Disorder: This is a group of rare genetic disorders that affect the body's ability to break down pyrimidines, leading to an accumulation of these compounds in the blood and urine. The patient has symptoms in common with this disease, including Abnormal circulating pyrimidine concentration and Uraciluria. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in this disease.

\n\n+2. DiGeorge Syndrome: This is a rare genetic disorder that affects the development of the immune system and can cause respiratory insufficiency. The patient has symptoms in common with this disease, including Respiratory insufficiency. However, the patient does not have symptoms such as heart defects, facial abnormalities, or immune system deficiencies, which are common in this disease.

\n\n+3. Trisomy 13 (Patau Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 13. It can cause respiratory insufficiency and neonatal death. The patient has symptoms in common with this disease, including Respiratory insufficiency and Neonatal death. However, the patient does not have symptoms such as microcephaly, cleft palate, or intellectual disability, which are common in this disease.

\n\n+4. Pyrimidine Deoxyriboside Deaminase Deficiency: This is a rare genetic disorder that affects the body's ability to break down pyrimidines. It can cause an accumulation of these compounds in the blood and urine. The patient has symptoms in common with this disease, including Abnormal circulating pyrimidine concentration and Uraciluria. However, the patient does not have symptoms such as recurrent infections or skin rashes, which are common in this disease.

\n\n+5. Mitochondrial DNA Depletion Syndrome: This is a rare genetic disorder that affects the mitochondria, the energy-producing structures within cells. It can cause respiratory insufficiency and neonatal death. The patient has symptoms in common with this disease, including Respiratory insufficiency and Neonatal death. However, the patient does not have symptoms such as muscle weakness, seizures, or developmental delays, which are common in this disease.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Tyrosinemia type 1'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Alpha-1 Antitrypsin Deficiency: This is a genetic disorder that affects the production of alpha-1 antitrypsin, a protein that helps protect the lungs and liver. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as respiratory problems or liver disease, which are common in alpha-1 antitrypsin deficiency.

\n\n+2. Biliary Atresia: This is a rare liver disease that occurs in infants and is characterized by the progressive destruction of the bile ducts. Symptoms include jaundice, ascites, and anemia, which the patient has in common. However, the patient does not have symptoms such as dark urine or pale stools, which are common in biliary atresia.

\n\n+3. Congenital Hepatic Fibrosis: This is a rare genetic disorder that affects the development of the liver and is characterized by the formation of scar tissue in the liver. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as jaundice or pale stools, which are common in congenital hepatic fibrosis.

\n\n+4. Galactosemia: This is a rare genetic disorder that affects the metabolism of galactose, a sugar found in milk and other dairy products. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or seizures, which are common in galactosemia.

\n\n+5. Neonatal Alkalosis: This is a rare condition that occurs in newborns and is characterized by an imbalance of electrolytes in the blood. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as muscle weakness or seizures, which are common in neonatal alkalosis.

\n\n+6. Pernicious Anemia: This is a type of anemia caused by a deficiency of vitamin B12, which is essential for the production of red blood cells. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as numbness or tingling in the hands and feet, which are common in pernicious anemia.

\n\n+7. Tyrosinemia: This is a rare genetic disorder that affects the metabolism of tyrosine, an amino acid found in many foods. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as liver disease or kidney stones, which are common in tyrosinemia.

\n\n+8. Wilson's Disease: This is a rare genetic disorder that affects the metabolism of copper, which is essential for the production of red blood cells. Symptoms include anemia, hypoalbuminemia, and hypoproteinemia, which the patient has in common. However, the patient does not have symptoms such as liver disease or kidney stones, which are common in Wilson's disease.

Please note that this is not an exhaustive list, and further testing and evaluation are necessary to confirm a diagnosis."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Canavan Disease: Canavan disease is a rare genetic disorder that affects the brain and spinal cord. It is characterized by a deficiency of the enzyme aspartoacylase, which is necessary for the breakdown of a amino acid called N-acetylaspartate (NAA). Symptoms include seizures, motor delay, and death in infancy. The patient has in common: Seizure, Motor delay, Death in infancy. The patient does not have in common: Abnormal circulating aspartate family amino acid concentration.

\n\n+2. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the body's ability to break down certain amino acids. It is characterized by a deficiency of the enzyme methylmalonyl-CoA mutase, which is necessary for the breakdown of the amino acid methionine. Symptoms include seizures, motor delay, and death in infancy. The patient has in common: Seizure, Motor delay, Death in infancy. The patient does not have in common: Abnormal circulating aspartate family amino acid concentration.

\n\n+3. Phenylketonuria (PKU): Phenylketonuria is a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine. It is characterized by a deficiency of the enzyme phenylalanine hydroxylase, which is necessary for the breakdown of phenylalanine. Symptoms include seizures, motor delay, and death in infancy. The patient has in common: Seizure, Motor delay, Death in infancy. The patient does not have in common: Abnormal circulating aspartate family amino acid concentration.

\n\n+4. Glutaric Acidemia Type I: Glutaric acidemia type I is a rare genetic disorder that affects the body's ability to break down certain amino acids. It is characterized by a deficiency of the enzyme glutaryl-CoA dehydrogenase, which is necessary for the breakdown of the amino acid lysine. Symptoms include seizures, motor delay, and death in infancy. The patient has in common: Seizure, Motor delay, Death in infancy. The patient does not have in common: Abnormal circulating aspartate family amino acid concentration.

\n\n+5. Organic Acidemia: Organic acidemia is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. It is characterized by a deficiency of one or more enzymes necessary for the breakdown of amino acids. Symptoms include seizures, motor delay, and death in infancy. The patient has in common: Seizure, Motor delay, Death in infancy. The patient does not have in common: Abnormal circulating aspartate family amino acid concentration.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Isovaleric acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids, leading to a buildup of toxic compounds in the body. The patient has symptoms in common with MSUD, such as vomiting, diarrhea, and abdominal pain. However, MSUD is typically diagnosed in infancy or early childhood, and the patient's symptoms do not include death in infancy or neonatal death.

\n\n+2. Carnitine Deficiency: Carnitine deficiency is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. The patient has symptoms in common with carnitine deficiency, such as vomiting, diarrhea, and abdominal pain. However, carnitine deficiency typically does not cause death in infancy or childhood.

\n\n+3. Glycine Encephalopathy: Glycine encephalopathy is a rare genetic disorder that affects the body's ability to break down glycine, an amino acid. The patient has symptoms in common with glycine encephalopathy, such as vomiting, diarrhea, and abdominal pain. However, glycine encephalopathy typically does not cause death in infancy or childhood.

\n\n+4. Reye's Syndrome: Reye's syndrome is a rare and potentially life-threatening condition that affects the brain and liver. The patient has symptoms in common with Reye's syndrome, such as vomiting, diarrhea, and abdominal pain. However, Reye's syndrome is typically caused by a viral infection and is not associated with death in infancy or childhood.

\n\n+5. Inborn Errors of Metabolism: Inborn errors of metabolism are a group of rare genetic disorders that affect the body's ability to break down certain nutrients. The patient has symptoms in common with inborn errors of metabolism, such as vomiting, diarrhea, and abdominal pain. However, the specific symptoms and severity of inborn errors of metabolism can vary widely.

\n\n+6. Gastrointestinal Infection: Gastrointestinal infection is a common condition that can cause symptoms such as vomiting, diarrhea, and abdominal pain. The patient has symptoms in common with gastrointestinal infection, but the presence of death in infancy, childhood, and adolescence suggests a more underlying condition.

\n\n+7. Genetic Disorder: Genetic disorder is a broad term that encompasses a wide range of rare genetic conditions that can affect various parts of the body. The patient has symptoms in common with genetic disorders, such as vomiting, diarrhea, and abdominal pain. However, the specific symptoms and severity of genetic disorders can vary widely.

Note: This is not an exhaustive list, and further testing and evaluation are necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, obesity, and elevated levels of phenylalanine in the blood. The patient has in common: Intellectual disability, Obesity. The patient does not have in common: Hypertension, Death in adolescence, Death in early adulthood.

\n\n+2. Tyrosinemia type I: Tyrosinemia type I is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include intellectual disability, liver disease, and elevated levels of tyrosine in the blood. The patient has in common: Intellectual disability, Elevated urinary carboxylic acid. The patient does not have in common: Hypertension, Obesity, Death in adolescence, Death in early adulthood.

\n\n+3. Hyperphenylalaninemia: Hyperphenylalaninemia is a condition where there is an excessive amount of phenylalanine in the blood. Symptoms include intellectual disability, obesity, and elevated levels of phenylalanine in the blood. The patient has in common: Intellectual disability, Obesity, Hyperphenylalaninemia. The patient does not have in common: Hypertension, Death in adolescence, Death in early adulthood.

\n\n+4. Hypertyrosinemia: Hypertyrosinemia is a condition where there is an excessive amount of tyrosine in the blood. Symptoms include intellectual disability, liver disease, and elevated levels of tyrosine in the blood. The patient has in common: Intellectual disability, Elevated urinary carboxylic acid. The patient does not have in common: Hypertension, Obesity, Death in adolescence, Death in early adulthood.

\n\n+5. Prader-Willi syndrome: Prader-Willi syndrome is a genetic disorder that affects the hypothalamus and causes obesity, intellectual disability, and short stature. Symptoms include intellectual disability, obesity, and short stature. The patient has in common: Intellectual disability, Obesity. The patient does not have in common: Hypertension, Hypertyrosinemia, Hyperphenylalaninemia, Death in adolescence, Death in early adulthood.

Note: The patient's symptoms do not match exactly with any of the proposed diseases, but some symptoms are common among them. Further testing and evaluation are needed to determine the exact diagnosis."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Zellweger Syndrome: Zellweger syndrome is a rare genetic disorder that affects the development of the brain and other organs. It is characterized by abnormal development of the brain, liver, and kidneys, and can cause death in infancy or early childhood.

Common symptoms: Abnormality of prenatal development or birth, Death in infancy, Death in childhood
Not common symptoms: Small for gestational age, Hyperalaninemia, Neonatal death, Severe hearing impairment

\n\n+2. Carnitine Deficiency: Carnitine deficiency is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. It can cause muscle weakness, fatigue, and heart problems.

Common symptoms: Abnormal circulating carnitine concentration
Not common symptoms: Abnormality of prenatal development or birth, Small for gestational age, Death in infancy, Death in childhood, Hyperalaninemia, Neonatal death, Severe hearing impairment

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the body's ability to break down certain amino acids. It can cause vomiting, diarrhea, and lethargy.

Common symptoms: Hyperalaninemia
Not common symptoms: Abnormality of prenatal development or birth, Small for gestational age, Death in infancy, Death in childhood, Abnormal circulating carnitine concentration, Neonatal death, Severe hearing impairment

\n\n+4. Nonketotic Hyperglycinemia: Nonketotic hyperglycinemia is a rare genetic disorder that affects the body's ability to break down the amino acid glycine. It can cause seizures, developmental delay, and muscle weakness.

Common symptoms: None
Not common symptoms: Abnormality of prenatal development or birth, Small for gestational age, Death in infancy, Death in childhood, Abnormal circulating carnitine concentration, Hyperalaninemia, Neonatal death, Severe hearing impairment

\n\n+5. Multiple Carboxylase Deficiency: Multiple carboxylase deficiency is a rare genetic disorder that affects the body's ability to break down certain amino acids. It can cause vomiting, diarrhea, and seizures.

Common symptoms: Hyperalaninemia
Not common symptoms: Abnormality of prenatal development or birth, Small for gestational age, Death in infancy, Death in childhood, Abnormal circulating carnitine concentration, Neonatal death, Severe hearing impairment

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Ornithine Transcarbamylase (OTC) Deficiency:
The patient has Oroticaciduria and Abnormal circulating ornithine concentration in common with this disease. The patient does not have in common Lethargy, Drowsiness, and Sleep abnormality, as OTC deficiency typically presents with severe hyperammonemia and vomiting, not lethargy or sleep disturbances.

\n\n+2. Hyperornithinemia-Hyperammonemia Syndrome:
The patient has Oroticaciduria and Abnormal circulating ornithine concentration in common with this disease. The patient does not have in common Lethargy, Drowsiness, and Sleep abnormality, as this syndrome typically presents with hyperammonemia, vomiting, and lethargy in infancy, but not in adulthood.

\n\n+3. Molybdenum Cofactor Deficiency:
The patient has Oroticaciduria in common with this disease. The patient does not have in common Lethargy, Drowsiness, and Sleep abnormality, as Molybdenum Cofactor Deficiency typically presents with seizures, developmental delay, and intellectual disability, but not lethargy or sleep disturbances.

\n\n+4. Argininosuccinic Aciduria:
The patient does not have any symptoms in common with this disease, as Argininosuccinic Aciduria typically presents with a range of symptoms including intellectual disability, seizures, and skin problems, but not Oroticaciduria or Abnormal circulating ornithine concentration.

\n\n+5. Citrullinemia Type I:
The patient does not have any symptoms in common with this disease, as Citrullinemia Type I typically presents with a range of symptoms including intellectual disability, seizures, and vomiting, but not Oroticaciduria or Abnormal circulating ornithine concentration.

Note: These are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of Ataxia, Dystonia, and Decreased plasma free carnitine in common with this disease. Glutaric Acidemia Type 1 is a rare genetic disorder caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase, leading to the accumulation of toxic compounds in the body. The patient does not have symptoms of Abnormal cerebral morphology, Abnormal myelination, or Death in childhood in common with this disease.

\n\n+2. Methylmalonic Acidemia:
The patient has symptoms of Ataxia, Dystonia, and Decreased plasma free carnitine in common with this disease. Methylmalonic Acidemia is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase, leading to the accumulation of toxic compounds in the body. The patient does not have symptoms of Abnormal cerebral morphology, Abnormal myelination, or Death in childhood in common with this disease.

\n\n+3. Carnitine Deficiency Disorders:
The patient has symptoms of Ataxia, Dystonia, and Decreased plasma free carnitine in common with this disease. Carnitine Deficiency Disorders are a group of rare genetic disorders caused by a deficiency of the enzyme carnitine palmitoyltransferase, leading to the accumulation of toxic compounds in the body. The patient does not have symptoms of Abnormal cerebral morphology, Abnormal myelination, or Death in childhood in common with this disease.

\n\n+4. Leukodystrophy:
The patient has symptoms of Abnormal myelination in common with this disease. Leukodystrophy is a group of rare genetic disorders caused by a deficiency of the enzyme myelin basic protein, leading to the degeneration of the myelin sheath in the central nervous system. The patient does not have symptoms of Ataxia, Dystonia, Decreased plasma free carnitine, Abnormal cerebral morphology, or Death in childhood in common with this disease.

\n\n+5. Glutaric Aciduria Type 2:
The patient has symptoms of Ataxia, Dystonia, and Decreased plasma free carnitine in common with this disease. Glutaric Aciduria Type 2 is a rare genetic disorder caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase, leading to the accumulation of toxic compounds in the body. The patient does not have symptoms of Abnormal cerebral morphology, Abnormal myelination, or Death in childhood in common with this disease.

Note: The patient's symptoms are consistent with several potential diseases, and further testing and evaluation would be necessary to confirm a specific diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has symptoms in common with PKU, such as hyperphenylalaninemia, but does not have symptoms of intellectual disability or seizures.

\n\n+2. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has symptoms in common with MSUD, such as hyperphenylalaninemia, but does not have symptoms of intellectual disability or seizures.

\n\n+3. Tyrosinemia Type I: Tyrosinemia Type I is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and a high risk of liver cancer. The patient has symptoms in common with Tyrosinemia Type I, such as hyperphenylalaninemia, but does not have symptoms of liver disease or kidney disease.

\n\n+4. Mucopolysaccharidosis Type VII: Mucopolysaccharidosis Type VII is a rare genetic disorder that affects the breakdown of certain sugars. Symptoms include intellectual disability, joint pain, and a characteristic ""dwarfism"" appearance. The patient has symptoms in common with Mucopolysaccharidosis Type VII, such as hyperphenylalaninemia, but does not have symptoms of intellectual disability or joint pain.

\n\n+5. Congenital Hypothyroidism: Congenital Hypothyroidism is a rare genetic disorder that affects the development of the thyroid gland. Symptoms include intellectual disability, short stature, and a high risk of developmental delays. The patient has symptoms in common with Congenital Hypothyroidism, such as hyperphenylalaninemia, but does not have symptoms of intellectual disability or short stature.

Please note that this is not an exhaustive list and a more detailed evaluation and testing would be necessary to confirm a diagnosis."
['Systemic primary carnitine deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Acute Hepatic Porphyria: This is a rare genetic disorder that affects the production of heme, a vital component of hemoglobin. Symptoms include abdominal pain, vomiting, and neurological symptoms such as seizures and coma. The patient has symptoms in common with this disease: vomiting, encephalopathy, and elevated circulating hepatic transaminase concentration. The patient does not have symptoms in common with this disease: irritability, cardiomyopathy, anemia, hypoglycemia, hepatomegaly, death in childhood, decreased plasma free carnitine, abnormal circulating porphyrin concentration, abnormal circulating aspartate family amino acid concentration, and abnormal circulating alanine concentration.

\n\n+2. Reye's Syndrome: This is a rare and potentially life-threatening condition that affects the brain and liver. Symptoms include vomiting, lethargy, and seizures. The patient has symptoms in common with this disease: vomiting, encephalopathy, and elevated circulating hepatic transaminase concentration. The patient does not have symptoms in common with this disease: irritability, coma, generalized hypotonia, cardiomyopathy, anemia, hypoglycemia, hepatomegaly, death in childhood, decreased plasma free carnitine, abnormal circulating porphyrin concentration, abnormal circulating aspartate family amino acid concentration, and abnormal circulating alanine concentration.

\n\n+3. Carnitine Deficiency: This is a rare genetic disorder that affects the body's ability to use fat for energy. Symptoms include muscle weakness, fatigue, and seizures. The patient has symptoms in common with this disease: generalized hypotonia, decreased plasma free carnitine. The patient does not have symptoms in common with this disease: irritability, coma, encephalopathy, cardiomyopathy, anemia, hypoglycemia, vomiting, hepatomegaly, elevated circulating hepatic transaminase concentration, death in childhood, abnormal circulating porphyrin concentration, abnormal circulating aspartate family amino acid concentration, and abnormal circulating alanine concentration.

\n\n+4. Mitochondrial Myopathy: This is a rare genetic disorder that affects the mitochondria, the energy-producing structures within cells. Symptoms include muscle weakness, fatigue, and seizures. The patient has symptoms in common with this disease: generalized hypotonia, abnormal circulating aspartate family amino acid concentration. The patient does not have symptoms in common with this disease: irritability, coma, encephalopathy, cardiomyopathy, anemia, hypoglycemia, vomiting, hepatomegaly, elevated circulating hepatic transaminase concentration, death in childhood, decreased plasma free carnitine, abnormal circulating porphyrin concentration, and abnormal circulating alanine concentration.

\n\n+5. Inborn Errors of Metabolism: This is a broad term that refers to a group of rare genetic disorders that affect the body's ability to break down and use certain nutrients. Symptoms can vary widely depending on the specific disorder, but may include vomiting, seizures, and coma. The patient has symptoms in common with this disease: vomiting, encephalopathy, elevated circulating hepatic transaminase concentration. The patient does not have symptoms in common with this disease: irritability, cardiomyopathy, anemia, hypoglycemia, hepatomegaly, death in childhood, decreased plasma free carnitine, abnormal circulating porphyrin concentration, abnormal circulating aspartate family amino acid concentration, and abnormal circulating alanine concentration.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Friedreich's Ataxia: Friedreich's Ataxia is a rare genetic disorder that affects the nervous system, causing progressive damage to the cerebellum and spinal cord. The patient has symptoms in common with Friedreich's Ataxia, such as Ataxia, Hyporeflexia, and Cerebellar atrophy. The patient does not have symptoms in common with Friedreich's Ataxia, such as vision loss, hearing loss, and heart problems.

\n\n+2. Cerebellar Hypoplasia: Cerebellar Hypoplasia is a condition where the cerebellum is underdeveloped or malformed, leading to coordination and balance problems. The patient has symptoms in common with Cerebellar Hypoplasia, such as Ataxia, Hyporeflexia, and Cerebellar atrophy. The patient does not have symptoms in common with Cerebellar Hypoplasia, such as normal cognitive function and no vision or hearing loss.

\n\n+3. Spinocerebellar Ataxia: Spinocerebellar Ataxia is a group of genetic disorders that affect the cerebellum and spinal cord, causing progressive damage and coordination problems. The patient has symptoms in common with Spinocerebellar Ataxia, such as Ataxia, Hyporeflexia, and Cerebellar atrophy. The patient does not have symptoms in common with Spinocerebellar Ataxia, such as vision loss, hearing loss, and heart problems.

\n\n+4. Cerebral Palsy: Cerebral Palsy is a neurological disorder that affects movement, muscle tone, and coordination. The patient does not have symptoms in common with Cerebral Palsy, such as normal cognitive function and no vision or hearing loss.

\n\n+5. Meningitis: Meningitis is an infection of the membranes surrounding the brain and spinal cord, which can cause inflammation and damage to the nervous system. The patient does not have symptoms in common with Meningitis, such as fever, headache, and stiff neck.

\n\n+6. Encephalitis: Encephalitis is an infection of the brain, which can cause inflammation and damage to the nervous system. The patient does not have symptoms in common with Encephalitis, such as fever, headache, and altered mental status.

\n\n+7. Cerebral Atrophy: Cerebral Atrophy is a condition where the brain shrinks and loses function, which can cause cognitive and motor problems. The patient has symptoms in common with Cerebral Atrophy, such as Ataxia, Hyporeflexia, and Cerebellar atrophy. The patient does not have symptoms in common with Cerebral Atrophy, such as normal cognitive function and no vision or hearing loss.

\n\n+8. Rett Syndrome: Rett Syndrome is a rare genetic disorder that affects brain development and function, causing intellectual disability, seizures, and motor problems. The patient does not have symptoms in common with Rett Syndrome, such as intellectual disability and seizures.

\n\n+9. Leigh Syndrome: Leigh Syndrome is a rare genetic disorder that affects the brain and spinal cord, causing progressive damage and coordination problems. The patient has symptoms in common with Leigh Syndrome, such as Ataxia, Hyporeflexia, and Cerebellar atrophy. The patient does not have symptoms in common with Leigh Syndrome, such as vision loss, hearing loss, and heart problems.

\n\n+10. Mucopolysaccharidosis: Mucopolysaccharidosis is a group of genetic disorders that affect the body's ability to break down and recycle sugars, leading to storage of abnormal amounts of sugar molecules in cells. The patient does not have symptoms in common with Mucopolysaccharidosis, such as joint pain, skin thickening, and intellectual disability.

Note: This is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Classic homocystinuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with each disease and which symptoms they do not have in common:

\n\n+1. Marfan Syndrome: Marfan syndrome is a genetic disorder that affects the body's connective tissue. It can cause a range of symptoms, including ectopia lentis, intellectual disability, and delayed speech and language development. The patient has ectopia lentis and delayed speech and language development in common with this disease, but does not have intellectual disability. The patient's death in infancy or childhood is not typical of Marfan syndrome, which often has a later onset.

\n\n+2. Homocystinuria: Homocystinuria is a genetic disorder that affects the metabolism of amino acids. It can cause symptoms such as hyperhomocystinemia, hypermethioninemia, and aminoaciduria. The patient has hyperhomocystinemia and aminoaciduria in common with this disease, but does not have ectopia lentis or delayed speech and language development. The patient's death in infancy or childhood is consistent with severe cases of homocystinuria.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a genetic disorder that affects the metabolism of amino acids. It can cause symptoms such as hyperhomocystinemia, hypermethioninemia, and aminoaciduria. The patient has hyperhomocystinemia and aminoaciduria in common with this disease, but does not have ectopia lentis or delayed speech and language development. The patient's death in infancy or childhood is consistent with severe cases of methylmalonic acidemia.

\n\n+4. Smith-Lemli-Opitz Syndrome: Smith-Lemli-Opitz syndrome is a genetic disorder that affects the metabolism of cholesterol. It can cause symptoms such as intellectual disability, delayed speech and language development, and dyskinesia. The patient has delayed speech and language development and intellectual disability in common with this disease, but does not have ectopia lentis or hyperhomocystinemia. The patient's death in infancy or childhood is consistent with severe cases of Smith-Lemli-Opitz syndrome.

\n\n+5. Aminoaciduria: Aminoaciduria is a condition characterized by the excretion of amino acids in the urine. It can cause symptoms such as hyperhomocystinemia, hypermethioninemia, and aminoaciduria. The patient has aminoaciduria in common with this disease, but does not have ectopia lentis or delayed speech and language development. The patient's death in infancy or childhood is not typical of aminoaciduria, which often has a later onset.

Note: The patient's symptoms are quite severe and may indicate a rare or genetic disorder. Further testing and evaluation would be necessary to confirm a diagnosis."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, ataxia, lethargy, hyperreflexia, metabolic acidosis, and hyperammonemia. The patient has in common: seizures, ataxia, lethargy, hyperreflexia, metabolic acidosis, and hyperammonemia. The patient does not have in common: diarrhea, fever, drowsiness, sleep abnormality, fasciculations, oroticaciduria, death in childhood or adolescence.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include seizures, ataxia, lethargy, hyperreflexia, metabolic acidosis, and hyperammonemia. The patient has in common: seizures, ataxia, lethargy, hyperreflexia, metabolic acidosis, and hyperammonemia. The patient does not have in common: diarrhea, fever, drowsiness, sleep abnormality, fasciculations, oroticaciduria, death in childhood or adolescence.

\n\n+3. Urea cycle disorders: These are a group of rare genetic disorders that affect the body's ability to break down protein and produce urea. Symptoms include seizures, ataxia, lethargy, hyperreflexia, metabolic acidosis, and hyperammonemia. The patient has in common: seizures, ataxia, lethargy, hyperreflexia, metabolic acidosis, and hyperammonemia. The patient does not have in common: diarrhea, fever, drowsiness, sleep abnormality, fasciculations, oroticaciduria, death in childhood or adolescence.

\n\n+4. Menkes disease: This is a rare genetic disorder that affects the body's ability to produce copper. Symptoms include seizures, ataxia, lethargy, hyperreflexia, and metabolic acidosis. The patient has in common: seizures, ataxia, lethargy, and hyperreflexia. The patient does not have in common: metabolic acidosis, hyperammonemia, diarrhea, fever, drowsiness, sleep abnormality, fasciculations, oroticaciduria, death in childhood or adolescence.

\n\n+5. Leigh syndrome: This is a rare genetic disorder that affects the brain and spinal cord. Symptoms include seizures, ataxia, lethargy, and sleep abnormality. The patient has in common: seizures, ataxia, and lethargy. The patient does not have in common: hyperreflexia, metabolic acidosis, hyperammonemia, diarrhea, fever, drowsiness, fasciculations, oroticaciduria, death in childhood or adolescence.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Smith-Lemli-Opitz syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder caused by a defect in the cholesterol biosynthesis pathway. Symptoms include microcephaly, intellectual disability, and facial dysmorphism, which the patient has in common. The patient also has strabismus, ptosis, and syndactyly, which are common symptoms of this disorder. However, the patient does not have the typical skin and skeletal abnormalities associated with this condition.

\n\n+2. Prader-Willi Syndrome: This is a genetic disorder caused by a deletion or mutation in the Prader-Willi syndrome critical region. Symptoms include short stature, obesity, and intellectual disability, which the patient does not have. However, the patient has hyperactivity, which is a common symptom of this disorder. The patient also has feeding difficulties, which are often seen in Prader-Willi syndrome.

\n\n+3. Rett Syndrome: This is a genetic disorder caused by a mutation in the MECP2 gene. Symptoms include intellectual disability, ataxia, and generalized hypotonia, which the patient has in common. The patient also has hyperreflexia, which is a common symptom of this disorder. However, the patient does not have the typical hand wringing and loss of purposeful hand movements associated with Rett syndrome.

\n\n+4. Mucolipidosis IV: This is a rare genetic disorder caused by a defect in the gene that codes for the enzyme glucocerebrosidase. Symptoms include intellectual disability, ataxia, and generalized hypotonia, which the patient has in common. The patient also has hyperreflexia, which is a common symptom of this disorder. However, the patient does not have the typical storage of lipids in the cells and tissues associated with this condition.

\n\n+5. Aicardi-Goutières Syndrome: This is a rare genetic disorder caused by a defect in the gene that codes for the enzyme adenosine deaminase. Symptoms include intellectual disability, ataxia, and generalized hypotonia, which the patient has in common. The patient also has hyperreflexia, which is a common symptom of this disorder. However, the patient does not have the typical white matter abnormalities in the brain associated with this condition.

\n\n+6. Zellweger Syndrome: This is a rare genetic disorder caused by a defect in the gene that codes for the enzyme peroxisomal biogenesis factor 1. Symptoms include intellectual disability, ataxia, and generalized hypotonia, which the patient has in common. The patient also has hyperreflexia, which is a common symptom of this disorder. However, the patient does not have the typical facial dysmorphism and skeletal abnormalities associated with this condition.

Please note that these are just potential diseases and a definitive diagnosis can only be made after further testing and evaluation."
['Glycogen storage disease due to glycogen debranching enzyme deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Mitochondrial Myopathy: Mitochondrial myopathies are a group of disorders caused by mutations in mitochondrial DNA or nuclear DNA that affect the function of mitochondria, leading to muscle weakness and fatigue. The patient has symptoms in common with this disease, such as generalized hypotonia, increased circulating lactate concentration, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as muscle weakness or fatigue.

\n\n+2. Carnitine Deficiency: Carnitine deficiency is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. The patient has symptoms in common with this disease, such as increased circulating lactate concentration, hypertriglyceridemia, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as muscle weakness or seizures.

\n\n+3. Glycogen Storage Disease: Glycogen storage diseases are a group of disorders caused by mutations in enzymes involved in glycogen metabolism, leading to accumulation of glycogen in tissues. The patient has symptoms in common with this disease, such as hepatomegaly and increased circulating lactate concentration. However, the patient does not have symptoms such as muscle weakness or hypoglycemia.

\n\n+4. Lactic Acidosis: Lactic acidosis is a condition characterized by an accumulation of lactic acid in the blood, often caused by a defect in the mitochondria or a lack of oxygen. The patient has symptoms in common with this disease, such as increased circulating lactate concentration and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as nausea or vomiting.

\n\n+5. Congenital Lactic Acidosis: Congenital lactic acidosis is a rare genetic disorder caused by a defect in the mitochondrial DNA, leading to an accumulation of lactic acid in the blood. The patient has symptoms in common with this disease, such as increased circulating lactate concentration, abnormal circulating aspartate family amino acid concentration, and neonatal death. However, the patient does not have symptoms such as seizures or developmental delay.

\n\n+6. Pyruvate Dehydrogenase Deficiency: Pyruvate dehydrogenase deficiency is a rare genetic disorder caused by a defect in the enzyme pyruvate dehydrogenase, leading to an accumulation of pyruvate in the blood. The patient has symptoms in common with this disease, such as increased circulating lactate concentration, abnormal circulating aspartate family amino acid concentration, and abnormal circulating alanine concentration. However, the patient does not have symptoms such as muscle weakness or developmental delay.

Note: This is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of Glutaric Acidemia Type 1, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of neonatal death, death in infancy, or death in adolescence, which are common in this disease.

\n\n+2. Carnitine Deficiency Disorders:
The patient has symptoms of Carnitine Deficiency Disorders, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+3. Mitochondrial Disorders:
The patient has symptoms of Mitochondrial Disorders, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+4. Organic Acidemias:
The patient has symptoms of Organic Acidemias, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+5. Methylmalonic Acidemia:
The patient has symptoms of Methylmalonic Acidemia, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+6. Multiple Carboxylase Deficiency:
The patient has symptoms of Multiple Carboxylase Deficiency, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+7. Propionic Acidemia:
The patient has symptoms of Propionic Acidemia, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+8. Isovaleric Acidemia:
The patient has symptoms of Isovaleric Acidemia, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+9. 3-Hydroxyacyl-CoA Dehydrogenase Deficiency:
The patient has symptoms of 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

\n\n+10. Medium-Chain Acyl-CoA Dehydrogenase Deficiency:
The patient has symptoms of Medium-Chain Acyl-CoA Dehydrogenase Deficiency, including decreased plasma free carnitine and abnormal circulating acylcarnitine concentration. The patient does not have symptoms of microcephaly, generalized hypotonia, cerebral cortical atrophy, athetosis, or glutaric aciduria.

Please note that this is not an exhaustive list, and further testing and evaluation are necessary to confirm a diagnosis."
['Propionic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include hyperammonemia, hyperglycinemia, and hyperglycinuria. The patient has hyperammonemia, hyperglycinemia, and hyperglycinuria in common with MSUD. The patient does not have elevated blood sugar levels, which is a characteristic of MSUD.

\n\n+2. Propionic Acidemia: Propionic acidemia is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid. The patient has hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid in common with propionic acidemia. The patient does not have vomiting, which is a common symptom of propionic acidemia.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid. The patient has hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid in common with methylmalonic acidemia. The patient does not have ichthyosis, which is a characteristic of some cases of methylmalonic acidemia.

\n\n+4. Glutaryl-CoA Dehydrogenase Deficiency: Glutaryl-CoA dehydrogenase deficiency is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid. The patient has hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid in common with glutaryl-CoA dehydrogenase deficiency. The patient does not have abnormal circulating glutamine concentration, which is a characteristic of glutaryl-CoA dehydrogenase deficiency.

\n\n+5. Carnitine-Deficient Disorders: Carnitine-deficient disorders are a group of rare genetic disorders that affect the breakdown of fatty acids. Symptoms include hyperammonemia, hyperglycinemia, and abnormal circulating carnitine concentration. The patient has hyperammonemia and hyperglycinemia in common with carnitine-deficient disorders. The patient does not have elevated urinary carboxylic acid, which is not typically seen in carnitine-deficient disorders.

Note: The patient's symptoms are consistent with a number of rare genetic disorders that affect the breakdown of amino acids. Further testing and evaluation would be necessary to confirm a specific diagnosis."
['Succinic semialdehyde dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Zellweger Syndrome: Zellweger syndrome is a rare genetic disorder caused by mutations in the PEX1, PEX2, or PEX6 genes. It is characterized by intellectual disability, motor delay, and abnormal facial shape. The patient has symptoms in common with Zellweger syndrome, including intellectual disability, motor delay, and abnormal facial shape. However, the patient does not have symptoms of liver dysfunction, which is a common feature of Zellweger syndrome.

\n\n+2. Methylmalonic acidemia: Methylmalonic acidemia is a rare genetic disorder caused by mutations in the MUT gene. It is characterized by intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. The patient has symptoms in common with Methylmalonic acidemia, including intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. However, the patient does not have symptoms of vomiting, diarrhea, or abdominal pain, which are common features of Methylmalonic acidemia.

\n\n+3. Glutaric acidemia type I: Glutaric acidemia type I is a rare genetic disorder caused by mutations in the GCDH gene. It is characterized by intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. The patient has symptoms in common with Glutaric acidemia type I, including intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. However, the patient does not have symptoms of seizures, which are common features of Glutaric acidemia type I.

\n\n+4. Carnitine-acylcarnitine translocase deficiency: Carnitine-acylcarnitine translocase deficiency is a rare genetic disorder caused by mutations in the SLC25A20 gene. It is characterized by intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. The patient has symptoms in common with Carnitine-acylcarnitine translocase deficiency, including intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. However, the patient does not have symptoms of muscle weakness or fatigue, which are common features of Carnitine-acylcarnitine translocase deficiency.

\n\n+5. 3-Methylglutaconic aciduria: 3-Methylglutaconic aciduria is a rare genetic disorder caused by mutations in the AUH gene. It is characterized by intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. The patient has symptoms in common with 3-Methylglutaconic aciduria, including intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. However, the patient does not have symptoms of seizures or developmental regression, which are common features of 3-Methylglutaconic aciduria.

\n\n+6. Mitochondrial disorders: Mitochondrial disorders are a group of rare genetic disorders caused by mutations in mitochondrial DNA or nuclear DNA. They are characterized by intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. The patient has symptoms in common with mitochondrial disorders, including intellectual disability, motor delay, and abnormal circulating monocarboxylic acid concentration. However, the patient does not have symptoms of muscle weakness or fatigue, which are common features of some mitochondrial disorders.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and laboratory tests."
['Classic galactosemia'],"Based on the symptoms provided, here are some potential diseases that the patient may have:

\n\n+1. Galactosemia: The patient has symptoms of delayed speech and language development, intellectual disability, and motor delay, which are common in galactosemia. The patient also has symptoms of diarrhea, increased total bilirubin, and prolonged partial thromboplastin time, which are also associated with galactosemia. However, the patient does not have symptoms of premature birth, neonatal death, or death in childhood, which are not typical of galactosemia.

\n\n+2. Congenital Disorders of Glycosylation: The patient has symptoms of delayed speech and language development, intellectual disability, and motor delay, which are common in congenital disorders of glycosylation. The patient also has symptoms of diarrhea, increased total bilirubin, and prolonged partial thromboplastin time, which are also associated with congenital disorders of glycosylation. However, the patient does not have symptoms of premature birth, neonatal death, or death in childhood, which are not typical of congenital disorders of glycosylation.

\n\n+3. Mitochondrial Disorders: The patient has symptoms of delayed speech and language development, intellectual disability, and motor delay, which are common in mitochondrial disorders. The patient also has symptoms of diarrhea, increased total bilirubin, and prolonged partial thromboplastin time, which are also associated with mitochondrial disorders. However, the patient does not have symptoms of premature birth, neonatal death, or death in childhood, which are not typical of mitochondrial disorders.

\n\n+4. Inborn Errors of Metabolism: The patient has symptoms of delayed speech and language development, intellectual disability, and motor delay, which are common in inborn errors of metabolism. The patient also has symptoms of diarrhea, increased total bilirubin, and prolonged partial thromboplastin time, which are also associated with inborn errors of metabolism. However, the patient does not have symptoms of premature birth, neonatal death, or death in childhood, which are not typical of inborn errors of metabolism.

\n\n+5. Other Genetic Disorders: The patient has symptoms of delayed speech and language development, intellectual disability, and motor delay, which are common in other genetic disorders. The patient also has symptoms of diarrhea, increased total bilirubin, and prolonged partial thromboplastin time, which are also associated with other genetic disorders. However, the patient does not have symptoms of premature birth, neonatal death, or death in childhood, which are not typical of other genetic disorders.

Note: These are just potential diseases that the patient may have based on the symptoms provided. A definitive diagnosis would require further testing and evaluation."
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Citrullinemia: Citrullinemia is a rare genetic disorder that affects the metabolism of the amino acid citrulline. Symptoms include hyperammonemia, aminoaciduria, and elevated plasma citrulline. The patient has hyperammonemia and elevated plasma citrulline in common with this disease, but does not have abnormality of prenatal development or birth, death in infancy, neonatal death, or death in childhood.

\n\n+2. Argininosuccinic Aciduria: Argininosuccinic aciduria is a rare genetic disorder that affects the metabolism of the amino acid arginine. Symptoms include hyperammonemia, aminoaciduria, and elevated levels of argininosuccinic acid in the urine. The patient has hyperammonemia and aminoaciduria in common with this disease, but does not have abnormal circulating proline concentration.

\n\n+3. Proline-Deficient Osteogenesis Imperfecta: Proline-deficient osteogenesis imperfecta is a rare genetic disorder that affects the production of collagen, a protein that gives structure to bones and connective tissue. Symptoms include abnormal circulating proline concentration, bone fragility, and blue sclerae. The patient has abnormal circulating proline concentration in common with this disease, but does not have hyperammonemia, aminoaciduria, or elevated plasma citrulline.

\n\n+4. Maple Syrup Urine Disease: Maple syrup urine disease is a rare genetic disorder that affects the metabolism of the amino acid branched-chain alpha-keto acids. Symptoms include hyperammonemia, aminoaciduria, and a sweet, maple syrup-like odor to the urine. The patient has hyperammonemia and aminoaciduria in common with this disease, but does not have abnormal circulating proline concentration or elevated plasma citrulline.

\n\n+5. Hyperammonemia due to Ornithine Transcarbamylase Deficiency: Hyperammonemia due to ornithine transcarbamylase deficiency is a rare genetic disorder that affects the metabolism of the amino acid ornithine. Symptoms include hyperammonemia, aminoaciduria, and elevated levels of ammonia in the blood. The patient has hyperammonemia and aminoaciduria in common with this disease, but does not have abnormal circulating proline concentration or elevated plasma citrulline.

Note that these are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with each disease and which symptoms they do not have in common:

\n\n+1. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver damage, kidney damage, and an increased risk of liver cancer. The patient has in common: Hypertyrosinemia, Abnormal circulating porphyrin concentration. The patient does not have in common: Death in infancy, Death in childhood, Death in adolescence, Recurrent viral infections, Decreased circulating ferritin concentration, Elevated urinary carboxylic acid.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Hyperphenylalaninemia. The patient does not have in common: Death in infancy, Death in childhood, Death in adolescence, Recurrent viral infections, Abnormal circulating porphyrin concentration, Decreased circulating ferritin concentration, Elevated urinary carboxylic acid.

\n\n+3. Porphyrinuria: Porphyrinuria is a rare genetic disorder that affects the production of heme, a component of hemoglobin. Symptoms include skin lesions, abdominal pain, and neurological problems. The patient has in common: Abnormal circulating porphyrin concentration. The patient does not have in common: Death in infancy, Death in childhood, Death in adolescence, Recurrent viral infections, Hypertyrosinemia, Decreased circulating ferritin concentration, Elevated urinary carboxylic acid.

\n\n+4. Iron deficiency anemia: Iron deficiency anemia is a condition where the body does not have enough iron to produce hemoglobin. Symptoms include fatigue, weakness, and pale skin. The patient has in common: Decreased circulating ferritin concentration. The patient does not have in common: Death in infancy, Death in childhood, Death in adolescence, Recurrent viral infections, Hypertyrosinemia, Abnormal circulating porphyrin concentration, Elevated urinary carboxylic acid.

\n\n+5. Mitochondrial disorder: Mitochondrial disorders are a group of genetic disorders that affect the production of energy in cells. Symptoms include muscle weakness, seizures, and developmental delays. The patient has in common: None of the symptoms listed. The patient does not have in common: Death in infancy, Death in childhood, Death in adolescence, Recurrent viral infections, Hypertyrosinemia, Abnormal circulating porphyrin concentration, Decreased circulating ferritin concentration, Elevated urinary carboxylic acid.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Methylmalonic Acidemia.

\n\n+2. Propionic Acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in Propionic Acidemia.

\n\n+3. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as developmental delays, intellectual disability, or seizures, which are common in Organic Acidemia.

\n\n+4. Leigh Syndrome: This is a rare genetic disorder that affects the brain and spinal cord. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Leigh Syndrome.

\n\n+5. Prader-Willi Syndrome: This is a rare genetic disorder that affects the brain and causes a range of physical and behavioral symptoms. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as short stature, obesity, or hyperphagia, which are common in Prader-Willi Syndrome.

\n\n+6. Hyperekplexia: This is a rare genetic disorder that affects the nervous system and causes excessive startle responses. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as excessive startle responses, which are common in Hyperekplexia.

\n\n+7. Congenital Myasthenic Syndrome: This is a rare genetic disorder that affects the nervous system and causes muscle weakness. Symptoms include lethargy, generalized hypotonia, and tremor, which the patient has in common. However, the patient does not have symptoms such as muscle weakness, which are common in Congenital Myasthenic Syndrome.

Note: The patient's symptoms of death in infancy, neonatal death, abnormal circulating leucine concentration, elevated urinary carboxylic acid, and body odor are not typical of the diseases listed above and may indicate a more severe or complex condition. Further testing and evaluation are needed to determine the underlying cause of the patient's symptoms."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and skin problems. The patient has in common: decreased circulating ferritin concentration, decreased serum iron, and abnormality of vitamin D metabolism. The patient does not have in common: generalized hypotonia, death in infancy, premature birth, anemia, hypertyrosinemia, neonatal death, death in childhood, hyperphenylalaninemia, and pregnancy exposure.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and anemia. The patient has in common: anemia, hypertyrosinemia, and abnormality of vitamin D metabolism. The patient does not have in common: generalized hypotonia, death in infancy, premature birth, decreased circulating ferritin concentration, decreased serum iron, neonatal death, death in childhood, hyperphenylalaninemia, and pregnancy exposure.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: hypertyrosinemia and abnormality of vitamin D metabolism. The patient does not have in common: generalized hypotonia, death in infancy, premature birth, anemia, decreased circulating ferritin concentration, decreased serum iron, neonatal death, death in childhood, hyperphenylalaninemia, and pregnancy exposure.

\n\n+4. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: any of the symptoms listed.

\n\n+5. Iron Deficiency Anemia: Iron deficiency anemia is a condition where the body does not have enough iron to produce hemoglobin. Symptoms include fatigue, weakness, and pale skin. The patient has in common: anemia, decreased circulating ferritin concentration, and decreased serum iron. The patient does not have in common: generalized hypotonia, death in infancy, premature birth, hypertyrosinemia, neonatal death, death in childhood, hyperphenylalaninemia, and pregnancy exposure.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Smith-Lemli-Opitz syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder caused by a defect in the DHCR7 gene, which is responsible for the production of cholesterol. Symptoms include intellectual disability, delayed speech and language development, hyperactivity, and seizures. The patient has in common: delayed speech and language development, hyperactivity, and seizures. The patient does not have in common: hypertelorism, anteverted nares, self-mutilation, syndactyly, abnormal foot morphology, hypocholesterolemia, elevated 8-dehydrocholesterol, neonatal death, death in childhood, elevated circulating 7-dehydrocholesterol concentration, severe hearing impairment.

\n\n+2. Williams Syndrome: This is a rare genetic disorder caused by a deletion of genetic material on chromosome 7. Symptoms include intellectual disability, delayed speech and language development, hyperactivity, and a distinctive facial appearance. The patient has in common: delayed speech and language development, hyperactivity. The patient does not have in common: hypertelorism, anteverted nares, self-mutilation, syndactyly, abnormal foot morphology, hypocholesterolemia, elevated 8-dehydrocholesterol, neonatal death, death in childhood, elevated circulating 7-dehydrocholesterol concentration, severe hearing impairment.

\n\n+3. Fragile X Syndrome: This is the most common inherited form of intellectual disability. Symptoms include intellectual disability, delayed speech and language development, hyperactivity, and a distinctive facial appearance. The patient has in common: delayed speech and language development, hyperactivity. The patient does not have in common: hypertelorism, anteverted nares, self-mutilation, syndactyly, abnormal foot morphology, hypocholesterolemia, elevated 8-dehydrocholesterol, neonatal death, death in childhood, elevated circulating 7-dehydrocholesterol concentration, severe hearing impairment.

\n\n+4. Rett Syndrome: This is a rare genetic disorder caused by a mutation in the MECP2 gene. Symptoms include intellectual disability, delayed speech and language development, hyperactivity, and a distinctive hand movement disorder. The patient has in common: delayed speech and language development, hyperactivity. The patient does not have in common: hypertelorism, anteverted nares, self-mutilation, syndactyly, abnormal foot morphology, hypocholesterolemia, elevated 8-dehydrocholesterol, neonatal death, death in childhood, elevated circulating 7-dehydrocholesterol concentration, severe hearing impairment.

\n\n+5. Angelman Syndrome: This is a rare genetic disorder caused by a mutation in the UBE3A gene. Symptoms include intellectual disability, delayed speech and language development, hyperactivity, and a distinctive facial appearance. The patient has in common: delayed speech and language development, hyperactivity. The patient does not have in common: hypertelorism, anteverted nares, self-mutilation, syndactyly, abnormal foot morphology, hypocholesterolemia, elevated 8-dehydrocholesterol, neonatal death, death in childhood, elevated circulating 7-dehydrocholesterol concentration, severe hearing impairment.

Please note that these are just potential diseases and a proper diagnosis would require a thorough medical examination and testing."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

\n\n+3. Glutaric acidemia type I: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

\n\n+5. Maple syrup urine disease: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

\n\n+6. Hyperglycinemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

\n\n+7. Methylmalonic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, delayed speech and language development, microcephaly, and failure to thrive. The patient has in common: microcephaly, delayed speech and language development, failure to thrive, and intellectual disability. The patient does not have in common: fever, pneumonia, hyperuricemia, and elevated circulating alkaline phosphatase concentration.

Note that these are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further testing and evaluation."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Molybdenum cofactor deficiency: This is a rare genetic disorder that affects the body's ability to break down certain compounds. The patient has ataxia, lethargy, and generalized hypotonia in common with this disease. However, the patient does not have seizures, which are a common symptom of this condition.

\n\n+2. Pyrimidine metabolism disorder: This is a group of rare genetic disorders that affect the body's ability to break down pyrimidines. The patient has abnormal circulating pyrimidine concentration and uraciluria in common with this disease. However, the patient does not have intellectual disability, which is a common symptom of this condition.

\n\n+3. Congenital disorder of glycosylation: This is a group of rare genetic disorders that affect the body's ability to produce certain proteins. The patient has ataxia, lethargy, and generalized hypotonia in common with this disease. However, the patient does not have liver dysfunction, which is a common symptom of this condition.

\n\n+4. Mitochondrial disorder: This is a group of rare genetic disorders that affect the body's ability to produce energy. The patient has ataxia, lethargy, and generalized hypotonia in common with this disease. However, the patient does not have muscle weakness, which is a common symptom of this condition.

\n\n+5. Prader-Willi syndrome: This is a rare genetic disorder that affects the body's ability to regulate appetite and metabolism. The patient does not have any symptoms in common with this disease.

\n\n+6. Rett syndrome: This is a rare genetic disorder that affects the brain and nervous system. The patient does not have any symptoms in common with this disease.

\n\n+7. Leigh syndrome: This is a rare genetic disorder that affects the brain and nervous system. The patient has ataxia, lethargy, and generalized hypotonia in common with this disease. However, the patient does not have seizures, which are a common symptom of this condition.

\n\n+8. MELAS syndrome: This is a rare genetic disorder that affects the brain and nervous system. The patient has ataxia, lethargy, and generalized hypotonia in common with this disease. However, the patient does not have headaches, which are a common symptom of this condition.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and testing."
['Isovaleric acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the blood. The patient has in common: 'Hyperammonemia', 'Abnormal circulating glycine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration'.

\n\n+2. Propionic Acidemia: Propionic acidemia is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the blood. The patient has in common: 'Hyperammonemia', 'Abnormal circulating glycine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration'.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the blood. The patient has in common: 'Hyperammonemia', 'Abnormal circulating glycine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration'.

\n\n+4. Glutaric Acidemia Type I: Glutaric acidemia type I is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the blood. The patient has in common: 'Hyperammonemia', 'Abnormal circulating glycine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Abnormal circulating carnitine concentration'.

\n\n+5. Carnitine Deficiency: Carnitine deficiency is a rare genetic disorder that affects the transport of fatty acids into the mitochondria, leading to the accumulation of toxic compounds in the blood. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperammonemia', 'Abnormal circulating glycine concentration'.

Note: The patient's symptoms are consistent with a genetic disorder affecting amino acid metabolism, but further testing and evaluation are needed to confirm the diagnosis."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Seizure, Generalized hypotonia, Death in infancy.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Seizure, Generalized hypotonia, Death in infancy.

\n\n+3. Glutaric acidemia type I: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Seizure, Generalized hypotonia, Death in infancy.

\n\n+4. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Seizure, Generalized hypotonia, Death in infancy.

\n\n+5. Organic acidemia: This is a broad term that refers to a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Seizure, Generalized hypotonia, Death in infancy.

\n\n+6. Leigh syndrome: This is a rare genetic disorder that affects the brain and spinal cord. The patient has in common: Seizure. The patient does not have in common: Generalized hypotonia, Death in infancy, Elevated urinary carboxylic acid.

\n\n+7. Hypotonia with seizures: This is a rare condition that affects the muscles and nervous system. The patient has in common: Seizure, Generalized hypotonia. The patient does not have in common: Death in infancy, Elevated urinary carboxylic acid.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Palmitoyltransferase II Deficiency: This is a rare genetic disorder that affects the body's ability to use fat for energy. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and decreased plasma free carnitine. The patient's symptoms of death in infancy, neonatal death, and death in childhood are also consistent with this disease. However, the patient does not have symptoms of muscle weakness or fatigue, which are common in this condition.

\n\n+2. 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: This is another rare genetic disorder that affects the body's ability to break down fatty acids. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and decreased 3-hydroxyacyl-CoA dehydrogenase level. The patient's symptoms of death in infancy, neonatal death, and death in childhood are also consistent with this disease. However, the patient does not have symptoms of muscle weakness or fatigue, which are common in this condition.

\n\n+3. Mitochondrial Myopathy: This is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and muscle weakness or fatigue. The patient's symptoms of death in infancy, neonatal death, and death in childhood are not typical of this condition, but it is possible that the patient has a more severe form of the disease.

\n\n+4. Congenital Myasthenic Syndrome: This is a group of rare genetic disorders that affect the nerve-muscle junction, leading to muscle weakness or fatigue. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and muscle weakness or fatigue. The patient's symptoms of death in infancy, neonatal death, and death in childhood are not typical of this condition, but it is possible that the patient has a more severe form of the disease.

\n\n+5. Prader-Willi Syndrome: This is a rare genetic disorder that affects the development of the brain and body. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and short stature. The patient's symptoms of death in infancy, neonatal death, and death in childhood are not typical of this condition, but it is possible that the patient has a more severe form of the disease.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Seizure, Motor delay, Metabolic acidosis, Feeding difficulties. The patient does not have in common: Spastic diplegia, Spastic tetraplegia, Opisthotonus, Body odor.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Seizure, Motor delay, Metabolic acidosis, Feeding difficulties. The patient does not have in common: Spastic diplegia, Spastic tetraplegia, Opisthotonus, Body odor.

\n\n+3. Leukodystrophy: This is a group of rare genetic disorders that affect the development and maintenance of the white matter in the brain. The patient has in common: Seizure, Motor delay, Spastic diplegia, Spastic tetraplegia. The patient does not have in common: Metabolic acidosis, Feeding difficulties, Body odor.

\n\n+4. Hypervalinemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Seizure, Motor delay, Hypervalinemia. The patient does not have in common: Spastic diplegia, Spastic tetraplegia, Opisthotonus, Feeding difficulties, Body odor.

\n\n+5. Hyperleucinemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Seizure, Motor delay, Hyperleucinemia. The patient does not have in common: Spastic diplegia, Spastic tetraplegia, Opisthotonus, Feeding difficulties, Body odor.

\n\n+6. Hyperisoleucinemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Seizure, Motor delay, Hyperisoleucinemia. The patient does not have in common: Spastic diplegia, Spastic tetraplegia, Opisthotonus, Feeding difficulties, Body odor.

\n\n+7. Congenital myasthenic syndrome: This is a group of rare genetic disorders that affect the transmission of nerve impulses. The patient has in common: Seizure, Motor delay, Spastic diplegia, Spastic tetraplegia. The patient does not have in common: Metabolic acidosis, Feeding difficulties, Body odor.

\n\n+8. Pompe disease: This is a rare genetic disorder that affects the body's ability to break down glycogen. The patient has in common: Seizure, Motor delay, Hypotonia. The patient does not have in common: Spastic diplegia, Spastic tetraplegia, Opisthotonus, Feeding difficulties, Body odor.

Please note that this is not an exhaustive list and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Propionic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids, leading to the accumulation of toxic compounds in the body. The patient has symptoms of Hyperammonemia, Hyperalaninemia, and Elevated urinary carboxylic acid in common with MSUD. The patient does not have symptoms of Psychosis, Osteoporosis, or Intellectual disability.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine, leading to the accumulation of toxic compounds in the body. The patient has symptoms of Hyperphenylalaninemia (not explicitly mentioned, but implied by the presence of Hyperalaninemia) in common with PKU. The patient does not have symptoms of Cerebral atrophy, Kyphoscoliosis, or Death in adolescence.

\n\n+3. Methylmalonic Acidemia (MMA): MMA is a rare genetic disorder that affects the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body. The patient has symptoms of Hyperammonemia, Hyperalaninemia, and Elevated urinary carboxylic acid in common with MMA. The patient does not have symptoms of Psychosis, Osteoporosis, or Intellectual disability.

\n\n+4. Organic Acidemia (OA): OA is a group of rare genetic disorders that affect the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body. The patient has symptoms of Hyperammonemia, Hyperalaninemia, and Elevated urinary carboxylic acid in common with OA. The patient does not have symptoms of Cerebral atrophy, Kyphoscoliosis, or Death in adolescence.

\n\n+5. Carnitine Deficiency (CD): CD is a rare genetic disorder that affects the transport of fatty acids into the mitochondria, leading to the accumulation of toxic compounds in the body. The patient has symptoms of Abnormal circulating carnitine concentration in common with CD. The patient does not have symptoms of Psychosis, Osteoporosis, or Intellectual disability.

Please note that these are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['L-2-hydroxyglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. L-2-Hydroxyglutaric Aciduria: This is a rare genetic disorder caused by a deficiency of the enzyme L-2-hydroxyglutarate dehydrogenase. Symptoms include intellectual disability, seizures, and ataxia. The patient has intellectual disability, seizure, and ataxia in common with this disease. However, the patient does not have tremor or death in childhood, which are not typical symptoms of L-2-hydroxyglutaric aciduria.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include intellectual disability, seizures, and ataxia. The patient has intellectual disability, seizure, and ataxia in common with this disease. However, the patient does not have tremor or death in childhood, which are not typical symptoms of methylmalonic acidemia.

\n\n+3. Pyridoxine-Dependent Epilepsy: This is a rare genetic disorder caused by a deficiency of the enzyme pyridoxine-dependent epilepsy. Symptoms include intellectual disability, seizures, and ataxia. The patient has intellectual disability, seizure, and ataxia in common with this disease. However, the patient does not have tremor or death in childhood, which are not typical symptoms of pyridoxine-dependent epilepsy.

\n\n+4. Leigh Syndrome: This is a rare genetic disorder caused by a deficiency of the enzyme NADH dehydrogenase. Symptoms include intellectual disability, seizures, and ataxia. The patient has intellectual disability, seizure, and ataxia in common with this disease. However, the patient does not have tremor or death in childhood, which are not typical symptoms of Leigh syndrome.

\n\n+5. Molybdenum Cofactor Deficiency Type A: This is a rare genetic disorder caused by a deficiency of the enzyme molybdenum cofactor. Symptoms include intellectual disability, seizures, and ataxia. The patient has intellectual disability, seizure, and ataxia in common with this disease. However, the patient does not have tremor or death in childhood, which are not typical symptoms of molybdenum cofactor deficiency type A.

\n\n+6. Glutaric Acidemia Type I: This is a rare genetic disorder caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase. Symptoms include intellectual disability, seizures, and ataxia. The patient has intellectual disability, seizure, and ataxia in common with this disease. However, the patient does not have tremor or death in childhood, which are not typical symptoms of glutaric acidemia type I.

Note: The patient's symptoms are consistent with several rare genetic disorders, and further testing would be necessary to confirm a specific diagnosis."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with each disease and which symptoms they do not have in common:

\n\n+1. Molybdenum Cofactor Deficiency Type A: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common with this disease: 'Abnormal circulating aspartate family amino acid concentration'. The patient does not have in common with this disease: 'Motor delay', 'Death in infancy'.

\n\n+2. Molybdenum Cofactor Deficiency Type B: This is another rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common with this disease: 'Abnormal circulating aspartate family amino acid concentration'. The patient does not have in common with this disease: 'Motor delay', 'Death in infancy'.

\n\n+3. Aspartylglucosaminuria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common with this disease: 'Abnormal circulating aspartate family amino acid concentration', 'Motor delay'. The patient does not have in common with this disease: 'Death in infancy'.

\n\n+4. Canavan Disease: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common with this disease: 'Abnormal circulating aspartate family amino acid concentration', 'Motor delay', 'Death in infancy'."
['Citrullinemia type I'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Citrullinemia Type I: Citrullinemia Type I is a rare genetic disorder that affects the body's ability to break down amino acids. Symptoms include hyperammonemia, increased total bilirubin, and elevated plasma citrulline. The patient has hyperammonemia, increased total bilirubin, and elevated plasma citrulline in common with this disease. However, the patient does not have the typical symptoms of Citrullinemia Type I, such as intellectual disability, seizures, and vomiting.

\n\n+2. Neonatal Hyperammonemia: Neonatal Hyperammonemia is a condition that occurs when there is an excessive buildup of ammonia in the blood of a newborn. Symptoms include hyperammonemia, increased total bilirubin, and elevated plasma citrulline. The patient has hyperammonemia, increased total bilirubin, and elevated plasma citrulline in common with this disease. However, the patient does not have the typical symptoms of Neonatal Hyperammonemia, such as lethargy, irritability, and poor feeding.

\n\n+3. Hyperbilirubinemia: Hyperbilirubinemia is a condition that occurs when there is an excessive buildup of bilirubin in the blood. Symptoms include increased total bilirubin. The patient has increased total bilirubin in common with this disease. However, the patient does not have the typical symptoms of Hyperbilirubinemia, such as yellowing of the skin and eyes.

\n\n+4. Lysinuric Protein Intolerance: Lysinuric Protein Intolerance is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include hyperammonemia, increased total bilirubin, and elevated plasma citrulline. The patient has hyperammonemia, increased total bilirubin, and elevated plasma citrulline in common with this disease. However, the patient does not have the typical symptoms of Lysinuric Protein Intolerance, such as failure to thrive, and recurrent infections.

\n\n+5. Maple Syrup Urine Disease: Maple Syrup Urine Disease is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include hyperammonemia, increased total bilirubin, and elevated plasma citrulline. The patient has hyperammonemia, increased total bilirubin, and elevated plasma citrulline in common with this disease. However, the patient does not have the typical symptoms of Maple Syrup Urine Disease, such as sweet-smelling urine, and developmental delay.

Note: The patient's symptoms of ""Death in infancy"" and ""Neonatal death"" are not typical symptoms of the diseases listed above, and may indicate a more severe or life-threatening condition. Further testing and evaluation are needed to determine the underlying cause of the patient's symptoms."
['3-hydroxy-3-methylglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include lethargy, vomiting, diarrhea, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as muscle weakness, seizures, or intellectual disability, which are common in Methylmalonic Acidemia.

\n\n+2. Organic Acidemia: This is a group of disorders that affect the body's ability to break down certain compounds, leading to the accumulation of toxic substances. Symptoms include lethargy, vomiting, diarrhea, metabolic acidosis, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delay, or intellectual disability, which are common in Organic Acidemia.

\n\n+3. Urea Cycle Disorders: These are a group of disorders that affect the body's ability to break down ammonia, leading to the accumulation of toxic substances. Symptoms include lethargy, vomiting, diarrhea, metabolic acidosis, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delay, or intellectual disability, which are common in Urea Cycle Disorders.

\n\n+4. Maple Syrup Urine Disease: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include lethargy, vomiting, diarrhea, metabolic acidosis, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as sweet-smelling urine, seizures, or developmental delay, which are common in Maple Syrup Urine Disease.

\n\n+5. Glutaric Acidemia Type I: This is a rare genetic disorder that affects the body's ability to break down certain compounds. Symptoms include lethargy, vomiting, diarrhea, metabolic acidosis, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delay, or intellectual disability, which are common in Glutaric Acidemia Type I.

\n\n+6. Multiple Carboxylase Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain compounds. Symptoms include lethargy, vomiting, diarrhea, metabolic acidosis, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delay, or intellectual disability, which are common in Multiple Carboxylase Deficiency.

Note that these are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further testing and evaluation."
['Cystinuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Pompe Disease: Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase. It is characterized by muscle weakness, respiratory failure, and cardiac problems. The patient has in common: Respiratory insufficiency. The patient does not have in common: Seizure, Death in infancy, Splenomegaly.

\n\n+2. Mucopolysaccharidosis Type II (Hunter Syndrome): Mucopolysaccharidosis Type II is a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. It is characterized by joint pain, muscle weakness, and respiratory problems. The patient has in common: Respiratory insufficiency. The patient does not have in common: Seizure, Death in infancy, Splenomegaly.

\n\n+3. Congenital Myasthenic Syndrome: Congenital Myasthenic Syndrome is a rare genetic disorder caused by a defect in the transmission of nerve impulses to muscles. It is characterized by muscle weakness, fatigue, and respiratory problems. The patient has in common: Respiratory insufficiency, Seizure. The patient does not have in common: Death in infancy, Splenomegaly.

\n\n+4. Rett Syndrome: Rett Syndrome is a rare genetic disorder caused by a mutation in the MECP2 gene. It is characterized by intellectual disability, seizures, and respiratory problems. The patient has in common: Seizure, Respiratory insufficiency. The patient does not have in common: Death in infancy, Splenomegaly.

\n\n+5. Krabbe Disease: Krabbe Disease is a rare genetic disorder caused by a deficiency of the enzyme galactocerebrosidase. It is characterized by muscle weakness, seizures, and respiratory problems. The patient has in common: Seizure, Respiratory insufficiency. The patient does not have in common: Death in infancy, Splenomegaly.

Please note that this is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, hypoproteinemia, increased blood urea nitrogen, hyperthreoninemia, and decreased serum creatinine. The patient does not have symptoms in common with this disease, such as death in infancy, neonatal death, death in childhood, recurrent viral infections, hypervalinemia, abnormal circulating isoleucine concentration, abnormal circulating carnitine concentration, and feeding difficulties.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, hypoproteinemia, increased blood urea nitrogen, and hyperthreoninemia. The patient does not have symptoms in common with this disease, such as death in infancy, neonatal death, death in childhood, recurrent viral infections, hypervalinemia, abnormal circulating isoleucine concentration, abnormal circulating carnitine concentration, and feeding difficulties.

\n\n+3. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. The patient has symptoms in common with this disease, such as intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, and hypoproteinemia. The patient does not have symptoms in common with this disease, such as death in infancy, neonatal death, death in childhood, recurrent viral infections, hypervalinemia, abnormal circulating isoleucine concentration, abnormal circulating carnitine concentration, and feeding difficulties.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, hypoproteinemia, increased blood urea nitrogen, and hyperthreoninemia. The patient does not have symptoms in common with this disease, such as death in infancy, neonatal death, death in childhood, recurrent viral infections, hypervalinemia, abnormal circulating isoleucine concentration, abnormal circulating carnitine concentration, and feeding difficulties.

\n\n+5. Urea cycle disorder: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, hypoproteinemia, increased blood urea nitrogen, and hyperthreoninemia. The patient does not have symptoms in common with this disease, such as death in infancy, neonatal death, death in childhood, recurrent viral infections, hypervalinemia, abnormal circulating isoleucine concentration, abnormal circulating carnitine concentration, and feeding difficulties.

Note: These are just a few potential diseases that the patient may have based on the symptoms provided. A definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Tyrosinemia: Tyrosinemia is a rare genetic disorder caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. Symptoms include liver damage, kidney damage, and an increased risk of liver cancer. The patient has in common: Elevated urinary carboxylic acid, Hyperphenylalaninemia. The patient does not have in common: Death in infancy, Death in childhood, Recurrent viral infections.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Hyperphenylalaninemia. The patient does not have in common: Death in infancy, Death in childhood, Recurrent viral infections, Elevated urinary carboxylic acid.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: Death in infancy, Death in childhood, Recurrent viral infections, Elevated urinary carboxylic acid, Hyperphenylalaninemia.

\n\n+4. Organic Acidemia: Organic acidemia is a group of rare genetic disorders caused by a deficiency of enzymes involved in the breakdown of certain amino acids. Symptoms include intellectual disability, seizures, and an increased risk of liver damage. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Death in childhood, Recurrent viral infections, Hyperphenylalaninemia.

\n\n+5. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include intellectual disability, seizures, and an increased risk of liver damage. The patient does not have in common: Death in infancy, Death in childhood, Recurrent viral infections, Elevated urinary carboxylic acid, Hyperphenylalaninemia.

Note: These are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common and which symptoms they do not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, obesity, and hyperphenylalaninemia. The patient has intellectual disability and hyperphenylalaninemia in common, but does not have obesity.

\n\n+2. Tyrosinemia type I: Tyrosinemia type I is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include intellectual disability, liver disease, and increased risk of liver cancer. The patient has intellectual disability in common, but does not have liver disease or increased risk of liver cancer.

\n\n+3. Congenital hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient has intellectual disability in common, but does not have short stature or delayed development.

\n\n+4. Prader-Willi syndrome: Prader-Willi syndrome is a genetic disorder that affects appetite regulation and growth. Symptoms include intellectual disability, short stature, and obesity. The patient has intellectual disability and obesity in common, but does not have short stature.

\n\n+5. Smith-Magenis syndrome: Smith-Magenis syndrome is a rare genetic disorder that affects the development of the brain and other organs. Symptoms include intellectual disability, delayed speech and language development, and behavioral problems. The patient has intellectual disability in common, but does not have delayed speech and language development or behavioral problems.

\n\n+6. Fragile X syndrome: Fragile X syndrome is the most common form of inherited intellectual disability. Symptoms include intellectual disability, delayed speech and language development, and behavioral problems. The patient has intellectual disability in common, but does not have delayed speech and language development or behavioral problems.

Note: The patient's symptoms do not match any of the above diseases perfectly, and further testing and evaluation would be necessary to make a definitive diagnosis."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Ornithine Transcarbamylase (OTC) Deficiency: OTC deficiency is a rare genetic disorder that affects the breakdown of ammonia in the body. Symptoms include hyperammonemia, vomiting, and abnormal bleeding. The patient has hyperammonemia and vomiting in common with this disease, but does not have abnormal bleeding. The patient's death in infancy and oroticaciduria are not typical symptoms of OTC deficiency.

\n\n+2. Argininosuccinic Aciduria (ASA): ASA is a rare genetic disorder that affects the breakdown of amino acids in the body. Symptoms include hyperammonemia, vomiting, and oroticaciduria. The patient has hyperammonemia, vomiting, and oroticaciduria in common with this disease. However, the patient's abnormal bleeding and death in infancy are not typical symptoms of ASA.

\n\n+3. Citrullinemia: Citrullinemia is a rare genetic disorder that affects the breakdown of amino acids in the body. Symptoms include hyperammonemia, vomiting, and oroticaciduria. The patient has hyperammonemia, vomiting, and oroticaciduria in common with this disease. However, the patient's abnormal bleeding and death in infancy are not typical symptoms of citrullinemia.

\n\n+4. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of certain amino acids in the body. Symptoms include hyperammonemia, vomiting, and abnormal bleeding. The patient has hyperammonemia and vomiting in common with this disease, but does not have oroticaciduria. The patient's death in infancy is not typical of methylmalonic acidemia.

\n\n+5. Hyperammonemia due to Liver Disease: Hyperammonemia can occur in individuals with liver disease, which can cause vomiting and abnormal bleeding. The patient has hyperammonemia, vomiting, and abnormal bleeding in common with this disease. However, the patient's oroticaciduria and death in infancy are not typical symptoms of liver disease.

\n\n+6. Other Inborn Errors of Metabolism: There are many other rare genetic disorders that can cause hyperammonemia, vomiting, and oroticaciduria. These disorders may not be listed here, but could be considered as potential causes of the patient's symptoms.

It is important to note that a definitive diagnosis can only be made through further testing and evaluation."
['L-2-hydroxyglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. L-2-Hydroxyglutaric Aciduria: This is a rare genetic disorder caused by a deficiency of the enzyme L-2-hydroxyglutarate dehydrogenase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of vomiting, diarrhea, and abdominal pain, which are typically seen in this disease.

\n\n+3. Pyruvate Dehydrogenase Deficiency: This is a rare genetic disorder caused by a deficiency of the enzyme pyruvate dehydrogenase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+4. Glutaric Acidemia Type I: This is a rare genetic disorder caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+5. 3-Methylglutaconic Aciduria: This is a rare genetic disorder caused by a deficiency of the enzyme 3-methylglutaconyl-CoA hydratase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+6. Succinic Semialdehyde Dehydrogenase Deficiency: This is a rare genetic disorder caused by a deficiency of the enzyme succinic semialdehyde dehydrogenase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+7. 4-Hydroxybutyric Aciduria: This is a rare genetic disorder caused by a deficiency of the enzyme succinic semialdehyde dehydrogenase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+8. Methylmalonyl-CoA Epimerase Deficiency: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA epimerase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+9. 3-Methylglutaconic Aciduria: This is a rare genetic disorder caused by a deficiency of the enzyme 3-methylglutaconyl-CoA hydratase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

\n\n+10. Succinic Semialdehyde Dehydrogenase Deficiency: This is a rare genetic disorder caused by a deficiency of the enzyme succinic semialdehyde dehydrogenase. Symptoms include intellectual disability, generalized hypotonia, and hyperreflexia, which the patient has in common. However, the patient does not have in common the symptoms of seizures, developmental delay, and progressive neurodegeneration, which are typically seen in this disease.

Based on the symptoms provided, the most likely diagnosis is L-2-Hydroxyglutaric Aciduria. However, further testing and evaluation are necessary to confirm the diagnosis."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Joubert Syndrome: Joubert Syndrome is a rare genetic disorder that affects the brain and spinal cord. It is characterized by intellectual disability, ataxia, and cerebellar atrophy. The patient has intellectual disability, ataxia, and cerebellar atrophy in common with this disease. However, the patient does not have thromboembolism, stroke-like episode, or cerebellar agenesis.

\n\n+2. Aicardi-Goutières Syndrome: Aicardi-Goutières Syndrome is a rare genetic disorder that affects the brain and spinal cord. It is characterized by intellectual disability, ataxia, and cerebellar atrophy. The patient has intellectual disability, ataxia, and cerebellar atrophy in common with this disease. However, the patient does not have thromboembolism, stroke-like episode, or cerebellar agenesis.

\n\n+3. MERRF Syndrome: MERRF Syndrome is a rare genetic disorder that affects the brain and spinal cord. It is characterized by intellectual disability, ataxia, and cerebellar atrophy. The patient has intellectual disability, ataxia, and cerebellar atrophy in common with this disease. However, the patient does not have thromboembolism, stroke-like episode, or cerebellar agenesis.

\n\n+4. MECP2-Related Disorders: MECP2-Related Disorders are a group of rare genetic disorders that affect the brain and spinal cord. They are characterized by intellectual disability, ataxia, and cerebellar atrophy. The patient has intellectual disability, ataxia, and cerebellar atrophy in common with this disease. However, the patient does not have thromboembolism, stroke-like episode, or cerebellar agenesis.

\n\n+5. Pontocerebellar Hypoplasia: Pontocerebellar Hypoplasia is a rare genetic disorder that affects the brain and spinal cord. It is characterized by intellectual disability, ataxia, and cerebellar atrophy. The patient has intellectual disability, ataxia, and cerebellar atrophy in common with this disease. However, the patient does not have thromboembolism, stroke-like episode, or cerebellar agenesis.

\n\n+6. Cerebellar Ataxia, Areflexia, and Pes Cavus Syndrome: Cerebellar Ataxia, Areflexia, and Pes Cavus Syndrome is a rare genetic disorder that affects the brain and spinal cord. It is characterized by intellectual disability, ataxia, and cerebellar atrophy. The patient has intellectual disability, ataxia, and cerebellar atrophy in common with this disease. However, the patient does not have thromboembolism, stroke-like episode, or cerebellar agenesis.

Note: The patient's symptoms of death in infancy and thromboembolism are not typical of these diseases, and further evaluation is needed to determine the underlying cause of the patient's condition."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia', 'Hypertyrosinemia'. The patient does not have in common: 'Death in infancy', 'Premature birth', 'Neonatal death'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Death in infancy', 'Premature birth', 'Neonatal death', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Death in infancy', 'Premature birth', 'Neonatal death', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+4. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include delayed development, short stature, and intellectual disability. The patient does not have in common: 'Death in infancy', 'Premature birth', 'Neonatal death', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+5. Neonatal Sepsis: Neonatal sepsis is a serious infection that occurs in newborns. Symptoms include fever, lethargy, and respiratory distress. The patient has in common: 'Premature birth', 'Neonatal death'. The patient does not have in common: 'Death in infancy', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

Note: These are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Propionic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient has in common: delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient does not have in common: fever, hyperammonemia, vomiting, gastroesophageal reflux, pneumonia, increased circulating lactate concentration, hyperglycinemia, drowsiness, difficulty walking, sleep abnormality, tachypnea, increased blood urea nitrogen, hypertyrosinemia, hyperalaninemia, difficulty climbing stairs, neonatal death, death in childhood, recurrent viral infections, hyperprolinemia, difficulty running, stomatitis, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia, severe hearing impairment.

\n\n+2. Methylmalonic Acidemia (MMA): MMA is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient has in common: delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient does not have in common: fever, hyperammonemia, vomiting, gastroesophageal reflux, pneumonia, increased circulating lactate concentration, hyperglycinemia, drowsiness, difficulty walking, sleep abnormality, tachypnea, increased blood urea nitrogen, hypertyrosinemia, hyperalaninemia, difficulty climbing stairs, neonatal death, death in childhood, recurrent viral infections, hyperprolinemia, difficulty running, stomatitis, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia, severe hearing impairment.

\n\n+3. Propionic Acidemia (PA): PA is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient has in common: delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient does not have in common: fever, hyperammonemia, vomiting, gastroesophageal reflux, pneumonia, increased circulating lactate concentration, hyperglycinemia, drowsiness, difficulty walking, sleep abnormality, tachypnea, increased blood urea nitrogen, hypertyrosinemia, hyperalaninemia, difficulty climbing stairs, neonatal death, death in childhood, recurrent viral infections, hyperprolinemia, difficulty running, stomatitis, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia, severe hearing impairment.

\n\n+4. Glutaric Acidemia Type I (GA1): GA1 is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient has in common: delayed speech and language development, intellectual disability, seizures, lethargy, and motor delay. The patient does not have in common: fever, hyperammonemia, vomiting, gastroesophageal reflux, pneumonia, increased circulating lactate concentration, hyperglycinemia, drowsiness, difficulty walking, sleep abnormality, tachypnea, increased blood urea nitrogen, hypertyrosinemia, hyperalaninemia, difficulty climbing stairs, neonatal death, death in childhood, recurrent viral infections, hyperprolinemia, difficulty running, stomatitis, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia, severe hearing impairment.

\n\n+5. Hyperammonemia: Hyperammonemia is a condition characterized by elevated levels of ammonia in the blood. Symptoms include lethargy, vomiting, and seizures. The patient has in common: lethargy, vomiting, and seizures. The patient does not have in common: delayed speech and language development, intellectual disability, motor delay, fever, hyperglycinemia, drowsiness, difficulty walking, sleep abnormality, tachypnea, increased blood urea nitrogen, hypertyrosinemia, hyperalaninemia, difficulty climbing stairs, neonatal death, death in childhood, recurrent viral infections, hyperprolinemia, difficulty running, stomatitis, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia, severe hearing impairment.

Note: The patient's symptoms are not a perfect match for any of these diseases, and further testing and evaluation would be necessary to confirm a diagnosis."
['Wilson disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Wilson's Disease: Wilson's Disease is a rare genetic disorder that affects the liver and brain, causing copper accumulation in the body. The patient has symptoms of decreased circulating ceruloplasmin concentration and decreased circulating copper concentration in common with this disease. However, the patient does not have symptoms of tremors, rigidity, or psychiatric disturbances, which are common in Wilson's Disease.

\n\n+2. Primary Biliary Cirrhosis: Primary Biliary Cirrhosis is a chronic liver disease that causes inflammation and scarring of the bile ducts. The patient has symptoms of elevated circulating hepatic transaminase concentration in common with this disease. However, the patient does not have symptoms of pruritus, fatigue, or jaundice, which are common in Primary Biliary Cirrhosis.

\n\n+3. Hemochromatosis: Hemochromatosis is a genetic disorder that causes the body to absorb too much iron from food and drinks. The patient does not have any symptoms in common with this disease.

\n\n+4. Menkes Syndrome: Menkes Syndrome is a rare genetic disorder that affects the development of the brain and nervous system. The patient has symptoms of death in adolescence in common with this disease. However, the patient does not have symptoms of kinky or brittle hair, which is a characteristic feature of Menkes Syndrome.

\n\n+5. Acute Hepatitis: Acute Hepatitis is a short-term inflammation of the liver that can be caused by a viral infection or other factors. The patient has symptoms of elevated circulating hepatic transaminase concentration in common with this disease. However, the patient does not have symptoms of fever, nausea, or vomiting, which are common in Acute Hepatitis.

\n\n+6. Chronic Hepatitis: Chronic Hepatitis is a long-term inflammation of the liver that can be caused by a viral infection or other factors. The patient has symptoms of elevated circulating hepatic transaminase concentration in common with this disease. However, the patient does not have symptoms of fatigue, weight loss, or dark urine, which are common in Chronic Hepatitis.

Note: The patient's symptoms of polydipsia are not specific to any of the diseases listed above, and further evaluation is needed to determine the underlying cause."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Molybdenum Cofactor Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, vomiting, and hyperglutaminemia. However, the patient does not have symptoms such as intellectual disability, which is often associated with this disease.

\n\n+2. Pyridoxine-Dependent Epilepsy: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as seizure, lethargy, and generalized hypotonia. However, the patient does not have symptoms such as developmental delay, which is often associated with this disease.

\n\n+3. Glutaryl-CoA Dehydrogenase Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, vomiting, and hyperglutaminemia. However, the patient does not have symptoms such as muscle weakness, which is often associated with this disease.

\n\n+4. Orotic Aciduria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as orotic aciduria and hyperglutaminemia. However, the patient does not have symptoms such as intellectual disability, which is often associated with this disease.

\n\n+5. Neonatal Adrenoleukodystrophy: This is a rare genetic disorder that affects the body's ability to break down certain fatty acids. The patient has symptoms in common with this disease, such as lethargy, generalized hypotonia, and vomiting. However, the patient does not have symptoms such as adrenal insufficiency, which is often associated with this disease.

\n\n+6. Mitochondrial DNA Depletion Syndrome: This is a rare genetic disorder that affects the body's ability to generate energy. The patient has symptoms in common with this disease, such as generalized hypotonia, vomiting, and sleep abnormality. However, the patient does not have symptoms such as muscle weakness, which is often associated with this disease.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Classic galactosemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Galactosemia: Galactosemia is a rare genetic disorder that affects the body's ability to break down galactose, a sugar found in milk and other dairy products. Symptoms include intellectual disability, delayed speech and language development, and feeding difficulties. The patient has in common: Delayed speech and language development, Intellectual disability, Feeding difficulties. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Obesity, Death in infancy, Anemia, Elevated circulating alkaline phosphatase concentration, Neonatal death, Death in childhood, Abnormality of galactoside metabolism, Abnormal circulating porphyrin concentration, Hypergalactosemia, Decreased circulating ferritin concentration, Decreased serum iron.

\n\n+2. Hypoglycemia: Hypoglycemia is a condition characterized by abnormally low blood sugar levels. Symptoms include delayed speech and language development, intellectual disability, and feeding difficulties. The patient has in common: Delayed speech and language development, Intellectual disability, Feeding difficulties. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Obesity, Death in infancy, Anemia, Elevated circulating alkaline phosphatase concentration, Neonatal death, Death in childhood, Abnormality of galactoside metabolism, Abnormal circulating porphyrin concentration, Hypergalactosemia, Decreased circulating ferritin concentration, Decreased serum iron.

\n\n+3. Congenital hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone, leading to intellectual disability, delayed speech and language development, and growth retardation. The patient has in common: Delayed speech and language development, Intellectual disability. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Obesity, Death in infancy, Anemia, Elevated circulating alkaline phosphatase concentration, Neonatal death, Death in childhood, Abnormality of galactoside metabolism, Abnormal circulating porphyrin concentration, Hypergalactosemia, Decreased circulating ferritin concentration, Decreased serum iron, Feeding difficulties.

\n\n+4. Rett syndrome: Rett syndrome is a rare genetic disorder that affects brain development and function, leading to intellectual disability, delayed speech and language development, and motor delay. The patient has in common: Delayed speech and language development, Intellectual disability, Motor delay. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Generalized hypotonia, Obesity, Death in infancy, Anemia, Elevated circulating alkaline phosphatase concentration, Neonatal death, Death in childhood, Abnormality of galactoside metabolism, Abnormal circulating porphyrin concentration, Hypergalactosemia, Decreased circulating ferritin concentration, Decreased serum iron, Feeding difficulties.

\n\n+5. Prader-Willi syndrome: Prader-Willi syndrome is a rare genetic disorder that affects brain development and function, leading to intellectual disability, delayed speech and language development, and obesity. The patient has in common: Delayed speech and language development, Intellectual disability. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Motor delay, Generalized hypotonia, Death in infancy, Anemia, Elevated circulating alkaline phosphatase concentration, Neonatal death, Death in childhood, Abnormality of galactoside metabolism, Abnormal circulating porphyrin concentration, Hypergalactosemia, Decreased circulating ferritin concentration, Decreased serum iron, Feeding difficulties, Obesity.

Note: These are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further evaluation and testing."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Prader-Willi Syndrome: Prader-Willi syndrome is a rare genetic disorder that affects the hypothalamus, leading to hyperphagia, obesity, and short stature. The patient has obesity and abnormal foot morphology in common with this disease, but does not have hyperammonemia or death in childhood.

\n\n+2. Mucopolysaccharidosis: Mucopolysaccharidosis is a group of genetic disorders caused by the deficiency of enzymes involved in the breakdown of glycosaminoglycans. The patient does not have any symptoms in common with this disease.

\n\n+3. Congenital Disorders of Glycosylation: Congenital disorders of glycosylation are a group of rare genetic disorders caused by defects in the synthesis of glycoproteins and glycolipids. The patient has hyperammonemia in common with this disease, but does not have obesity, abnormal foot morphology, or death in childhood.

\n\n+4. Mitochondrial Disorders: Mitochondrial disorders are a group of genetic disorders caused by defects in the mitochondria, leading to impaired energy production. The patient does not have any symptoms in common with this disease.

\n\n+5. Inborn Errors of Metabolism: Inborn errors of metabolism are a group of genetic disorders caused by defects in the metabolism of amino acids, carbohydrates, or fatty acids. The patient has hyperammonemia in common with this disease, but does not have obesity, abnormal foot morphology, or death in childhood.

\n\n+6. Smith-Magenis Syndrome: Smith-Magenis syndrome is a rare genetic disorder caused by a deletion of the RAI1 gene, leading to a range of physical and behavioral symptoms. The patient does not have any symptoms in common with this disease.

\n\n+7. Aarskog-Scott Syndrome: Aarskog-Scott syndrome is a rare genetic disorder caused by a mutation in the FSHR gene, leading to short stature, facial dysmorphism, and other physical symptoms. The patient does not have any symptoms in common with this disease.

Note: This is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Canavan Disease: Canavan disease is a rare genetic disorder that affects the brain and spinal cord. It is characterized by a deficiency of the enzyme aspartoacylase, which is necessary for the breakdown of a amino acid called N-acetylaspartate (NAA). Symptoms include developmental delay, muscle weakness, and seizures. The patient has in common: Abnormal circulating aspartate family amino acid concentration, Abnormal myelination. The patient does not have in common: Hyperactivity, Death in infancy, Feeding difficulties.

\n\n+2. Krabbe Disease: Krabbe disease is a rare genetic disorder that affects the brain and spinal cord. It is characterized by a deficiency of the enzyme galactocerebrosidase, which is necessary for the breakdown of a fatty substance called galactocerebroside. Symptoms include developmental delay, muscle weakness, and seizures. The patient has in common: Abnormal circulating aspartate family amino acid concentration, Abnormal myelination. The patient does not have in common: Hyperactivity, Death in infancy, Feeding difficulties.

\n\n+3. Mucopolysaccharidosis Type II (Hunter Syndrome): Mucopolysaccharidosis Type II is a rare genetic disorder that affects the body's ability to break down and remove certain sugars. Symptoms include developmental delay, joint pain, and heart problems. The patient does not have in common: Abnormal circulating aspartate family amino acid concentration, Abnormal myelination, Hyperactivity, Death in infancy, Feeding difficulties.

\n\n+4. Tay-Sachs Disease: Tay-Sachs disease is a rare genetic disorder that affects the brain and spinal cord. It is characterized by a deficiency of the enzyme hexosaminidase A, which is necessary for the breakdown of a fatty substance called ganglioside. Symptoms include developmental delay, muscle weakness, and seizures. The patient has in common: Abnormal circulating aspartate family amino acid concentration, Abnormal myelination. The patient does not have in common: Hyperactivity, Death in infancy, Feeding difficulties.

\n\n+5. Leukodystrophy: Leukodystrophy is a group of rare genetic disorders that affect the brain and spinal cord. It is characterized by a deficiency of the enzyme galactocerebrosidase, which is necessary for the breakdown of a fatty substance called galactocerebroside. Symptoms include developmental delay, muscle weakness, and seizures. The patient has in common: Abnormal circulating aspartate family amino acid concentration, Abnormal myelination. The patient does not have in common: Hyperactivity, Death in infancy, Feeding difficulties.

Please note that this is not an exhaustive list and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone, leading to growth and developmental delays. Symptoms include delayed speech and language development, and short stature. The patient does not have in common: 'Hyperphenylalaninemia'.

\n\n+3. Trisomy 13 (Patau Syndrome): Trisomy 13 is a rare genetic disorder where there is an extra copy of chromosome 13. Symptoms include intellectual disability, heart defects, and facial abnormalities. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Hyperphenylalaninemia'.

\n\n+4. Fetal Alcohol Syndrome: Fetal alcohol syndrome is a condition caused by prenatal exposure to alcohol, leading to growth and developmental delays. Symptoms include facial abnormalities, heart defects, and intellectual disability. The patient does not have in common: 'Hyperphenylalaninemia'.

\n\n+5. Prader-Willi Syndrome: Prader-Willi syndrome is a genetic disorder that affects the hypothalamus, leading to short stature, obesity, and intellectual disability. Symptoms include hypotonia, and behavioral problems. The patient does not have in common: 'Hyperphenylalaninemia'.

Please note that this is not an exhaustive list, and a more detailed medical evaluation and testing would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and hyperphenylalaninemia. The patient has these symptoms in common with PKU. However, the patient does not have symptoms such as intellectual disability, seizures, or skin rash, which are common in PKU.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and hypertyrosinemia. The patient has these symptoms in common with tyrosinemia. However, the patient does not have symptoms such as liver disease, kidney disease, or skin lesions, which are common in tyrosinemia.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and hyperphenylalaninemia. The patient has these symptoms in common with MSUD. However, the patient does not have symptoms such as sweet-smelling urine, vomiting, or seizures, which are common in MSUD.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of mucopolysaccharides. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and death in infancy or childhood. The patient has these symptoms in common with MPS. However, the patient does not have symptoms such as joint stiffness, short stature, or coarse facial features, which are common in MPS.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include delayed speech and language development, abnormality of prenatal development or birth, and hypothyroidism. The patient has these symptoms in common with congenital hypothyroidism. However, the patient does not have symptoms such as goiter, constipation, or cold intolerance, which are common in congenital hypothyroidism.

Note: The patient's symptoms are quite severe, with a high mortality rate in infancy and childhood. Further testing and evaluation are needed to confirm the diagnosis and develop a treatment plan."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Holt-Oram Syndrome: Holt-Oram Syndrome is a rare genetic disorder characterized by heart defects, such as ventricular septal defect and pulmonic stenosis, and upper limb abnormalities. The patient has in common: Ventricular septal defect, Pulmonic stenosis. The patient does not have in common: Nephritis, Generalized hypotonia, Death in infancy, Cardiomyopathy.

\n\n+2. Noonan Syndrome: Noonan Syndrome is a rare genetic disorder characterized by short stature, facial dysmorphism, and heart defects, such as ventricular septal defect and pulmonic stenosis. The patient has in common: Ventricular septal defect, Pulmonic stenosis. The patient does not have in common: Nephritis, Generalized hypotonia, Death in infancy, Cardiomyopathy.

\n\n+3. Williams Syndrome: Williams Syndrome is a rare genetic disorder characterized by intellectual disability, distinctive facial features, and heart defects, such as supravalvular aortic stenosis and pulmonic stenosis. The patient has in common: Pulmonic stenosis. The patient does not have in common: Nephritis, Generalized hypotonia, Death in infancy, Ventricular septal defect, Cardiomyopathy.

\n\n+4. Trisomy 13 (Patau Syndrome): Trisomy 13 is a rare genetic disorder characterized by intellectual disability, microcephaly, and heart defects, such as ventricular septal defect and atrial septal defect. The patient has in common: Ventricular septal defect. The patient does not have in common: Nephritis, Generalized hypotonia, Death in infancy, Pulmonic stenosis, Cardiomyopathy.

\n\n+5. Barth Syndrome: Barth Syndrome is a rare genetic disorder characterized by cardiomyopathy, muscle weakness, and intellectual disability. The patient has in common: Cardiomyopathy. The patient does not have in common: Nephritis, Generalized hypotonia, Death in infancy, Ventricular septal defect, Pulmonic stenosis.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a unique condition that is not listed here. Further evaluation and testing would be necessary to determine the exact diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Hyperphenylalaninemia, Irritability, and Spasticity. The patient does not have in common: Neonatal death, Death in infancy, Death in childhood, and Death in adolescence.

\n\n+2. Tyrosinemia type I: Tyrosinemia type I is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Hypertyrosinemia, Irritability, and Spasticity. The patient does not have in common: Neonatal death, Death in infancy, Death in childhood, and Death in adolescence.

\n\n+3. Mucopolysaccharidosis type VII: Mucopolysaccharidosis type VII is a rare genetic disorder that affects the breakdown of glycosaminoglycans. Symptoms include intellectual disability, joint pain, and respiratory problems. The patient does not have in common: Any of the symptoms listed.

\n\n+4. Leukodystrophy: Leukodystrophy is a group of rare genetic disorders that affect the breakdown of fatty substances in the brain. Symptoms include intellectual disability, seizures, and muscle weakness. The patient has in common: Irritability, Spasticity, and Hyperreflexia. The patient does not have in common: Neonatal death, Death in infancy, Death in childhood, and Death in adolescence.

\n\n+5. Mitochondrial disease: Mitochondrial disease is a group of rare genetic disorders that affect the energy-producing structures within cells. Symptoms include muscle weakness, seizures, and developmental delays. The patient has in common: Irritability, Spasticity, and Hyperreflexia. The patient does not have in common: Neonatal death, Death in infancy, Death in childhood, and Death in adolescence.

Note: The patient's symptoms are quite severe, and it is possible that the patient may have a combination of these diseases or a different disease altogether. Further testing and evaluation would be necessary to determine the correct diagnosis."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Syndrome: This is a rare genetic disorder that affects the body's ability to use carnitine, an amino acid that plays a crucial role in energy production. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Trisomy 13 (Patau Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 13. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+3. Trisomy 18 (Edwards Syndrome): This is a rare genetic disorder caused by an extra copy of chromosome 18. It is characterized by severe physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

\n\n+4. Mitochondrial Disorders: These are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. They can cause a range of symptoms, including muscle weakness, seizures, and developmental delays. The patient has in common: 'Abnormal circulating carnitine concentration'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+5. Fetal Alcohol Syndrome: This is a condition caused by prenatal exposure to alcohol, characterized by physical and intellectual disabilities, and often results in stillbirth or death in infancy. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Abnormal circulating carnitine concentration'.

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include delayed speech and language development, intellectual disability, and seizures. The patient has delayed speech and language development in common with PKU, but does not have intellectual disability or seizures.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include delayed speech and language development, hypotonia, and liver damage. The patient has delayed speech and language development and hypotonia in common with tyrosinemia, but does not have liver damage.

\n\n+3. Congenital hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include delayed speech and language development, hypotonia, and intellectual disability. The patient has delayed speech and language development and hypotonia in common with congenital hypothyroidism, but does not have intellectual disability.

\n\n+4. Prader-Willi syndrome: Prader-Willi syndrome is a genetic disorder that affects the development of the brain and body. Symptoms include delayed speech and language development, hypotonia, and hyperphagia (excessive eating). The patient has delayed speech and language development and hypotonia in common with Prader-Willi syndrome, but does not have hyperphagia.

\n\n+5. Rett syndrome: Rett syndrome is a genetic disorder that affects the development of the brain and body. Symptoms include delayed speech and language development, hypotonia, and seizures. The patient has delayed speech and language development and hypotonia in common with Rett syndrome, but does not have seizures.

Note: The patient's symptoms do not match exactly with any of the proposed diseases, but some of the symptoms are common to multiple diseases. Further testing and evaluation would be necessary to determine the exact diagnosis."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms in common: Glutaric aciduria, Elevated circulating glutaric acid concentration, Decreased plasma free carnitine, Elevated urinary carboxylic acid. The patient does not have symptoms in common: Seizure, Encephalopathy, Death in infancy, Opisthotonus.

\n\n+2. Glutaric Acidemia Type 2:
The patient has symptoms in common: Glutaric aciduria, Elevated circulating glutaric acid concentration, Decreased plasma free carnitine, Elevated urinary carboxylic acid. The patient does not have symptoms in common: Seizure, Encephalopathy, Death in infancy, Opisthotonus.

\n\n+3. Multiple Carboxylase Deficiency:
The patient has symptoms in common: Glutaric aciduria, Elevated circulating glutaric acid concentration, Decreased plasma free carnitine, Elevated urinary carboxylic acid. The patient does not have symptoms in common: Seizure, Encephalopathy, Death in infancy, Opisthotonus.

\n\n+4. Carnitine Deficiency:
The patient has symptoms in common: Decreased plasma free carnitine. The patient does not have symptoms in common: Glutaric aciduria, Elevated circulating glutaric acid concentration, Elevated urinary carboxylic acid, Seizure, Encephalopathy, Death in infancy, Opisthotonus.

\n\n+5. Mitochondrial Disease:
The patient has symptoms in common: Seizure, Encephalopathy. The patient does not have symptoms in common: Glutaric aciduria, Elevated circulating glutaric acid concentration, Decreased plasma free carnitine, Elevated urinary carboxylic acid, Death in infancy, Opisthotonus.

Note: These are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Muscular Dystrophy: This is a group of genetic disorders that affect the muscles, leading to muscle weakness, wasting, and degeneration. The patient has symptoms in common with this disease, such as: Strabismus, Nystagmus, Motor delay, Generalized hypotonia, and Spastic diplegia. The patient does not have symptoms in common with this disease, such as: Diarrhea, Pneumonia, Dyspnea, Hyperkalemia, Opisthotonus, Hepatomegaly, Fair hair, Spastic tetraplegia, Hypocalcemia, Neonatal death, Stridor, and Severe hearing impairment.

\n\n+2. Rett Syndrome: This is a rare genetic disorder that affects brain development, leading to intellectual disability, seizures, and motor problems. The patient has symptoms in common with this disease, such as: Intellectual disability, Seizure, Motor delay, and Generalized hypotonia. The patient does not have symptoms in common with this disease, such as: Strabismus, Nystagmus, Hyperactivity, Cyanosis, Edema, Diarrhea, Pneumonia, Dyspnea, Hyperkalemia, Opisthotonus, Hepatomegaly, Fair hair, Spastic tetraplegia, Hypocalcemia, Neonatal death, Stridor, and Severe hearing impairment.

\n\n+3. Prader-Willi Syndrome: This is a rare genetic disorder that affects brain development, leading to intellectual disability, short stature, and obesity. The patient has symptoms in common with this disease, such as: Intellectual disability, Motor delay, and Generalized hypotonia. The patient does not have symptoms in common with this disease, such as: Strabismus, Nystagmus, Hyperactivity, Cyanosis, Edema, Seizure, Spastic diplegia, Diarrhea, Pneumonia, Dyspnea, Hyperkalemia, Opisthotonus, Hepatomegaly, Fair hair, Spastic tetraplegia, Hypocalcemia, Neonatal death, Stridor, and Severe hearing impairment.

\n\n+4. Mucopolysaccharidosis: This is a group of genetic disorders that affect the body's ability to break down and recycle sugars, leading to a buildup of toxic substances in the body. The patient has symptoms in common with this disease, such as: Edema, Diarrhea, and Pneumonia. The patient does not have symptoms in common with this disease, such as: Strabismus, Nystagmus, Hyperactivity, Cyanosis, Intellectual disability, Seizure, Spastic diplegia, Motor delay, Generalized hypotonia, Opisthotonus, Hepatomegaly, Fair hair, Spastic tetraplegia, Hypocalcemia, Neonatal death, Stridor, and Severe hearing impairment.

\n\n+5. Pompe Disease: This is a rare genetic disorder that affects the body's ability to break down glycogen, leading to muscle weakness, fatigue, and respiratory problems. The patient has symptoms in common with this disease, such as: Motor delay, Generalized hypotonia, and Respiratory problems (Dyspnea). The patient does not have symptoms in common with this disease, such as: Strabismus, Nystagmus, Hyperactivity, Cyanosis, Edema, Intellectual disability, Seizure, Spastic diplegia, Diarrhea, Pneumonia, Hyperkalemia, Opisthotonus, Hepatomegaly, Fair hair, Spastic tetraplegia, Hypocalcemia, Neonatal death, Stridor, and Severe hearing impairment.

Please note that this is not an exhaustive list, and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Friedrich's Ataxia: This is a rare genetic disorder that affects the nervous system, causing progressive damage to the cerebellum and spinal cord. The patient has ataxia, cerebellar atrophy, and generalized hypotonia in common with this disease. However, the patient does not have muscle weakness, vision loss, or heart problems, which are common symptoms of Friedrich's Ataxia.

\n\n+2. Rett Syndrome: This is a rare genetic disorder that affects brain development, causing intellectual disability, motor delay, and ataxia. The patient has intellectual disability, motor delay, and ataxia in common with this disease. However, the patient does not have seizures, sleep disturbances, or distinctive hand movements, which are common symptoms of Rett Syndrome.

\n\n+3. Spinocerebellar Ataxia: This is a group of rare genetic disorders that affect the cerebellum and spinal cord, causing ataxia, tremors, and muscle weakness. The patient has ataxia and cerebellar atrophy in common with this disease. However, the patient does not have muscle weakness, vision loss, or hearing loss, which are common symptoms of Spinocerebellar Ataxia.

\n\n+4. Zellweger Syndrome: This is a rare genetic disorder that affects brain development, causing intellectual disability, motor delay, and ataxia. The patient has intellectual disability, motor delay, and ataxia in common with this disease. However, the patient does not have distinctive facial features, heart defects, or liver problems, which are common symptoms of Zellweger Syndrome.

\n\n+5. Mucopolysaccharidosis: This is a group of rare genetic disorders that affect the body's ability to break down and recycle sugars, causing a range of symptoms including intellectual disability, motor delay, and ataxia. The patient has intellectual disability, motor delay, and ataxia in common with this disease. However, the patient does not have distinctive facial features, joint stiffness, or skin thickening, which are common symptoms of Mucopolysaccharidosis.

Note that these are just a few potential diseases that the patient may have, and a more thorough evaluation and testing would be necessary to make a definitive diagnosis."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Molybdenum cofactor deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, hyperreflexia, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as intellectual disability, which is often associated with this disease.

\n\n+2. Glutamic acidemia type I: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, hyperreflexia, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as vomiting, which is often associated with this disease.

\n\n+3. Canavan disease: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, hyperreflexia, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as macrocephaly, which is often associated with this disease.

\n\n+4. Phenylketonuria (PKU): This is a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine. The patient does not have symptoms in common with this disease, as PKU is typically characterized by intellectual disability, seizures, and skin problems.

\n\n+5. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, hyperreflexia, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as liver dysfunction, which is often associated with this disease.

\n\n+6. Pyridoxine-dependent epilepsy: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as seizure and hyperreflexia. However, the patient does not have symptoms such as developmental delay, which is often associated with this disease.

\n\n+7. Amino acid disorders: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as generalized hypotonia, hyperreflexia, and abnormal circulating aspartate family amino acid concentration. However, the patient does not have symptoms such as intellectual disability, which is often associated with this disease.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and laboratory tests."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and skin problems. The patient has in common: 'Hyperphenylalaninemia', 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Gastrointestinal inflammation'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and skin problems. The patient has in common: 'Hypertyrosinemia', 'Gastrointestinal inflammation'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Gastrointestinal inflammation', 'Hyperphenylalaninemia'.

\n\n+4. Congenital Hypertrophic Pyloric Stenosis (CHPS): CHPS is a condition that affects the stomach and can cause vomiting, dehydration, and weight loss. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+5. Neonatal Sepsis: Neonatal sepsis is a serious infection that can occur in newborns. Symptoms include fever, lethargy, and poor feeding. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

Note: These are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include ataxia, coma, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or skin rashes, which are common in methylmalonic acidemia.

\n\n+2. Leukodystrophy: This is a group of rare genetic disorders that affect the development and maintenance of the white matter in the brain. Symptoms include ataxia, abnormal cerebral white matter morphology, and death in childhood or adolescence, which the patient has in common. However, the patient does not have symptoms such as vision loss, hearing loss, or muscle weakness, which are common in leukodystrophy.

\n\n+3. Mitochondrial disease: This is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include ataxia, coma, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as muscle weakness, fatigue, or seizures, which are common in mitochondrial disease.

\n\n+4. Krabbe disease: This is a rare genetic disorder that affects the development and maintenance of the white matter in the brain. Symptoms include ataxia, abnormal cerebral white matter morphology, and death in childhood, which the patient has in common. However, the patient does not have symptoms such as vision loss, hearing loss, or muscle weakness, which are common in Krabbe disease.

\n\n+5. Adrenoleukodystrophy: This is a rare genetic disorder that affects the development and maintenance of the white matter in the brain. Symptoms include ataxia, abnormal cerebral white matter morphology, and death in childhood or adolescence, which the patient has in common. However, the patient does not have symptoms such as vision loss, hearing loss, or muscle weakness, which are common in adrenoleukodystrophy.

Note that these are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further testing and evaluation."
['Acute intermittent porphyria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Porphyria: Porphyria is a group of rare genetic disorders that affect the production of heme, a vital component of hemoglobin. Symptoms include abdominal pain, which is a common feature of many porphyria types. The patient's elevated urinary delta-aminolevulinic acid is also consistent with porphyria. However, death in childhood is not typically associated with porphyria, so this symptom is not in common with the proposed disease.

\n\n+2. Mucopolysaccharidosis: Mucopolysaccharidosis is a group of genetic disorders that affect the body's ability to break down and recycle certain sugars. Some symptoms of mucopolysaccharidosis include abdominal pain, which could be related to the patient's symptoms. However, elevated urinary delta-aminolevulinic acid is not typically associated with mucopolysaccharidosis, so this symptom is not in common with the proposed disease. Death in childhood is also not a typical symptom of mucopolysaccharidosis.

\n\n+3. Acute Intermittent Porphyria: Acute intermittent porphyria is a type of porphyria that is characterized by recurring episodes of abdominal pain, which is consistent with the patient's symptoms. Elevated urinary delta-aminolevulinic acid is also a common feature of this disease. However, death in childhood is not typically associated with acute intermittent porphyria, so this symptom is not in common with the proposed disease.

\n\n+4. Congenital Erythropoietic Porphyria: Congenital erythropoietic porphyria is a rare genetic disorder that affects the production of heme. Symptoms include abdominal pain, which is consistent with the patient's symptoms. Elevated urinary delta-aminolevulinic acid is also a common feature of this disease. Death in childhood is a possible complication of congenital erythropoietic porphyria, so this symptom is in common with the proposed disease.

\n\n+5. Lead Poisoning: Lead poisoning is a type of environmental poisoning that can cause a range of symptoms, including abdominal pain. However, elevated urinary delta-aminolevulinic acid is not typically associated with lead poisoning, so this symptom is not in common with the proposed disease. Death in childhood is also not typically associated with lead poisoning.

Note that this is not an exhaustive list, and there may be other potential diseases that could be causing the patient's symptoms. A more thorough evaluation and diagnostic workup would be necessary to determine the underlying cause of the patient's symptoms."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, seizures, and developmental delays. The patient has in common: Metabolic acidosis, Seizure. The patient does not have in common: Death in infancy, Neonatal death, Methylmalonic aciduria.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include metabolic acidosis, seizures, and developmental delays. The patient has in common: Metabolic acidosis, Seizure. The patient does not have in common: Death in infancy, Neonatal death, Methylmalonic aciduria.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include metabolic acidosis, seizures, and developmental delays. The patient has in common: Metabolic acidosis, Seizure. The patient does not have in common: Death in infancy, Neonatal death, Methylmalonic aciduria.

\n\n+4. Glutaric acidemia type I: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include metabolic acidosis, seizures, and developmental delays. The patient has in common: Metabolic acidosis, Seizure. The patient does not have in common: Death in infancy, Neonatal death, Methylmalonic aciduria.

\n\n+5. Isovaleric acidemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include metabolic acidosis, seizures, and developmental delays. The patient has in common: Metabolic acidosis, Seizure. The patient does not have in common: Death in infancy, Neonatal death, Methylmalonic aciduria.

Note that these are just a few potential diseases that the patient may have, and a more thorough diagnosis would require further testing and evaluation."
['Alkaptonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Meningitis: Meningitis is a serious infection that causes inflammation of the protective membranes (meninges) surrounding the brain and spinal cord. The patient has symptoms in common with meningitis such as Lethargy, Drowsiness, and Seizure. However, the patient does not have symptoms such as Fever, Headache, or Nausea, which are common in meningitis.

\n\n+2. Hypothyroidism: Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormones, leading to a range of symptoms. The patient has symptoms in common with hypothyroidism such as Lethargy, Drowsiness, and Growth delay. However, the patient does not have symptoms such as Dry skin, Hair loss, or Cold intolerance, which are common in hypothyroidism.

\n\n+3. Prader-Willi Syndrome: Prader-Willi Syndrome is a rare genetic disorder that affects the development of the brain and body. The patient has symptoms in common with Prader-Willi Syndrome such as Growth delay, Lethargy, and Drowsiness. However, the patient does not have symptoms such as Hyperphagia (excessive hunger), Short stature, or Intellectual disability, which are common in Prader-Willi Syndrome.

\n\n+4. Leigh Syndrome: Leigh Syndrome is a rare genetic disorder that affects the development of the brain and nervous system. The patient has symptoms in common with Leigh Syndrome such as Seizure, Lethargy, and Drowsiness. However, the patient does not have symptoms such as Muscle weakness, Vision loss, or Developmental delay, which are common in Leigh Syndrome.

\n\n+5. Mitochondrial Disease: Mitochondrial Disease is a group of disorders that affect the mitochondria, the energy-producing structures within cells. The patient has symptoms in common with Mitochondrial Disease such as Lethargy, Drowsiness, and Seizure. However, the patient does not have symptoms such as Muscle weakness, Fatigue, or Vision loss, which are common in Mitochondrial Disease.

\n\n+6. Krabbe Disease: Krabbe Disease is a rare genetic disorder that affects the development of the brain and nervous system. The patient has symptoms in common with Krabbe Disease such as Seizure, Lethargy, and Drowsiness. However, the patient does not have symptoms such as Muscle weakness, Vision loss, or Developmental delay, which are common in Krabbe Disease.

\n\n+7. Hypokalemia: Hypokalemia is a condition where the level of potassium in the blood is too low. The patient has symptoms in common with hypokalemia such as Lethargy, Drowsiness, and Seizure. However, the patient does not have symptoms such as Muscle weakness, Fatigue, or Abnormal heart rhythms, which are common in hypokalemia.

Note: This is not an exhaustive list, and further testing and evaluation are necessary to confirm a diagnosis."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids, leading to a buildup of toxic compounds in the body. Symptoms include seizures, developmental delays, and intellectual disability. The patient has in common: Seizure, Abnormal circulating leucine concentration, Abnormal circulating isoleucine concentration, Abnormal circulating valine concentration. The patient does not have in common: Death in infancy, Neonatal death.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine, leading to a buildup of toxic compounds in the body. Symptoms include seizures, intellectual disability, and behavioral problems. The patient has in common: Seizure, Abnormal circulating phenylalanine concentration (not listed, but implied). The patient does not have in common: Death in infancy, Neonatal death, Aminoaciduria.

\n\n+3. Methylmalonic Acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of certain amino acids, leading to a buildup of toxic compounds in the body. Symptoms include seizures, developmental delays, and intellectual disability. The patient has in common: Seizure, Abnormal circulating amino acid concentration (not specified, but implied). The patient does not have in common: Death in infancy, Neonatal death.

\n\n+4. Organic Acidemia: Organic acidemia is a group of rare genetic disorders that affect the breakdown of certain amino acids, leading to a buildup of toxic compounds in the body. Symptoms include seizures, developmental delays, and intellectual disability. The patient has in common: Seizure, Abnormal circulating amino acid concentration (not specified, but implied). The patient does not have in common: Death in infancy, Neonatal death.

\n\n+5. Aminoaciduria: Aminoaciduria is a rare genetic disorder that affects the kidneys' ability to reabsorb certain amino acids, leading to excessive excretion in the urine. Symptoms include seizures, developmental delays, and intellectual disability. The patient has in common: Aminoaciduria. The patient does not have in common: Death in infancy, Neonatal death, Abnormal circulating amino acid concentration.

Note: The patient's symptoms are consistent with a genetic disorder affecting amino acid metabolism, but further testing and evaluation are needed to confirm the diagnosis."
['Very long chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Syndrome: This is a rare genetic disorder that affects the body's ability to use fat for energy. Symptoms include hypoglycemia, hepatomegaly, and abnormal circulating carnitine concentration. The patient has symptoms in common with this disease: hypoglycemia, hepatomegaly, and abnormal circulating carnitine concentration. The patient does not have symptoms in common with this disease: death in infancy, cardiomegaly, tachypnea, dicarboxylic aciduria, neonatal death, death in childhood, recurrent viral infections.

\n\n+2. Mitochondrial Myopathy: This is a group of genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include muscle weakness, fatigue, and lactic acidosis. The patient has symptoms in common with this disease: increased circulating lactate concentration. The patient does not have symptoms in common with this disease: death in infancy, cardiomegaly, hypoglycemia, hepatomegaly, tachypnea, dicarboxylic aciduria, neonatal death, death in childhood, recurrent viral infections.

\n\n+3. Organic Acidemia: This is a group of genetic disorders that affect the body's ability to break down certain amino acids. Symptoms include vomiting, lethargy, and seizures. The patient has symptoms in common with this disease: dicarboxylic aciduria. The patient does not have symptoms in common with this disease: death in infancy, cardiomegaly, hypoglycemia, hepatomegaly, tachypnea, neonatal death, death in childhood, recurrent viral infections.

\n\n+4. Neonatal Sepsis: This is a serious infection that occurs in newborns. Symptoms include fever, lethargy, and respiratory distress. The patient has symptoms in common with this disease: tachypnea. The patient does not have symptoms in common with this disease: death in infancy, cardiomegaly, hypoglycemia, hepatomegaly, increased circulating lactate concentration, dicarboxylic aciduria, neonatal death, death in childhood, recurrent viral infections.

\n\n+5. Congenital Heart Disease: This is a group of genetic disorders that affect the heart. Symptoms include cyanosis, congestive heart failure, and arrhythmias. The patient has symptoms in common with this disease: cardiomegaly. The patient does not have symptoms in common with this disease: death in infancy, hypoglycemia, hepatomegaly, increased circulating lactate concentration, tachypnea, dicarboxylic aciduria, neonatal death, death in childhood, recurrent viral infections.

Note: This is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['3-hydroxy-3-methylglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Glutaric Acidemia Type 1:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

\n\n+2. 3-Methylglutaric Acidemia:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

\n\n+3. Methylmalonic Acidemia:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

\n\n+4. Propionic Acidemia:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

\n\n+5. Isovaleric Acidemia:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

\n\n+6. Multiple Carboxylase Deficiency:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

\n\n+7. Organic Acidemia:
The patient has symptoms of metabolic acidosis, hypoglycemia, and progressive neurologic deterioration in common with this disease. The patient does not have symptoms of seizure, lethargy, death in infancy, fever, vomiting, drowsiness, sleep abnormality, recurrent viral infections, or abnormal circulating glycine concentration.

Note: The patient's symptoms are more consistent with a diagnosis of Glutaric Acidemia Type 1 or 3-Methylglutaric Acidemia, but further testing and evaluation are necessary to confirm the diagnosis."
['MODY'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Porphyrinuria: Porphyrinuria is a rare genetic disorder that affects the production of heme, a vital component of hemoglobin. Symptoms include increased levels of porphyrins in the urine, which can cause a range of symptoms including abdominal pain, fatigue, and neurological problems. The patient has in common: Abnormal circulating porphyrin concentration. The patient does not have in common: Hypoglycemia, Glycosuria.

\n\n+2. Diabetes Mellitus: Diabetes Mellitus is a group of metabolic disorders characterized by high blood sugar levels. Symptoms include increased thirst and urination, blurred vision, and fatigue. The patient has in common: Glycosuria. The patient does not have in common: Hypoglycemia, Abnormal circulating porphyrin concentration.

\n\n+3. Hypoglycemia: Hypoglycemia is a condition characterized by low blood sugar levels. Symptoms include shakiness, dizziness, and confusion. The patient has in common: Hypoglycemia. The patient does not have in common: Glycosuria, Abnormal circulating porphyrin concentration.

\n\n+4. Porphyria: Porphyria is a group of genetic disorders that affect the production of heme. Symptoms include abdominal pain, fatigue, and neurological problems. The patient has in common: Abnormal circulating porphyrin concentration. The patient does not have in common: Hypoglycemia, Glycosuria.

\n\n+5. Renal Glycosuria: Renal Glycosuria is a rare genetic disorder that affects the kidneys' ability to reabsorb glucose. Symptoms include increased urine production and glycosuria. The patient has in common: Glycosuria. The patient does not have in common: Hypoglycemia, Abnormal circulating porphyrin concentration.

Note: These are just potential diseases based on the symptoms provided, and a proper diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone, leading to growth and developmental delays. Symptoms include delayed speech and language development, and short stature. The patient does not have in common: 'Hyperphenylalaninemia'.

\n\n+3. Trisomy 13 (Patau Syndrome): Trisomy 13 is a rare genetic disorder where there is an extra copy of chromosome 13. Symptoms include intellectual disability, heart defects, and facial abnormalities. The patient has in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'. The patient does not have in common: 'Hyperphenylalaninemia'.

\n\n+4. Fetal Alcohol Syndrome: Fetal alcohol syndrome is a condition caused by prenatal exposure to alcohol, leading to growth and developmental delays. Symptoms include facial abnormalities, heart defects, and intellectual disability. The patient does not have in common: 'Hyperphenylalaninemia'.

\n\n+5. Prader-Willi Syndrome: Prader-Willi syndrome is a genetic disorder that affects the hypothalamus, leading to short stature, obesity, and intellectual disability. Symptoms include hypotonia, and behavioral problems. The patient does not have in common: 'Hyperphenylalaninemia'.

Please note that this is not an exhaustive list, and a more detailed medical evaluation and testing would be necessary to confirm a diagnosis."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Hydrocephalus: Hydrocephalus is a condition where there is an accumulation of cerebrospinal fluid (CSF) in the brain, leading to increased intracranial pressure. The patient has symptoms of Macrocephaly, Seizure, Lethargy, Dystonia, Hyperreflexia, and Increased CSF protein concentration in common with this disease. The patient does not have symptoms of Anemia, Fever, Vomiting, Cerebral atrophy, Opisthotonus, Drowsiness, Sleep abnormality, Fasciculations, Upper airway obstruction, Glutaric aciduria, Chronic pulmonary obstruction, Death in infancy, Death in childhood, or Death in adolescence.

\n\n+2. Glutaric aciduria: Glutaric aciduria is a rare genetic disorder that affects the breakdown of certain amino acids, leading to the accumulation of toxic compounds in the body. The patient has symptoms of Macrocephaly, Seizure, Lethargy, Dystonia, Hyperreflexia, and Death in childhood in common with this disease. The patient does not have symptoms of Anemia, Fever, Vomiting, Cerebral atrophy, Opisthotonus, Drowsiness, Sleep abnormality, Fasciculations, Upper airway obstruction, Hydrocephalus, Increased CSF protein concentration, Chronic pulmonary obstruction, Death in infancy, or Death in adolescence.

\n\n+3. Meningitis: Meningitis is an infection of the membranes surrounding the brain and spinal cord. The patient has symptoms of Fever, Vomiting, Seizure, Lethargy, and Drowsiness in common with this disease. The patient does not have symptoms of Macrocephaly, Hyperhidrosis, Dystonia, Hyperreflexia, Anemia, Cerebral atrophy, Opisthotonus, Sleep abnormality, Fasciculations, Upper airway obstruction, Glutaric aciduria, Chronic pulmonary obstruction, Death in infancy, Death in childhood, or Death in adolescence.

\n\n+4. Cerebral palsy: Cerebral palsy is a group of disorders that affect movement, muscle tone, and posture. The patient has symptoms of Macrocephaly, Seizure, Lethargy, Dystonia, and Hyperreflexia in common with this disease. The patient does not have symptoms of Anemia, Fever, Vomiting, Cerebral atrophy, Opisthotonus, Drowsiness, Sleep abnormality, Fasciculations, Upper airway obstruction, Glutaric aciduria, Chronic pulmonary obstruction, Death in infancy, Death in childhood, or Death in adolescence.

\n\n+5. Rett syndrome: Rett syndrome is a rare genetic disorder that affects brain development and function. The patient has symptoms of Macrocephaly, Seizure, Lethargy, Dystonia, and Hyperreflexia in common with this disease. The patient does not have symptoms of Anemia, Fever, Vomiting, Cerebral atrophy, Opisthotonus, Drowsiness, Sleep abnormality, Fasciculations, Upper airway obstruction, Glutaric aciduria, Chronic pulmonary obstruction, Death in infancy, Death in childhood, or Death in adolescence.

Please note that this is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver damage, kidney damage, and an increased risk of liver cancer. The patient has 'Hypertyrosinemia' in common with this disease, but does not have 'Hyperphenylalaninemia', 'Preeclampsia', or 'Death in early adulthood'.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has 'Hyperphenylalaninemia' in common with this disease, but does not have 'Hypertyrosinemia', 'Preeclampsia', or 'Death in early adulthood'.

\n\n+3. Preeclampsia: Preeclampsia is a pregnancy complication characterized by high blood pressure and damage to organs such as the kidneys and liver. Symptoms include headaches, vision changes, and abdominal pain. The patient has 'Preeclampsia' in common with this disease, but does not have 'Hypertyrosinemia', 'Hyperphenylalaninemia', or 'Death in early adulthood'.

\n\n+4. Leukodystrophy: Leukodystrophy is a group of rare genetic disorders that affect the breakdown of fatty substances in the brain and spinal cord. Symptoms include muscle weakness, loss of coordination, and cognitive decline. The patient does not have any symptoms in common with this disease.

\n\n+5. Mitochondrial disease: Mitochondrial disease is a group of rare genetic disorders that affect the energy-producing structures within cells. Symptoms include muscle weakness, fatigue, and cognitive decline. The patient does not have any symptoms in common with this disease.

Note: The patient's symptoms are quite specific and do not match with most common diseases. Further testing and evaluation are needed to determine the exact cause of the patient's symptoms."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia', 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in early adulthood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia', 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in early adulthood'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in early adulthood', 'Hyperphenylalaninemia'.

\n\n+4. Organic Acidemia: Organic acidemia is a group of rare genetic disorders that affect the breakdown of certain compounds in the body. Symptoms include intellectual disability, seizures, and a range of physical and neurological problems. The patient has in common: 'Elevated urinary carboxylic acid'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in early adulthood', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

\n\n+5. Fetal Alcohol Syndrome (FAS): FAS is a condition that occurs when a woman drinks alcohol during pregnancy. Symptoms include intellectual disability, facial abnormalities, and growth problems. The patient does not have in common: 'Hyperphenylalaninemia', 'Hypertyrosinemia', 'Elevated urinary carboxylic acid', 'Death in infancy', 'Neonatal death', 'Death in early adulthood'.

Note: These are just a few potential diseases that the patient may have, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['Hereditary orotic aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Tyrosinemia Type 1: A rare genetic disorder caused by a deficiency of the enzyme fumarylacetoacetate hydrolase, leading to the accumulation of toxic compounds in the body. The patient has in common: fever, vomiting, lethargy, and death in infancy. The patient does not have in common: skin rash, splenomegaly, hepatomegaly, abnormal circulating alanine concentration, and feeding difficulties.

\n\n+2. Mucopolysaccharidosis Type VII: A lysosomal storage disorder caused by a deficiency of the enzyme beta-glucuronidase, leading to the accumulation of glycosaminoglycans in the body. The patient has in common: skin rash, lethargy, and death in childhood. The patient does not have in common: fever, vomiting, splenomegaly, hepatomegaly, abnormal circulating alanine concentration, and feeding difficulties.

\n\n+3. Maple Syrup Urine Disease: A rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex, leading to the accumulation of toxic compounds in the body. The patient has in common: lethargy, vomiting, and death in infancy. The patient does not have in common: skin rash, splenomegaly, hepatomegaly, abnormal circulating alanine concentration, and feeding difficulties.

\n\n+4. Citrullinemia Type 1: A rare genetic disorder caused by a deficiency of the enzyme argininosuccinate lyase, leading to the accumulation of toxic compounds in the body. The patient has in common: lethargy, vomiting, and death in infancy. The patient does not have in common: skin rash, splenomegaly, hepatomegaly, abnormal circulating alanine concentration, and feeding difficulties.

\n\n+5. Hyperammonemia: A condition caused by a deficiency of the enzyme ornithine transcarbamylase, leading to the accumulation of toxic compounds in the body. The patient has in common: lethargy, vomiting, and death in infancy. The patient does not have in common: skin rash, splenomegaly, hepatomegaly, abnormal circulating alanine concentration, and feeding difficulties.

Please note that this is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Holocarboxylase synthetase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Propionic Acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase, which is necessary for the breakdown of certain amino acids. The patient has symptoms in common with this disease, including 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', and 'Death in infancy'. The patient does not have symptoms in common with this disease, such as 'Cyanosis', 'obsolete Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Anemia', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', and 'Elevated urinary carboxylic acid'.

\n\n+2. Methylmalonic Acidemia: This is another rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase, which is necessary for the breakdown of certain amino acids. The patient has symptoms in common with this disease, including 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', and 'Death in infancy'. The patient does not have symptoms in common with this disease, such as 'Cyanosis', 'obsolete Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Anemia', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', and 'Elevated urinary carboxylic acid'.

\n\n+3. Maple Syrup Urine Disease (MSUD): This is a rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex, which is necessary for the breakdown of certain amino acids. The patient does not have symptoms in common with this disease, such as 'Cyanosis', 'obsolete Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Anemia', 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', 'Death in infancy', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', and 'Elevated urinary carboxylic acid'.

\n\n+4. Glycine Encephalopathy: This is a rare genetic disorder caused by a deficiency of the enzyme glycine cleavage system, which is necessary for the breakdown of certain amino acids. The patient has symptoms in common with this disease, including 'Abnormal circulating glycine concentration' and 'Abnormal circulating monocarboxylic acid concentration'. The patient does not have symptoms in common with this disease, such as 'Cyanosis', 'obsolete Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Anemia', 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', 'Death in infancy', 'Decreased pyruvate carboxylase activity', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', and 'Elevated urinary carboxylic acid'.

\n\n+5. Organic Acidemia: This is a general term that refers to a group of rare genetic disorders caused by a deficiency of enzymes involved in the breakdown of certain amino acids. The patient has symptoms in common with this disease, including 'Metabolic acidosis', 'Hyperammonemia', 'Diarrhea', 'Tachypnea', and 'Death in infancy'. The patient does not have symptoms in common with this disease, such as 'Cyanosis', 'obsolete Eczematoid dermatitis', 'Skin rash', 'Generalized hypotonia', 'Anemia', 'Propionyl-CoA carboxylase deficiency', 'Aminoaciduria', 'Abnormal circulating glycine concentration', 'Abnormal circulating monocarboxylic acid concentration', and 'Elevated urinary carboxylic acid'.

Note: These are just a few potential diseases that the patient may have, and a more comprehensive diagnosis would require further testing and evaluation."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include lethargy, vomiting, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Methylmalonic Acidemia.

\n\n+2. Urea Cycle Disorders: This group of disorders affects the body's ability to remove waste products from the blood. Symptoms include hyperammonemia, vomiting, and lethargy, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Urea Cycle Disorders.

\n\n+3. Organic Acidemias: This is a group of disorders that affect the body's ability to break down certain proteins and fats. Symptoms include lethargy, vomiting, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Organic Acidemias.

\n\n+4. Mitochondrial Disorders: This is a group of disorders that affect the body's energy-producing structures, known as mitochondria. Symptoms include lethargy, vomiting, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as muscle weakness, seizures, or developmental delays, which are common in Mitochondrial Disorders.

\n\n+5. Inborn Errors of Metabolism: This is a group of disorders that affect the body's ability to break down certain proteins and fats. Symptoms include lethargy, vomiting, and hyperammonemia, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Inborn Errors of Metabolism.

\n\n+6. Orotic Aciduria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include orotic aciduria, which the patient has in common. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Orotic Aciduria.

Note: The patient's symptoms of apathy, ataxia, sleep abnormality, and death in adolescence are not typical of these diseases, and further evaluation is needed to determine the underlying cause of the patient's condition."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Ethylmalonic Aciduria: This is a rare genetic disorder that affects the metabolism of fatty acids. Symptoms include vomiting, abnormal circulating carnitine concentration, and decreased 3-hydroxyacyl-CoA dehydrogenase level. The patient has in common: vomiting, abnormal circulating carnitine concentration, and decreased 3-hydroxyacyl-CoA dehydrogenase level. The patient does not have in common: death in childhood, death in adolescence.

\n\n+2. Carnitine Deficiency: This is a condition where the body is unable to produce or process carnitine, a vital nutrient for energy production. Symptoms include vomiting, abnormal circulating carnitine concentration, and muscle weakness. The patient has in common: vomiting, abnormal circulating carnitine concentration. The patient does not have in common: death in childhood, death in adolescence, decreased 3-hydroxyacyl-CoA dehydrogenase level.

\n\n+3. Mitochondrial Myopathy: This is a group of disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include muscle weakness, fatigue, and vomiting. The patient has in common: vomiting. The patient does not have in common: abnormal circulating carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, death in childhood, death in adolescence.

\n\n+4. Organic Acidemia: This is a group of disorders that affect the metabolism of organic acids, which are byproducts of energy production. Symptoms include vomiting, lethargy, and developmental delay. The patient has in common: vomiting. The patient does not have in common: abnormal circulating carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, death in childhood, death in adolescence.

\n\n+5. Mucopolysaccharidosis: This is a group of disorders that affect the metabolism of mucopolysaccharides, complex carbohydrates found in connective tissue. Symptoms include joint pain, skin thickening, and developmental delay. The patient does not have in common: vomiting, abnormal circulating carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, death in childhood, death in adolescence.

Please note that this is not an exhaustive list, and a definitive diagnosis can only be made through further testing and evaluation."
['Smith-Lemli-Opitz syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder caused by a defect in the DHCR7 gene, which is responsible for the production of cholesterol. The patient has symptoms such as low-set ears, wide nasal bridge, anteverted nares, ptosis, syndactyly, intellectual disability, motor delay, generalized hypotonia, and hypocholesterolemia in common with this disease. The patient does not have symptoms such as neonatal death, elevated 8-dehydrocholesterol, and elevated circulating 7-dehydrocholesterol concentration in common with this disease.

\n\n+2. Congenital Diaphragmatic Hernia: This is a rare birth defect where the diaphragm does not form properly, allowing organs to move into the chest cavity. The patient does not have any symptoms in common with this disease.

\n\n+3. Trisomy 13: This is a rare genetic disorder caused by an extra copy of chromosome 13. The patient has symptoms such as intellectual disability, motor delay, and generalized hypotonia in common with this disease. The patient does not have symptoms such as low-set ears, wide nasal bridge, anteverted nares, ptosis, syndactyly, hypocholesterolemia, and death in infancy in common with this disease.

\n\n+4. Williams Syndrome: This is a rare genetic disorder caused by a deletion of genetic material on chromosome 7. The patient does not have any symptoms in common with this disease.

\n\n+5. Prader-Willi Syndrome: This is a rare genetic disorder caused by a deletion or mutation of genetic material on chromosome 15. The patient does not have any symptoms in common with this disease.

\n\n+6. Rett Syndrome: This is a rare genetic disorder caused by a mutation of the MECP2 gene. The patient does not have any symptoms in common with this disease.

\n\n+7. Angelman Syndrome: This is a rare genetic disorder caused by a mutation of the UBE3A gene. The patient does not have any symptoms in common with this disease.

\n\n+8. CHARGE Syndrome: This is a rare genetic disorder caused by a mutation of the CHD7 gene. The patient does not have any symptoms in common with this disease.

\n\n+9. Mucolipidosis IV: This is a rare genetic disorder caused by a mutation of the GNPTAB gene. The patient does not have any symptoms in common with this disease.

\n\n+10. Aicardi-Goutières Syndrome: This is a rare genetic disorder caused by a mutation of the TREX1 gene. The patient does not have any symptoms in common with this disease.

Based on the symptoms provided, Smith-Lemli-Opitz Syndrome appears to be the most likely diagnosis. However, further testing and evaluation would be necessary to confirm the diagnosis."
['L-2-hydroxyglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. L-2-Hydroxyglutaric Aciduria: This is a rare genetic disorder caused by a deficiency of the enzyme L-2-hydroxyglutarate dehydrogenase. Symptoms include intellectual disability, ataxia, and cerebral atrophy, which the patient has in common. The patient also has abnormal basal ganglia morphology, which is consistent with this disease. However, the patient does not have symptoms such as tremor, neonatal death, or death in infancy/childhood.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include intellectual disability, ataxia, and cerebral atrophy, which the patient has in common. However, the patient does not have symptoms such as tremor, abnormal basal ganglia morphology, or death in infancy/childhood.

\n\n+3. Pyruvate Dehydrogenase Deficiency: This is a rare genetic disorder caused by a deficiency of the enzyme pyruvate dehydrogenase. Symptoms include intellectual disability, ataxia, and cerebral atrophy, which the patient has in common. However, the patient does not have symptoms such as tremor, abnormal basal ganglia morphology, or death in infancy/childhood.

\n\n+4. Leigh Syndrome: This is a rare genetic disorder caused by a deficiency of the enzyme pyruvate dehydrogenase. Symptoms include intellectual disability, ataxia, and cerebral atrophy, which the patient has in common. However, the patient does not have symptoms such as tremor, abnormal basal ganglia morphology, or death in infancy/childhood.

\n\n+5. Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS): This is a rare genetic disorder caused by a deficiency of the enzyme pyruvate dehydrogenase. Symptoms include intellectual disability, ataxia, and cerebral atrophy, which the patient has in common. However, the patient does not have symptoms such as tremor, abnormal basal ganglia morphology, or death in infancy/childhood.

Note: The patient's symptoms are consistent with L-2-Hydroxyglutaric Aciduria, but further testing and evaluation are needed to confirm the diagnosis."
['3-hydroxy-3-methylglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include irritability, seizures, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in methylmalonic acidemia.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include irritability, seizures, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in propionic acidemia.

\n\n+3. 3-Methylglutaconic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include irritability, seizures, and 3-methylglutaconic aciduria, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in 3-methylglutaconic aciduria.

\n\n+4. Dicarboxylic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include irritability, seizures, and dicarboxylic aciduria, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in dicarboxylic aciduria.

\n\n+5. Neonatal adrenoleukodystrophy: This is a rare genetic disorder that affects the body's ability to break down certain fats. Symptoms include irritability, seizures, and neonatal death, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in neonatal adrenoleukodystrophy.

\n\n+6. Mitochondrial disease: This is a group of rare genetic disorders that affect the body's energy-producing structures called mitochondria. Symptoms include irritability, seizures, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as muscle weakness, fatigue, or vision loss, which are common in mitochondrial disease.

\n\n+7. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Symptoms include irritability, seizures, and metabolic acidosis, which the patient has in common. However, the patient does not have symptoms such as vomiting, diarrhea, or muscle weakness, which are common in organic acidemia.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and testing."
['L-2-hydroxyglutaric aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. L-2-Hydroxyglutaric Aciduria: This is a rare genetic disorder that affects the metabolism of certain amino acids. Symptoms include skin rash, elevated circulating C-reactive protein concentration, and decreased serum iron. The patient has skin rash and elevated circulating C-reactive protein concentration in common with this disease, but does not have seizure, death in infancy, or fever.

\n\n+2. Eczematoid Dermatitis: This is a type of skin condition characterized by inflammation and itching. Symptoms include skin rash, and the patient has this symptom in common with this disease. However, the patient does not have seizure, death in infancy, or fever.

\n\n+3. Meningitis: This is a serious infection that can cause fever, seizure, and death in infancy. The patient has fever and seizure in common with this disease, but does not have skin rash, elevated circulating C-reactive protein concentration, or decreased serum iron.

\n\n+4. Iron Deficiency Anemia: This is a condition where the body does not have enough iron to produce healthy red blood cells. Symptoms include decreased serum iron, and the patient has this symptom in common with this disease. However, the patient does not have skin rash, seizure, death in infancy, or fever.

\n\n+5. Inflammatory Bowel Disease: This is a condition that causes chronic inflammation in the digestive tract. Symptoms include elevated circulating C-reactive protein concentration, and the patient has this symptom in common with this disease. However, the patient does not have skin rash, seizure, death in infancy, or decreased serum iron.

Note that this is not an exhaustive list, and further testing and evaluation would be necessary to make a definitive diagnosis."
['X-linked hypophosphatemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Hypophosphatasia: This is a rare genetic disorder characterized by impaired bone mineralization, leading to skeletal deformities and short stature. The patient has in common: Hypophosphatemia, Abnormal limb bone morphology, and Abnormal circulating hormone concentration. The patient does not have in common: Nephritis, Death in infancy, Death in childhood, Elevated circulating alkaline phosphatase concentration.

\n\n+2. Rickets: This is a condition caused by vitamin D deficiency or resistance, leading to softening of the bones and skeletal deformities. The patient has in common: Hypophosphatemia, Abnormal limb bone morphology, and Abnormal circulating hormone concentration. The patient does not have in common: Nephritis, Death in infancy, Death in childhood, Elevated circulating alkaline phosphatase concentration.

\n\n+3. Osteogenesis Imperfecta: This is a genetic disorder characterized by brittle bones that are prone to fractures. The patient has in common: Abnormal limb bone morphology, Abnormal circulating hormone concentration. The patient does not have in common: Nephritis, Death in infancy, Death in childhood, Hypophosphatemia, Elevated circulating alkaline phosphatase concentration.

\n\n+4. Familial Hypophosphatemic Rickets: This is a rare genetic disorder characterized by impaired phosphate reabsorption in the kidneys, leading to hypophosphatemia and rickets. The patient has in common: Hypophosphatemia, Abnormal limb bone morphology, Abnormal circulating hormone concentration. The patient does not have in common: Nephritis, Death in infancy, Death in childhood, Elevated circulating alkaline phosphatase concentration.

\n\n+5. Mucopolysaccharidosis: This is a group of genetic disorders caused by enzyme deficiencies, leading to storage of mucopolysaccharides in cells and tissues. The patient does not have in common: Any of the symptoms listed.

Note: The diagnosis is not definitive and further testing and evaluation are necessary to confirm the diagnosis."
['Propionic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include delayed speech and language development, skin rash, and intellectual disability. The patient has in common: delayed speech and language development, skin rash. The patient does not have in common: intellectual disability (not mentioned in the symptoms).

\n\n+2. Hyperammonemia: Hyperammonemia is a condition characterized by elevated levels of ammonia in the blood. Symptoms include hyperammonemia, hyperglycinemia, and hyperglycinuria. The patient has in common: hyperammonemia, hyperglycinemia, hyperglycinuria. The patient does not have in common: elevated ammonia levels (not mentioned in the symptoms).

\n\n+3. Carnitine deficiency: Carnitine deficiency is a condition that affects the transport of fatty acids into the mitochondria, leading to impaired energy production. Symptoms include leukopenia, hyperammonemia, and abnormal circulating carnitine concentration. The patient has in common: leukopenia, hyperammonemia. The patient does not have in common: abnormal circulating carnitine concentration (not mentioned in the symptoms).

\n\n+4. Organic acidemia: Organic acidemia is a group of disorders that affect the breakdown of certain amino acids, leading to the accumulation of toxic compounds. Symptoms include hyperammonemia, hyperglycinemia, and elevated urinary carboxylic acid. The patient has in common: hyperammonemia, hyperglycinemia. The patient does not have in common: elevated urinary carboxylic acid (not mentioned in the symptoms).

\n\n+5. Alkaptonuria: Alkaptonuria is a rare genetic disorder that affects the breakdown of tyrosine, leading to the accumulation of homogentisic acid in the urine. Symptoms include skin rash, and elevated circulating alkaline phosphatase concentration. The patient has in common: skin rash. The patient does not have in common: elevated circulating alkaline phosphatase concentration (not mentioned in the symptoms).

\n\n+6. Maple syrup urine disease (MSUD): MSUD is a genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include delayed speech and language development, skin rash, and death in infancy. The patient has in common: delayed speech and language development, skin rash. The patient does not have in common: death in infancy (not mentioned in the symptoms).

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
"['Methylmalonic acidemia with homocystinuria, type cblC']","Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: delayed speech and language development, generalized hypotonia, hyperhomocystinemia, abnormal cerebral white matter morphology, decreased plasma free carnitine, and methylmalonic aciduria. The patient does not have in common: gastrointestinal inflammation, neonatal death, death in infancy, and death in childhood.

\n\n+2. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. The patient has in common: delayed speech and language development, generalized hypotonia, decreased plasma free carnitine, and methylmalonic aciduria. The patient does not have in common: hyperhomocystinemia, abnormal cerebral white matter morphology, gastrointestinal inflammation, neonatal death, death in infancy, death in childhood.

\n\n+3. Leukodystrophy: This is a group of rare genetic disorders that affect the development and maintenance of the white matter in the brain. The patient has in common: delayed speech and language development, generalized hypotonia, abnormal cerebral white matter morphology, and methylmalonic aciduria. The patient does not have in common: hyperhomocystinemia, decreased plasma free carnitine, gastrointestinal inflammation, neonatal death, death in infancy, death in childhood.

\n\n+4. Homocystinuria: This is a rare genetic disorder that affects the body's ability to break down the amino acid methionine. The patient has in common: delayed speech and language development, generalized hypotonia, hyperhomocystinemia, and methylmalonic aciduria. The patient does not have in common: abnormal cerebral white matter morphology, decreased plasma free carnitine, gastrointestinal inflammation, neonatal death, death in infancy, death in childhood.

\n\n+5. Mitochondrial disorder: This is a group of rare genetic disorders that affect the mitochondria's ability to generate energy for the body. The patient has in common: delayed speech and language development, generalized hypotonia, and methylmalonic aciduria. The patient does not have in common: hyperhomocystinemia, abnormal cerebral white matter morphology, decreased plasma free carnitine, gastrointestinal inflammation, neonatal death, death in infancy, death in childhood.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include developmental delays, seizures, and intellectual disability. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Neonatal death.

\n\n+2. Propionic acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include developmental delays, seizures, and intellectual disability. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Neonatal death.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and intellectual disability. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Neonatal death.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and intellectual disability. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Neonatal death.

\n\n+5. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms include muscle weakness, fatigue, and heart problems. The patient does not have in common: Death in infancy, Neonatal death, Elevated urinary carboxylic acid.

Note: These are just a few potential diseases that may be related to the symptoms provided. A more thorough evaluation and testing would be necessary to confirm a diagnosis."
['Carbamoyl-phosphate synthetase 1 deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms of lethargy, spasticity, and hyperreflexia in common with this disease. However, the patient does not have symptoms of vomiting, diarrhea, or skin rashes, which are common in Methylmalonic Acidemia.

\n\n+2. Phenylketonuria (PKU): This is a genetic disorder that affects the body's ability to break down the amino acid phenylalanine. The patient has symptoms of lethargy, spasticity, and hyperreflexia in common with this disease. However, the patient does not have symptoms of intellectual disability, seizures, or eczema, which are common in PKU.

\n\n+3. Maple Syrup Urine Disease (MSUD): This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms of lethargy, spasticity, and hyperreflexia in common with this disease. However, the patient does not have symptoms of sweet-smelling urine, seizures, or intellectual disability, which are common in MSUD.

\n\n+4. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain organic compounds. The patient has symptoms of lethargy, spasticity, and hyperreflexia in common with this disease. However, the patient does not have symptoms of vomiting, diarrhea, or skin rashes, which are common in Organic Acidemia.

\n\n+5. Leigh Syndrome: This is a rare genetic disorder that affects the brain and spinal cord. The patient has symptoms of lethargy, spasticity, and hyperreflexia in common with this disease. However, the patient does not have symptoms of seizures, intellectual disability, or vision loss, which are common in Leigh Syndrome.

\n\n+6. Hyperekplexia: This is a rare genetic disorder that affects the nervous system. The patient has symptoms of spasticity and hyperreflexia in common with this disease. However, the patient does not have symptoms of muscle weakness, tremors, or intellectual disability, which are common in Hyperekplexia.

\n\n+7. Congenital Muscular Dystrophy: This is a group of rare genetic disorders that affect the muscles. The patient has symptoms of spasticity and generalized hypotonia in common with this disease. However, the patient does not have symptoms of muscle weakness, muscle cramps, or intellectual disability, which are common in Congenital Muscular Dystrophy.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and testing."
['Vitamin B12-unresponsive methylmalonic acidemia'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and death in childhood. The patient does not have in common: death in infancy.

\n\n+2. Propionic acidemia: This is another rare genetic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase. Symptoms include metabolic acidosis, decreased propionyl-CoA carboxylase activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, death in childhood. The patient does not have in common: decreased propionyl-CoA carboxylase activity, death in infancy.

\n\n+3. Multiple carboxylase deficiency: This is a rare genetic disorder caused by a deficiency of multiple enzymes involved in the metabolism of amino acids and fatty acids. Symptoms include metabolic acidosis, decreased enzyme activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, death in childhood. The patient does not have in common: decreased enzyme activity, death in infancy.

\n\n+4. Organic acidemia: This is a group of rare genetic disorders caused by a deficiency of enzymes involved in the metabolism of amino acids and fatty acids. Symptoms include metabolic acidosis, decreased enzyme activity, and often death in infancy or childhood. The patient has in common: metabolic acidosis, death in childhood. The patient does not have in common: decreased enzyme activity, death in infancy.

Note that these are just a few potential diseases that may be related to the symptoms provided, and a more comprehensive diagnosis would require further testing and evaluation."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Aplastic Anemia: Aplastic anemia is a rare blood disorder characterized by a decrease in the production of all types of blood cells. The patient has symptoms of hemolytic anemia, metabolic acidosis, and increased total bilirubin in common with this disease. However, the patient does not have symptoms of hyperactivity, spasticity, or recurrent viral infections.

\n\n+2. Porphyria: Porphyria is a group of rare genetic disorders that affect the production of heme, a vital component of hemoglobin. The patient has symptoms of abnormal circulating porphyrin concentration and increased circulating lactate dehydrogenase concentration in common with this disease. However, the patient does not have symptoms of hyperactivity, spasticity, or recurrent viral infections.

\n\n+3. Leukemia: Leukemia is a type of cancer that affects the blood and bone marrow. The patient has symptoms of hemolytic anemia, metabolic acidosis, and increased total bilirubin in common with this disease. However, the patient does not have symptoms of hyperactivity, spasticity, or recurrent viral infections.

\n\n+4. Mitochondrial Disease: Mitochondrial diseases are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. The patient has symptoms of metabolic acidosis, increased total bilirubin, and recurrent viral infections in common with this disease. However, the patient does not have symptoms of hyperactivity, spasticity, or abnormal circulating porphyrin concentration.

\n\n+5. Fanconi Anemia: Fanconi anemia is a rare genetic disorder that affects the bone marrow and increases the risk of cancer and other health problems. The patient has symptoms of hemolytic anemia, metabolic acidosis, and increased total bilirubin in common with this disease. However, the patient does not have symptoms of hyperactivity, spasticity, or recurrent viral infections.

Note: The patient's symptoms of death in infancy and neonatal death are concerning and may indicate a more severe or life-threatening condition. Further evaluation and testing are necessary to determine the underlying cause of the patient's symptoms."
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Citrullinemia: Citrullinemia is a rare genetic disorder that affects the metabolism of amino acids. The patient has symptoms of hyperammonemia, elevated plasma citrulline, and respiratory acidosis in common with this disease. However, the patient does not have symptoms of seizures, intellectual disability, or liver dysfunction, which are common in citrullinemia.

\n\n+2. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids. The patient has symptoms of hyperammonemia and elevated plasma citrulline in common with this disease. However, the patient does not have symptoms of sweet-smelling urine, intellectual disability, or seizures, which are common in MSUD.

\n\n+3. Neonatal Sepsis: Neonatal sepsis is a serious infection that can occur in newborns. The patient has symptoms of respiratory distress, apnea, and hypoxemia in common with this disease. However, the patient does not have symptoms of fever, lethargy, or skin lesions, which are common in neonatal sepsis.

\n\n+4. Congenital Diaphragmatic Hernia: Congenital diaphragmatic hernia is a birth defect that occurs when the diaphragm does not form properly. The patient has symptoms of respiratory distress and hypoxemia in common with this disease. However, the patient does not have symptoms of abdominal distension, vomiting, or bowel obstruction, which are common in congenital diaphragmatic hernia.

\n\n+5. Hypoxic-Ischemic Encephalopathy: Hypoxic-ischemic encephalopathy is a condition that occurs when the brain is deprived of oxygen and blood flow. The patient has symptoms of apnea, hypoxemia, and respiratory acidosis in common with this disease. However, the patient does not have symptoms of seizures, developmental delay, or cerebral palsy, which are common in hypoxic-ischemic encephalopathy.

\n\n+6. Neonatal Abstinence Syndrome: Neonatal abstinence syndrome is a condition that occurs when a newborn is exposed to substances such as opioids or benzodiazepines in the womb. The patient does not have any symptoms in common with this disease.

\n\n+7. Meconium Aspiration Syndrome: Meconium aspiration syndrome is a condition that occurs when a newborn inhales meconium, a thick, greenish-black substance that is present in the intestines of a newborn. The patient does not have any symptoms in common with this disease.

\n\n+8. Pulmonary Hypoplasia: Pulmonary hypoplasia is a condition that occurs when the lungs do not develop properly. The patient has symptoms of respiratory distress and hypoxemia in common with this disease. However, the patient does not have symptoms of cyanosis, clubbing, or respiratory failure, which are common in pulmonary hypoplasia.

\n\n+9. Congenital Heart Disease: Congenital heart disease is a birth defect that occurs when the heart or its blood vessels do not form properly. The patient does not have any symptoms in common with this disease.

\n\n+10. Inborn Errors of Metabolism: Inborn errors of metabolism are a group of genetic disorders that affect the breakdown of nutrients. The patient has symptoms of hyperammonemia and elevated plasma citrulline in common with this disease. However, the patient does not have symptoms of seizures, intellectual disability, or liver dysfunction, which are common in inborn errors of metabolism.

Please note that this is not an exhaustive list, and a definitive diagnosis can only be made after a thorough physical examination, medical history, and laboratory tests."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, seizures, coma, and death in infancy or childhood. The patient has symptoms in common with this disease, such as intellectual disability, seizures, and coma. However, the patient does not have symptoms of death in infancy or childhood.

\n\n+2. Methylmalonic aciduria: This is a milder form of methylmalonic acidemia, characterized by intellectual disability, seizures, and abnormal blood tests. The patient has symptoms in common with this disease, such as intellectual disability, seizures, and abnormal blood tests. However, the patient does not have symptoms of coma or death in infancy or childhood.

\n\n+3. Atransferrinemia: This is a rare genetic disorder that affects the body's ability to transport iron. Symptoms include intellectual disability, seizures, and abnormal blood tests. The patient has symptoms in common with this disease, such as intellectual disability and seizures. However, the patient does not have symptoms of coma, death in infancy or childhood, or abnormal blood tests related to iron deficiency.

\n\n+4. Chronic kidney disease: This is a condition characterized by progressive loss of kidney function over time. Symptoms include hypertension, edema, and abnormal blood tests. The patient has symptoms in common with this disease, such as hypertension and edema. However, the patient does not have symptoms of intellectual disability, seizures, coma, or death in infancy or childhood.

\n\n+5. Gout: This is a type of arthritis characterized by sudden, severe joint pain and swelling. Symptoms include gout, hyperuricemia, and increased circulating lactate concentration. The patient does not have symptoms in common with this disease, as they do not have joint pain or swelling.

\n\n+6. Kyphoscoliosis: This is a type of spinal curvature that can cause respiratory problems and other symptoms. Symptoms include kyphoscoliosis, poor coordination, and clumsiness. The patient has symptoms in common with this disease, such as poor coordination and clumsiness. However, the patient does not have symptoms of intellectual disability, seizures, coma, or death in infancy or childhood.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Dihydropteridine reductase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Rett Syndrome: Rett Syndrome is a rare genetic disorder that affects brain development and function. Common symptoms include microcephaly, intellectual disability, seizures, and motor delay. The patient's symptoms of nystagmus, abnormal cerebral white matter morphology, and hypertyrosinemia are not typically associated with Rett Syndrome. However, the patient's generalized hypotonia and cerebral atrophy are consistent with this diagnosis.

\n\n+2. Methylmalonic Acidemia: Methylmalonic Acidemia is a rare genetic disorder that affects the body's ability to break down certain amino acids. Common symptoms include intellectual disability, seizures, and motor delay. The patient's symptoms of microcephaly, nystagmus, and abnormal cerebral white matter morphology are not typically associated with Methylmalonic Acidemia. However, the patient's generalized hypotonia, cerebral atrophy, and hypertyrosinemia are consistent with this diagnosis.

\n\n+3. Phenylketonuria (PKU): Phenylketonuria is a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine. Common symptoms include intellectual disability, seizures, and motor delay. The patient's symptoms of microcephaly, nystagmus, and abnormal cerebral white matter morphology are not typically associated with PKU. However, the patient's generalized hypotonia, cerebral atrophy, and hyperphenylalaninemia are consistent with this diagnosis.

\n\n+4. Aicardi-Goutières Syndrome: Aicardi-Goutières Syndrome is a rare genetic disorder that affects brain development and function. Common symptoms include microcephaly, intellectual disability, seizures, and motor delay. The patient's symptoms of nystagmus, abnormal cerebral white matter morphology, and hypertyrosinemia are consistent with this diagnosis.

\n\n+5. Zellweger Syndrome: Zellweger Syndrome is a rare genetic disorder that affects brain development and function. Common symptoms include microcephaly, intellectual disability, seizures, and motor delay. The patient's symptoms of nystagmus, abnormal cerebral white matter morphology, and hypertyrosinemia are consistent with this diagnosis.

\n\n+6. Smith-Lemli-Opitz Syndrome: Smith-Lemli-Opitz Syndrome is a rare genetic disorder that affects cholesterol synthesis. Common symptoms include microcephaly, intellectual disability, seizures, and motor delay. The patient's symptoms of nystagmus, abnormal cerebral white matter morphology, and hypertyrosinemia are not typically associated with this diagnosis. However, the patient's generalized hypotonia and cerebral atrophy are consistent with this diagnosis.

Please note that this is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Glycogen Storage Disease: This is a group of genetic disorders that affect the body's ability to store and use glycogen, a complex carbohydrate. The patient has in common: Abnormal circulating glycine concentration, Glycosuria. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+2. Maple Syrup Urine Disease: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Glycosuria, Abnormal circulating glycine concentration. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+3. Mucopolysaccharidosis: This is a group of genetic disorders that affect the body's ability to break down and recycle certain sugars. The patient has in common: Glycosuria, Abnormal circulating glycine concentration. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+4. Phenylketonuria (PKU): This is a genetic disorder that affects the body's ability to break down the amino acid phenylalanine. The patient has in common: Glycosuria, Abnormal circulating glycine concentration. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+5. Tyrosinemia: This is a genetic disorder that affects the body's ability to break down the amino acid tyrosine. The patient has in common: Glycosuria, Abnormal circulating glycine concentration. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+6. Fabry Disease: This is a genetic disorder that affects the body's ability to break down certain fats. The patient has in common: Glycosuria, Abnormal circulating glycine concentration. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+7. Gaucher Disease: This is a genetic disorder that affects the body's ability to break down certain fats. The patient has in common: Glycosuria, Abnormal circulating glycine concentration. The patient does not have in common: Skin rash, Death in infancy, Cytochrome C oxidase-negative muscle fibers, Ethylmalonic aciduria, Feeding difficulties, Functional abnormality of the gastrointestinal tract, Erythematous plaque, Erythematous macule, Erythematous papule.

Please note that this is not an exhaustive list and the patient may have a different diagnosis. Further testing and evaluation are necessary to determine the correct diagnosis."
['Carbamoyl-phosphate synthetase 1 deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Citrullinemia Type I: Citrullinemia Type I is a rare genetic disorder that affects the metabolism of the amino acid citrulline. Symptoms include hyperammonemia, cerebral edema, and seizures. The patient has symptoms in common with this disease: hyperammonemia, cerebral edema, and seizures. The patient does not have symptoms in common with this disease: cyanosis, fasciculations, oroticaciduria, low plasma citrulline, neonatal death, or hypoargininemia.

\n\n+2. Argininosuccinic Aciduria: Argininosuccinic Aciduria is a rare genetic disorder that affects the metabolism of the amino acid arginine. Symptoms include hyperammonemia, seizures, and oroticaciduria. The patient has symptoms in common with this disease: hyperammonemia, seizures, and oroticaciduria. The patient does not have symptoms in common with this disease: cyanosis, fasciculations, low plasma citrulline, neonatal death, or hypoargininemia.

\n\n+3. Methylmalonic Acidemia: Methylmalonic Acidemia is a rare genetic disorder that affects the metabolism of the amino acid methionine. Symptoms include hyperammonemia, seizures, and death in infancy. The patient has symptoms in common with this disease: hyperammonemia, seizures, and death in infancy. The patient does not have symptoms in common with this disease: cyanosis, fasciculations, oroticaciduria, low plasma citrulline, or hypoargininemia.

\n\n+4. Pyruvate Dehydrogenase Deficiency: Pyruvate Dehydrogenase Deficiency is a rare genetic disorder that affects the metabolism of pyruvate. Symptoms include seizures, cerebral edema, and death in infancy. The patient has symptoms in common with this disease: seizures, cerebral edema, and death in infancy. The patient does not have symptoms in common with this disease: cyanosis, fasciculations, oroticaciduria, low plasma citrulline, or hypoargininemia.

\n\n+5. Neonatal Adrenoleukodystrophy: Neonatal Adrenoleukodystrophy is a rare genetic disorder that affects the metabolism of fatty acids. Symptoms include seizures, cerebral edema, and death in infancy. The patient has symptoms in common with this disease: seizures, cerebral edema, and death in infancy. The patient does not have symptoms in common with this disease: cyanosis, fasciculations, oroticaciduria, low plasma citrulline, or hypoargininemia.

Note: These are just a few potential diseases that the patient may have based on the symptoms provided. A definitive diagnosis would require further testing and evaluation."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Hyperglycinemia: Hyperglycinemia is a rare genetic disorder caused by a deficiency of the enzyme glycine cleavage system. Symptoms include seizures, developmental delay, and skin rash. The patient has in common: Skin rash, Seizure. The patient does not have in common: Death in infancy, Hyperammonemia, Aminoaciduria, Neonatal death, Abnormal circulating glycine concentration, Abnormal circulating aspartate family amino acid concentration, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+2. Glycine Encephalopathy: Glycine Encephalopathy is a rare genetic disorder caused by a deficiency of the enzyme glycine cleavage system. Symptoms include seizures, developmental delay, and skin rash. The patient has in common: Skin rash, Seizure. The patient does not have in common: Death in infancy, Hyperammonemia, Aminoaciduria, Neonatal death, Abnormal circulating glycine concentration, Abnormal circulating aspartate family amino acid concentration, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex. Symptoms include seizures, developmental delay, and skin rash. The patient has in common: Skin rash, Seizure. The patient does not have in common: Death in infancy, Hyperammonemia, Aminoaciduria, Neonatal death, Abnormal circulating glycine concentration, Abnormal circulating aspartate family amino acid concentration, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+4. Methylmalonic Acidemia: Methylmalonic Acidemia is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include seizures, developmental delay, and skin rash. The patient has in common: Skin rash, Seizure. The patient does not have in common: Death in infancy, Hyperammonemia, Aminoaciduria, Neonatal death, Abnormal circulating glycine concentration, Abnormal circulating aspartate family amino acid concentration, Erythematous plaque, Erythematous macule, Erythematous papule.

\n\n+5. Propionic Acidemia: Propionic Acidemia is a rare genetic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase. Symptoms include seizures, developmental delay, and skin rash. The patient has in common: Skin rash, Seizure. The patient does not have in common: Death in infancy, Hyperammonemia, Aminoaciduria, Neonatal death, Abnormal circulating glycine concentration, Abnormal circulating aspartate family amino acid concentration, Erythematous plaque, Erythematous macule, Erythematous papule.

Please note that these are just potential diseases and a definitive diagnosis would require further testing and evaluation."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include seizures, developmental delays, and feeding difficulties. The patient has in common: Seizure, Feeding difficulties. The patient does not have in common: Death in infancy, Respiratory insufficiency, Opisthotonus, Neonatal death, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Sepsis.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include seizures, intellectual disability, and behavioral problems. The patient has in common: Seizure. The patient does not have in common: Death in infancy, Respiratory insufficiency, Opisthotonus, Neonatal death, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Feeding difficulties, Sepsis.

\n\n+3. Methylmalonic Acidemia (MMA): MMA is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include seizures, developmental delays, and feeding difficulties. The patient has in common: Seizure, Feeding difficulties. The patient does not have in common: Death in infancy, Respiratory insufficiency, Opisthotonus, Neonatal death, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Sepsis.

\n\n+4. Organic Acidemia (OA): OA is a group of rare genetic disorders that affect the breakdown of certain amino acids. Symptoms include seizures, developmental delays, and feeding difficulties. The patient has in common: Seizure, Feeding difficulties. The patient does not have in common: Death in infancy, Respiratory insufficiency, Opisthotonus, Neonatal death, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Sepsis.

\n\n+5. Leukodystrophy: Leukodystrophy is a group of rare genetic disorders that affect the breakdown of certain fatty substances in the brain. Symptoms include seizures, developmental delays, and feeding difficulties. The patient has in common: Seizure, Feeding difficulties. The patient does not have in common: Death in infancy, Respiratory insufficiency, Opisthotonus, Neonatal death, Hypervalinemia, Hyperleucinemia, Hyperisoleucinemia, Sepsis.

Note: These are just a few potential diseases that the patient may have, and a more thorough diagnosis would require further testing and evaluation."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Disorder: This is a group of rare genetic disorders that affect the body's ability to use fat for energy. The patient has symptoms in common with this disease, such as Abnormal circulating carnitine concentration and Decreased 3-hydroxyacyl-CoA dehydrogenase level. However, the patient does not have symptoms such as Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, or Death in childhood.

\n\n+2. Mitochondrial Myopathy: This is a group of genetic disorders that affect the mitochondria, the energy-producing structures within cells. The patient has symptoms in common with this disease, such as Abnormal circulating carnitine concentration and Decreased 3-hydroxyacyl-CoA dehydrogenase level. However, the patient does not have symptoms such as Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, or Death in childhood.

\n\n+3. Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: This is a rare genetic disorder that affects the breakdown of fatty acids for energy. The patient has symptoms in common with this disease, such as Abnormal circulating carnitine concentration and Decreased 3-hydroxyacyl-CoA dehydrogenase level. However, the patient does not have symptoms such as Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, or Death in childhood.

\n\n+4. Carnitine Palmitoyltransferase II Deficiency: This is a rare genetic disorder that affects the transport of fatty acids into the mitochondria for energy production. The patient has symptoms in common with this disease, such as Abnormal circulating carnitine concentration and Decreased 3-hydroxyacyl-CoA dehydrogenase level. However, the patient does not have symptoms such as Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, or Death in childhood.

\n\n+5. Multiple Acyl-CoA Dehydrogenase Deficiency: This is a rare genetic disorder that affects the breakdown of fatty acids for energy. The patient has symptoms in common with this disease, such as Abnormal circulating carnitine concentration and Decreased 3-hydroxyacyl-CoA dehydrogenase level. However, the patient does not have symptoms such as Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, or Death in childhood.

Please note that these are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizure, and motor delay. The patient has in common: Intellectual disability, Seizure, Motor delay. The patient does not have in common: Death in infancy, Abnormal cerebral white matter morphology, Hypertyrosinemia, Death in childhood, Death in early adulthood, Dyskinesia.

\n\n+2. Leukodystrophy: Leukodystrophy is a group of genetic disorders that affect the development and maintenance of the white matter in the brain. Symptoms include intellectual disability, seizure, and motor delay. The patient has in common: Intellectual disability, Seizure, Motor delay. The patient does not have in common: Death in infancy, Hypertyrosinemia, Death in childhood, Death in early adulthood, Dyskinesia.

\n\n+3. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include intellectual disability, seizure, and motor delay. The patient has in common: Intellectual disability, Seizure, Motor delay. The patient does not have in common: Death in infancy, Abnormal cerebral white matter morphology, Death in childhood, Death in early adulthood, Dyskinesia.

\n\n+4. Methylmalonic acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizure, and motor delay. The patient has in common: Intellectual disability, Seizure, Motor delay. The patient does not have in common: Death in infancy, Abnormal cerebral white matter morphology, Hypertyrosinemia, Death in childhood, Death in early adulthood, Dyskinesia.

\n\n+5. Maple syrup urine disease: Maple syrup urine disease is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizure, and motor delay. The patient has in common: Intellectual disability, Seizure, Motor delay. The patient does not have in common: Death in infancy, Abnormal cerebral white matter morphology, Hypertyrosinemia, Death in childhood, Death in early adulthood, Dyskinesia.

Note: The patient's symptoms are quite severe, and it's possible that the patient may have a combination of these diseases or a different disease altogether. Further testing and evaluation would be necessary to determine the exact diagnosis."
['Wilson disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Wilson's Disease: Wilson's Disease is a rare genetic disorder that affects the body's ability to remove excess copper from the body. Symptoms include liver damage, kidney damage, and neurological problems. The patient has the following symptoms in common with Wilson's Disease: Hepatomegaly, Elevated circulating hepatic transaminase concentration, Decreased circulating ceruloplasmin concentration, Increased urinary copper concentration, Decreased circulating copper concentration, Copper accumulation in liver. The patient does not have the following symptoms in common with Wilson's Disease: Generalized hypotonia, Splenomegaly, Death in childhood, Death in adolescence.

\n\n+2. Menkes Syndrome: Menkes Syndrome is a rare genetic disorder that affects the body's ability to produce a protein called copper-transporting ATPase. Symptoms include brittle hair, intellectual disability, and seizures. The patient does not have any symptoms in common with Menkes Syndrome.

\n\n+3. Keshan Disease: Keshan Disease is a rare genetic disorder that affects the body's ability to produce a protein called copper-transporting ATPase. Symptoms include heart problems, muscle weakness, and fatigue. The patient does not have any symptoms in common with Keshan Disease.

\n\n+4. Acute Hepatitis: Acute Hepatitis is a short-term inflammation of the liver that can be caused by a viral infection or other factors. Symptoms include fever, fatigue, and yellowing of the skin and eyes. The patient has the following symptoms in common with Acute Hepatitis: Hepatomegaly, Elevated circulating hepatic transaminase concentration. The patient does not have the following symptoms in common with Acute Hepatitis: Generalized hypotonia, Splenomegaly, Death in childhood, Death in adolescence, Decreased circulating ceruloplasmin concentration, Increased urinary copper concentration, Decreased circulating copper concentration, Copper accumulation in liver.

\n\n+5. Liver Cirrhosis: Liver Cirrhosis is a chronic condition that occurs when the liver is damaged and scar tissue forms. Symptoms include jaundice, fatigue, and abdominal swelling. The patient has the following symptoms in common with Liver Cirrhosis: Hepatomegaly, Elevated circulating hepatic transaminase concentration. The patient does not have the following symptoms in common with Liver Cirrhosis: Generalized hypotonia, Splenomegaly, Death in childhood, Death in adolescence, Decreased circulating ceruloplasmin concentration, Increased urinary copper concentration, Decreased circulating copper concentration, Copper accumulation in liver.

Please note that this is not an exhaustive list and a definitive diagnosis can only be made after a thorough medical examination and further testing."
['PMM2-CDG'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Joubert Syndrome: Joubert Syndrome is a rare genetic disorder that affects the brain and spinal cord. Symptoms include ataxia, hypotonia, and abnormal facial features. The patient has ataxia and generalized hypotonia in common with Joubert Syndrome, but does not have intellectual disability, cerebellar atrophy, or death in infancy.

\n\n+2. Aicardi-Goutières Syndrome: Aicardi-Goutières Syndrome is a rare genetic disorder that affects the brain and spinal cord. Symptoms include ataxia, intellectual disability, and abnormal facial features. The patient has ataxia and abnormal facial shape in common with Aicardi-Goutières Syndrome, but does not have generalized hypotonia, cerebellar atrophy, or death in infancy.

\n\n+3. Mowat-Wilson Syndrome: Mowat-Wilson Syndrome is a rare genetic disorder that affects the brain and spinal cord. Symptoms include intellectual disability, ataxia, and abnormal facial features. The patient has intellectual disability and abnormal facial shape in common with Mowat-Wilson Syndrome, but does not have ataxia, cerebellar atrophy, or death in infancy.

\n\n+4. Cerebellar Hypoplasia: Cerebellar Hypoplasia is a rare condition where the cerebellum is underdeveloped. Symptoms include ataxia, hypotonia, and abnormal facial features. The patient has ataxia and generalized hypotonia in common with Cerebellar Hypoplasia, but does not have intellectual disability, cerebellar atrophy, or death in infancy.

\n\n+5. Congenital Muscular Dystrophy: Congenital Muscular Dystrophy is a group of rare genetic disorders that affect muscle development. Symptoms include generalized hypotonia, intellectual disability, and abnormal facial features. The patient has generalized hypotonia and abnormal facial shape in common with Congenital Muscular Dystrophy, but does not have ataxia, cerebellar atrophy, or death in infancy.

\n\n+6. Cerebro-Oculo-Facial Syndrome: Cerebro-Oculo-Facial Syndrome is a rare genetic disorder that affects the brain, eyes, and face. Symptoms include intellectual disability, ataxia, and abnormal facial features. The patient has intellectual disability and abnormal facial shape in common with Cerebro-Oculo-Facial Syndrome, but does not have generalized hypotonia, cerebellar atrophy, or death in infancy.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and further testing."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hyperphenylalaninemia', 'Death in adolescence'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia', 'Death in infancy'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Neonatal death', 'Death in adolescence'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in adolescence'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in adolescence'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in adolescence', 'Hyperphenylalaninemia', 'Hypertyrosinemia'.

Please note that this is not an exhaustive list, and a definitive diagnosis would require further testing and evaluation."
['Glutaryl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has in common: Macrocephaly, Abnormal cerebral morphology, Increased circulating lactate concentration, and Abnormal circulating carnitine concentration. The patient does not have in common: Generalized hypotonia, Death in infancy, Hypercalcemia, Glutaric aciduria, Abnormal circulating lysine concentration.

\n\n+2. Glutaric acidemia type I: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has in common: Macrocephaly, Abnormal cerebral morphology, Increased circulating lactate concentration, and Glutaric aciduria. The patient does not have in common: Generalized hypotonia, Death in infancy, Hypercalcemia, Abnormal circulating lysine concentration, Abnormal circulating carnitine concentration.

\n\n+3. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. The patient has in common: Macrocephaly, Abnormal cerebral morphology, Increased circulating lactate concentration, and Abnormal circulating carnitine concentration. The patient does not have in common: Generalized hypotonia, Death in infancy, Hypercalcemia, Glutaric aciduria, Abnormal circulating lysine concentration.

\n\n+4. Lysinuric protein intolerance: This is a rare genetic disorder that affects the body's ability to absorb certain amino acids. The patient has in common: Macrocephaly, Abnormal cerebral morphology, and Abnormal circulating lysine concentration. The patient does not have in common: Generalized hypotonia, Death in infancy, Hypercalcemia, Glutaric aciduria, Increased circulating lactate concentration, Abnormal circulating carnitine concentration.

\n\n+5. Mitochondrial disorder: This is a group of rare genetic disorders that affect the body's ability to produce energy. The patient has in common: Macrocephaly, Abnormal cerebral morphology, Increased circulating lactate concentration, and Abnormal circulating carnitine concentration. The patient does not have in common: Generalized hypotonia, Death in infancy, Hypercalcemia, Glutaric aciduria, Abnormal circulating lysine concentration.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Prader-Willi Syndrome: Prader-Willi syndrome is a rare genetic disorder that affects growth and development. Common symptoms include small stature, feeding difficulties, and hypotonia. The patient has in common: Small for gestational age, Feeding difficulties. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Pericardial effusion, Pleural effusion, Hypertyrosinemia, Severe short stature, Neonatal death, Death in childhood, Hyperphenylalaninemia.

\n\n+2. Smith-Magenis Syndrome: Smith-Magenis syndrome is a rare genetic disorder that affects growth and development. Common symptoms include short stature, feeding difficulties, and behavioral problems. The patient has in common: Small for gestational age, Feeding difficulties. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Pericardial effusion, Pleural effusion, Hypertyrosinemia, Severe short stature, Neonatal death, Death in childhood, Hyperphenylalaninemia.

\n\n+3. Williams Syndrome: Williams syndrome is a rare genetic disorder that affects growth and development. Common symptoms include short stature, hypercalcemia, and a distinctive facial appearance. The patient has in common: Small for gestational age. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Pericardial effusion, Pleural effusion, Hypertyrosinemia, Severe short stature, Neonatal death, Death in childhood, Hyperphenylalaninemia, Feeding difficulties.

\n\n+4. Aicardi-Goutières Syndrome: Aicardi-Goutières syndrome is a rare genetic disorder that affects the brain and spinal cord. Common symptoms include microcephaly, developmental delay, and seizures. The patient has in common: Microcephaly. The patient does not have in common: Abnormality of prenatal development or birth, Small for gestational age, Pericardial effusion, Pleural effusion, Hypertyrosinemia, Severe short stature, Neonatal death, Death in childhood, Hyperphenylalaninemia, Feeding difficulties.

\n\n+5. Mucopolysaccharidosis: Mucopolysaccharidosis is a group of rare genetic disorders that affect the body's ability to break down and recycle sugars. Common symptoms include short stature, joint pain, and intellectual disability. The patient has in common: Small for gestational age. The patient does not have in common: Microcephaly, Abnormality of prenatal development or birth, Pericardial effusion, Pleural effusion, Hypertyrosinemia, Severe short stature, Neonatal death, Death in childhood, Hyperphenylalaninemia, Feeding difficulties.

Please note that this is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Ornithine Transcarbamylase (OTC) Deficiency:
The patient has Hyperammonemia, Hyperglutaminemia, and Vomiting in common with this disease. OTC deficiency is a rare genetic disorder that affects the breakdown of amino acids, leading to elevated levels of ammonia in the blood. The patient does not have Oroticaciduria or Death in childhood in common with this disease.

\n\n+2. Citrullinemia:
The patient has Hyperammonemia, Hyperglutaminemia, and Vomiting in common with this disease. Citrullinemia is a rare genetic disorder that affects the breakdown of amino acids, leading to elevated levels of ammonia in the blood. The patient does not have Oroticaciduria or Death in childhood in common with this disease.

\n\n+3. Argininosuccinic Aciduria (ASA):
The patient has Hyperammonemia, Hyperglutaminemia, and Vomiting in common with this disease. ASA is a rare genetic disorder that affects the breakdown of amino acids, leading to elevated levels of ammonia in the blood. The patient does not have Oroticaciduria or Death in childhood in common with this disease.

\n\n+4. Urea Cycle Disorders (UCDs):
The patient has Hyperammonemia, Hyperglutaminemia, and Vomiting in common with this disease. UCDs are a group of rare genetic disorders that affect the breakdown of amino acids, leading to elevated levels of ammonia in the blood. The patient does not have Oroticaciduria or Death in childhood in common with this disease.

\n\n+5. Molybdenum Cofactor Deficiency Type A:
The patient has Hyperammonemia, Hyperglutaminemia, and Vomiting in common with this disease. Molybdenum Cofactor Deficiency Type A is a rare genetic disorder that affects the breakdown of amino acids, leading to elevated levels of ammonia in the blood. The patient does not have Oroticaciduria or Death in childhood in common with this disease.

\n\n+6. X-Linked Argininosuccinic Aciduria (X-ASA):
The patient has Hyperammonemia, Hyperglutaminemia, and Vomiting in common with this disease. X-ASA is a rare genetic disorder that affects the breakdown of amino acids, leading to elevated levels of ammonia in the blood. The patient does not have Oroticaciduria or Death in childhood in common with this disease.

Note: The patient's symptoms are consistent with a urea cycle disorder, but further testing and evaluation are needed to determine the specific diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Abnormal circulating tyrosine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, Hyperphenylalaninemia, Death in early adulthood.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Abnormal circulating tyrosine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, Hyperphenylalaninemia, Death in early adulthood.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Abnormal circulating tyrosine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, Hyperphenylalaninemia, Death in early adulthood.

\n\n+4. Homocystinuria: Homocystinuria is a rare genetic disorder that affects the breakdown of the amino acid homocysteine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Abnormal circulating tyrosine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, Hyperphenylalaninemia, Death in early adulthood.

\n\n+5. Methylmalonic acidemia: Methylmalonic acidemia is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Abnormal circulating tyrosine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Abnormality of prenatal development or birth, Obesity, Death in infancy, Neonatal death, Hyperphenylalaninemia, Death in early adulthood.

Please note that these are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Pearson syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include vomiting, lethargy, and developmental delays. The patient has symptoms in common with this disease, such as vomiting, lethargy, and increased circulating lactate concentration. However, the patient does not have symptoms such as developmental delays.

\n\n+2. 3-Methylglutaric Aciduria: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and intellectual disability. The patient has symptoms in common with this disease, such as 3-Methylglutaric aciduria and increased serum pyruvate. However, the patient does not have symptoms such as seizures and intellectual disability.

\n\n+3. Congenital Heart Disease: This is a condition where the heart does not develop properly before birth. Symptoms include congestive heart failure, short stature, and recurrent viral infections. The patient has symptoms in common with this disease, such as congestive heart failure and short stature. However, the patient does not have symptoms such as recurrent viral infections.

\n\n+4. Fanconi Syndrome: This is a rare genetic disorder that affects the kidneys and causes them to excrete too much protein and sugar in the urine. Symptoms include vomiting, lethargy, and developmental delays. The patient has symptoms in common with this disease, such as vomiting, lethargy, and Fanconi syndrome. However, the patient does not have symptoms such as developmental delays.

\n\n+5. Mitochondrial Disease: This is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include muscle weakness, seizures, and developmental delays. The patient has symptoms in common with this disease, such as muscle weakness and developmental delays. However, the patient does not have symptoms such as seizures.

\n\n+6. Pyruvate Dehydrogenase Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. Symptoms include developmental delays, seizures, and intellectual disability. The patient has symptoms in common with this disease, such as increased serum pyruvate. However, the patient does not have symptoms such as seizures and intellectual disability.

\n\n+7. Carnitine Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain fats. Symptoms include muscle weakness, fatigue, and developmental delays. The patient has symptoms in common with this disease, such as decreased plasma free carnitine. However, the patient does not have symptoms such as muscle weakness and fatigue.

\n\n+8. Glycogen Storage Disease: This is a group of rare genetic disorders that affect the body's ability to break down and store glycogen, a type of sugar. Symptoms include vomiting, lethargy, and developmental delays. The patient has symptoms in common with this disease, such as vomiting and lethargy. However, the patient does not have symptoms such as developmental delays.

Note: This is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
['Smith-Lemli-Opitz syndrome'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Smith-Lemli-Opitz Syndrome: This is a rare genetic disorder caused by a defect in the DHCR7 gene, which is responsible for the production of cholesterol. Symptoms include broad philtrum, anteverted nares, and syndactyly, which the patient has in common. The patient also has generalized hypotonia, which is a common symptom of this disorder. However, the patient does not have in common the symptoms of death in infancy, neonatal death, and feeding difficulties, which are not typical of this disorder.

\n\n+2. Congenital Cholestatic Liver Disease: This is a group of rare genetic disorders that affect the liver's ability to process bile. Symptoms include generalized hypotonia, which the patient has in common. The patient also has hypocholesterolemia, which is a common symptom of this disorder. However, the patient does not have in common the symptoms of broad philtrum, anteverted nares, and syndactyly, which are not typical of this disorder.

\n\n+3. RSH Syndrome: This is a rare genetic disorder caused by a defect in the DHCR7 gene, which is responsible for the production of cholesterol. Symptoms include broad philtrum, anteverted nares, and syndactyly, which the patient has in common. The patient also has generalized hypotonia, which is a common symptom of this disorder. However, the patient does not have in common the symptoms of death in infancy, neonatal death, and feeding difficulties, which are not typical of this disorder.

\n\n+4. Smith-Magenis Syndrome: This is a rare genetic disorder caused by a defect in the RAI1 gene, which is responsible for the production of a protein involved in the development of the brain and other organs. Symptoms include broad philtrum, anteverted nares, and syndactyly, which the patient has in common. The patient also has generalized hypotonia, which is a common symptom of this disorder. However, the patient does not have in common the symptoms of death in infancy, neonatal death, and feeding difficulties, which are not typical of this disorder.

\n\n+5. 7-Dehydrocholesterol Reductase Deficiency: This is a rare genetic disorder caused by a defect in the DHCR24 gene, which is responsible for the production of cholesterol. Symptoms include elevated 8-dehydrocholesterol, which the patient has in common. The patient also has hypocholesterolemia, which is a common symptom of this disorder. However, the patient does not have in common the symptoms of broad philtrum, anteverted nares, and syndactyly, which are not typical of this disorder.

Note: The patient's symptoms are quite specific and may indicate a rare genetic disorder. Further testing and evaluation would be necessary to confirm a diagnosis."
['Acute intermittent porphyria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Rotavirus Gastroenteritis:
The patient has vomiting and abdominal pain, which are common symptoms of rotavirus gastroenteritis. However, the patient does not have fever, which is a typical symptom of this disease. Death in childhood is not a typical symptom of rotavirus gastroenteritis, and recurrent viral infections are not a defining feature of this disease.

\n\n+2. Cystic Fibrosis:
The patient does not have any symptoms that are typically associated with cystic fibrosis, such as respiratory symptoms, malnutrition, or failure to thrive. The patient's symptoms are more consistent with a gastrointestinal disorder.

\n\n+3. Inflammatory Bowel Disease (IBD):
The patient has abdominal pain and vomiting, which are common symptoms of IBD. However, the patient does not have diarrhea, which is a typical symptom of IBD. Death in childhood is not a typical symptom of IBD, and recurrent viral infections are not a defining feature of this disease.

\n\n+4. Congenital Abnormalities:
The patient's symptoms, particularly death in childhood, suggest that there may be a congenital abnormality present. However, without further information, it is difficult to determine which specific congenital abnormality may be present.

\n\n+5. Mitochondrial Disorders:
The patient's symptoms, particularly recurrent viral infections and death in childhood, suggest that there may be a mitochondrial disorder present. However, without further information, it is difficult to determine which specific mitochondrial disorder may be present.

\n\n+6. Primary Immunodeficiency Disorders:
The patient's symptoms, particularly recurrent viral infections, suggest that there may be a primary immunodeficiency disorder present. However, without further information, it is difficult to determine which specific primary immunodeficiency disorder may be present.

Note: These are just a few potential diseases that may be considered based on the symptoms provided. A more detailed medical history and physical examination would be necessary to make a definitive diagnosis."
['Citrullinemia type I'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Argininosuccinic Aciduria (ASA): ASA is a rare genetic disorder caused by a deficiency of the enzyme argininosuccinate lyase, which is necessary for the breakdown of the amino acid arginine. Symptoms include metabolic acidosis, hyperammonemia, and hyperglycinuria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, neonatal death, and abnormal circulating arginine concentration.

\n\n+2. Citrullinemia (Type I): Citrullinemia is a rare genetic disorder caused by a deficiency of the enzyme argininosuccinate synthase, which is necessary for the breakdown of the amino acid citrulline. Symptoms include metabolic acidosis, hyperammonemia, and elevated plasma citrulline, which the patient has in common. The patient does not have in common the symptoms of death in infancy, neonatal death, and abnormal circulating arginine concentration.

\n\n+3. Hyperargininemia: Hyperargininemia is a rare genetic disorder caused by a deficiency of the enzyme arginase, which is necessary for the breakdown of the amino acid arginine. Symptoms include hyperargininemia, metabolic acidosis, and hyperglycinuria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, neonatal death, and abnormal circulating arginine concentration.

\n\n+4. Ornithine Transcarbamylase (OTC) Deficiency: OTC deficiency is a rare genetic disorder caused by a deficiency of the enzyme ornithine transcarbamylase, which is necessary for the breakdown of the amino acid ornithine. Symptoms include metabolic acidosis, hyperammonemia, and hyperglycinuria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, neonatal death, and abnormal circulating arginine concentration.

\n\n+5. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder caused by a deficiency of the enzyme branched-chain alpha-keto acid dehydrogenase complex, which is necessary for the breakdown of the amino acids leucine, isoleucine, and valine. Symptoms include metabolic acidosis, hyperammonemia, and hyperglycinuria, which the patient has in common. The patient does not have in common the symptoms of death in infancy, neonatal death, and abnormal circulating arginine concentration.

Note: The patient's symptoms are more consistent with a urea cycle disorder, such as Argininosuccinic Aciduria (ASA), Citrullinemia (Type I), or Hyperargininemia. Further testing and evaluation would be necessary to confirm the diagnosis."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include delayed speech and language development, lethargy, generalized hypotonia, and hyperammonemia. The patient has in common: delayed speech and language development, lethargy, generalized hypotonia, and hyperammonemia. The patient does not have in common: death in infancy, dehydration, hyperhomocystinemia, drowsiness, sleep abnormality, decreased plasma free carnitine, and methylmalonic aciduria.

\n\n+2. Methylmalonic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include delayed speech and language development, lethargy, generalized hypotonia, and hyperammonemia. The patient has in common: delayed speech and language development, lethargy, generalized hypotonia, and hyperammonemia. The patient does not have in common: death in infancy, dehydration, hyperhomocystinemia, drowsiness, sleep abnormality, decreased plasma free carnitine, and methylmalonic acidemia.

\n\n+3. Hyperhomocystinemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include delayed speech and language development, lethargy, generalized hypotonia, and hyperhomocystinemia. The patient has in common: delayed speech and language development, lethargy, generalized hypotonia, and hyperhomocystinemia. The patient does not have in common: death in infancy, dehydration, hyperammonemia, drowsiness, sleep abnormality, decreased plasma free carnitine, and methylmalonic acidemia.

\n\n+4. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include delayed speech and language development, lethargy, generalized hypotonia, and decreased plasma free carnitine. The patient has in common: delayed speech and language development, lethargy, generalized hypotonia, and decreased plasma free carnitine. The patient does not have in common: death in infancy, dehydration, hyperammonemia, hyperhomocystinemia, drowsiness, sleep abnormality, and methylmalonic acidemia.

\n\n+5. Organic acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include delayed speech and language development, lethargy, generalized hypotonia, and hyperammonemia. The patient has in common: delayed speech and language development, lethargy, generalized hypotonia, and hyperammonemia. The patient does not have in common: death in infancy, dehydration, hyperhomocystinemia, drowsiness, sleep abnormality, decreased plasma free carnitine, and methylmalonic acidemia.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and testing."
['Very long chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Disorder: This is a group of rare genetic disorders that affect the body's ability to use fat for energy. The patient has symptoms of decreased plasma free carnitine, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, and abnormal circulating creatine kinase concentration in common with this disease. However, the patient does not have symptoms of hyperactivity, generalized hypotonia, or death in infancy.

\n\n+2. Hyperammonemia: This is a condition characterized by high levels of ammonia in the blood, which can cause brain damage and death. The patient has symptoms of hyperammonemia in common with this disease. However, the patient does not have symptoms of premature birth, neonatal death, death in childhood, or decreased plasma free carnitine.

\n\n+3. Mitochondrial Disease: This is a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. The patient has symptoms of hyperammonemia, decreased plasma free carnitine, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, and abnormal circulating creatine kinase concentration in common with this disease. However, the patient does not have symptoms of hyperactivity, generalized hypotonia, or death in infancy.

\n\n+4. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. The patient has symptoms of hyperammonemia, decreased plasma free carnitine, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, and abnormal circulating creatine kinase concentration in common with this disease. However, the patient does not have symptoms of hyperactivity, generalized hypotonia, or death in infancy.

\n\n+5. Urea Cycle Disorder: This is a group of rare genetic disorders that affect the body's ability to break down protein and produce urea. The patient has symptoms of hyperammonemia, decreased plasma free carnitine, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, and abnormal circulating creatine kinase concentration in common with this disease. However, the patient does not have symptoms of hyperactivity, generalized hypotonia, or death in infancy.

Please note that these are just potential diseases based on the symptoms provided, and a definitive diagnosis would require further testing and evaluation."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Diaphragmatic Hernia: This is a birth defect where the diaphragm does not form properly, allowing organs to move into the chest cavity. The patient has symptoms of 'Abnormality of prenatal development or birth', 'Upper airway obstruction', and 'Neonatal death' in common with this disease. The patient does not have symptoms of 'Death in infancy', 'Hypertyrosinemia', 'Hyperphenylalaninemia', or 'Chronic pulmonary obstruction' in common with this disease.

\n\n+2. Tracheoesophageal Fistula: This is a congenital anomaly where the trachea and esophagus are abnormally connected, leading to respiratory and digestive problems. The patient has symptoms of 'Abnormality of prenatal development or birth', 'Upper airway obstruction', and 'Neonatal death' in common with this disease. The patient does not have symptoms of 'Death in infancy', 'Hypertyrosinemia', 'Hyperphenylalaninemia', or 'Chronic pulmonary obstruction' in common with this disease.

\n\n+3. Cystic Fibrosis: This is a genetic disorder that affects the respiratory, digestive, and reproductive systems. The patient does not have symptoms in common with this disease.

\n\n+4. Pulmonary Atresia: This is a congenital heart defect where the pulmonary valve does not form properly, leading to respiratory problems. The patient does not have symptoms in common with this disease.

\n\n+5. Hypertrophic Pyloric Stenosis: This is a condition where the muscle in the stomach becomes thickened, causing difficulty feeding and vomiting. The patient does not have symptoms in common with this disease.

\n\n+6. Phenylketonuria (PKU): This is a genetic disorder that affects the breakdown of the amino acid phenylalanine, leading to intellectual disability and other symptoms. The patient has symptoms of 'Hyperphenylalaninemia' in common with this disease. The patient does not have symptoms of 'Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hypertyrosinemia', or 'Chronic pulmonary obstruction' in common with this disease.

\n\n+7. Tyrosinemia: This is a genetic disorder that affects the breakdown of the amino acid tyrosine, leading to liver and kidney damage. The patient has symptoms of 'Hypertyrosinemia' in common with this disease. The patient does not have symptoms of 'Abnormality of prenatal development or birth', 'Death in infancy', 'Upper airway obstruction', 'Hyperphenylalaninemia', or 'Chronic pulmonary obstruction' in common with this disease.

Note: This is not an exhaustive list, and further evaluation and testing would be necessary to confirm a diagnosis."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Disorder: This is a group of rare genetic disorders caused by a deficiency of the enzyme carnitine palmitoyltransferase. Symptoms include decreased plasma free carnitine, decreased circulating ferritin concentration, and decreased 3-hydroxyacyl-CoA dehydrogenase level. The patient has in common: decreased plasma free carnitine, decreased circulating ferritin concentration, and decreased 3-hydroxyacyl-CoA dehydrogenase level. The patient does not have in common: Spasticity, Death in infancy, Premature birth, Ileus, Neonatal death, Death in childhood, Hypoxemia, Peritoneal effusion, Abnormal circulating vitamin B12 concentration.

\n\n+2. Mitochondrial Myopathy: This is a group of rare genetic disorders caused by mutations in the mitochondrial DNA. Symptoms include muscle weakness, fatigue, and decreased muscle tone. The patient does not have in common: Spasticity, Death in infancy, Premature birth, Ileus, Neonatal death, Death in childhood, Decreased plasma free carnitine, Decreased circulating ferritin concentration, Decreased 3-hydroxyacyl-CoA dehydrogenase level, Hypoxemia, Peritoneal effusion, Abnormal circulating vitamin B12 concentration.

\n\n+3. Congenital Myasthenic Syndrome: This is a group of rare genetic disorders caused by mutations in the genes that encode the acetylcholine receptor. Symptoms include muscle weakness, fatigue, and decreased muscle tone. The patient does not have in common: Spasticity, Death in infancy, Premature birth, Ileus, Neonatal death, Death in childhood, Decreased plasma free carnitine, Decreased circulating ferritin concentration, Decreased 3-hydroxyacyl-CoA dehydrogenase level, Hypoxemia, Peritoneal effusion, Abnormal circulating vitamin B12 concentration.

\n\n+4. Neonatal Sepsis: This is a serious infection that occurs in newborns, often caused by bacteria such as E. coli or Group B strep. Symptoms include fever, lethargy, and poor feeding. The patient does not have in common: Spasticity, Death in infancy, Premature birth, Ileus, Neonatal death, Death in childhood, Decreased plasma free carnitine, Decreased circulating ferritin concentration, Decreased 3-hydroxyacyl-CoA dehydrogenase level, Hypoxemia, Peritoneal effusion, Abnormal circulating vitamin B12 concentration.

\n\n+5. Congenital Diaphragmatic Hernia: This is a rare birth defect in which the diaphragm does not form properly, allowing organs to move into the chest cavity. Symptoms include respiratory distress, cyanosis, and abdominal distension. The patient does not have in common: Spasticity, Death in infancy, Premature birth, Ileus, Neonatal death, Death in childhood, Decreased plasma free carnitine, Decreased circulating ferritin concentration, Decreased 3-hydroxyacyl-CoA dehydrogenase level, Hypoxemia, Peritoneal effusion, Abnormal circulating vitamin B12 concentration.

These are just a few potential diseases that the patient may have based on the symptoms provided. A more thorough evaluation and testing would be necessary to determine the exact diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Death in childhood, Hyperphenylalaninemia. The patient does not have in common: Death in infancy, Recurrent viral infections.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and anemia. The patient has in common: Death in infancy, Hypertyrosinemia. The patient does not have in common: Death in childhood, Recurrent viral infections, Hyperphenylalaninemia.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: Death in infancy, Death in childhood. The patient does not have in common: Recurrent viral infections, Hyperphenylalaninemia.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient has in common: Death in childhood. The patient does not have in common: Death in infancy, Recurrent viral infections, Hyperphenylalaninemia.

\n\n+5. Leukodystrophy: Leukodystrophy is a group of genetic disorders that affect the breakdown of fatty substances in the brain. Symptoms include intellectual disability, seizures, and vision loss. The patient has in common: Death in childhood. The patient does not have in common: Death in infancy, Recurrent viral infections, Hyperphenylalaninemia.

Note: These are just a few potential diseases that may be related to the symptoms provided. A more comprehensive diagnosis would require further testing and evaluation."
['3-methylcrotonyl-CoA carboxylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, along with the symptoms the patient has in common and those they do not have in common:

\n\n+1. Nonketotic Hyperglycinemia: This is a rare genetic disorder caused by a deficiency of the enzyme glycine cleavage system. Symptoms include seizures, developmental delay, and abnormal muscle tone. The patient has in common: Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Aminoaciduria.

\n\n+2. Glycine Encephalopathy: This is a rare genetic disorder caused by a deficiency of the enzyme glycine cleavage system. Symptoms include seizures, developmental delay, and abnormal muscle tone. The patient has in common: Abnormal circulating glycine concentration, Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Aminoaciduria.

\n\n+3. Methylmalonic Acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme methylmalonyl-CoA mutase. Symptoms include developmental delay, seizures, and abnormal muscle tone. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Abnormal circulating glycine concentration, Aminoaciduria.

\n\n+4. Propionic Acidemia: This is a rare genetic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase. Symptoms include developmental delay, seizures, and abnormal muscle tone. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Death in infancy, Abnormal circulating glycine concentration, Aminoaciduria.

\n\n+5. Aminoaciduria: This is a rare genetic disorder caused by a deficiency of the enzyme responsible for the transport of certain amino acids. Symptoms include developmental delay, seizures, and abnormal muscle tone. The patient has in common: Aminoaciduria. The patient does not have in common: Death in infancy, Abnormal circulating glycine concentration, Elevated urinary carboxylic acid.

Note: The patient's symptoms of ""Death in infancy"" and ""Aminoaciduria"" are not common to any of the proposed diseases, and may indicate a more severe or complex condition. Further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms."
['Succinic semialdehyde dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Rett Syndrome: Rett Syndrome is a rare genetic disorder that affects brain development, leading to intellectual disability, seizures, and motor problems. The patient has in common: Seizure, Ataxia, Motor delay, Generalized hypotonia. The patient does not have in common: Delayed speech and language development (although some patients with Rett Syndrome may have delayed speech development, it is not a universal symptom).

\n\n+2. Angelman Syndrome: Angelman Syndrome is a neurogenetic disorder that causes intellectual disability, speech impairment, and seizures. The patient has in common: Seizure, Delayed speech and language development. The patient does not have in common: Ataxia, Motor delay, Generalized hypotonia.

\n\n+3. Prader-Willi Syndrome: Prader-Willi Syndrome is a genetic disorder that affects growth, development, and behavior. It is characterized by short stature, obesity, and intellectual disability. The patient does not have in common: Seizure, Ataxia, Motor delay, Generalized hypotonia.

\n\n+4. Mitochondrial Disorders: Mitochondrial disorders are a group of genetic disorders that affect the mitochondria, the energy-producing structures within cells. They can cause a range of symptoms, including seizures, muscle weakness, and developmental delays. The patient has in common: Seizure, Motor delay, Generalized hypotonia. The patient does not have in common: Ataxia, Delayed speech and language development.

\n\n+5. Leukodystrophies: Leukodystrophies are a group of genetic disorders that affect the white matter of the brain, leading to progressive damage and disability. They can cause a range of symptoms, including seizures, muscle weakness, and developmental delays. The patient has in common: Seizure, Motor delay, Generalized hypotonia. The patient does not have in common: Ataxia, Delayed speech and language development.

\n\n+6. Methylmalonic Acidemia: Methylmalonic Acidemia is a rare genetic disorder that affects the metabolism of amino acids, leading to the accumulation of toxic compounds in the body. The patient has in common: Elevated urinary carboxylic acid. The patient does not have in common: Seizure, Ataxia, Motor delay, Generalized hypotonia.

Note: The patient's symptoms are quite severe, and it is possible that they may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['Argininosuccinic aciduria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Hypertrophic Pyloric Stenosis: This is a condition where the muscle at the bottom of the esophagus is too thick, causing difficulty in feeding and vomiting. The patient has in common: Vomiting, Tachypnea. The patient does not have in common: Death in infancy, Tachycardia, Metabolic acidosis, Hepatomegaly, Neonatal death.

\n\n+2. Neonatal Sepsis: This is a life-threatening condition caused by bacterial infection in newborns. The patient has in common: Tachycardia, Metabolic acidosis, Vomiting, Tachypnea. The patient does not have in common: Death in infancy, Hepatomegaly, Neonatal death.

\n\n+3. Congenital Diaphragmatic Hernia: This is a birth defect where the diaphragm does not form properly, allowing organs to move into the chest cavity. The patient has in common: Tachypnea, Vomiting. The patient does not have in common: Death in infancy, Tachycardia, Metabolic acidosis, Hepatomegaly, Neonatal death.

\n\n+4. Neonatal Hypoglycemia: This is a condition where the newborn's blood sugar levels are too low, causing symptoms such as vomiting, lethargy, and seizures. The patient has in common: Vomiting, Tachypnea. The patient does not have in common: Death in infancy, Tachycardia, Metabolic acidosis, Hepatomegaly, Neonatal death.

\n\n+5. Neonatal Respiratory Distress Syndrome: This is a condition where the lungs are not fully developed, causing difficulty in breathing and oxygenation. The patient has in common: Tachypnea. The patient does not have in common: Death in infancy, Tachycardia, Metabolic acidosis, Vomiting, Hepatomegaly, Neonatal death.

\n\n+6. Inborn Errors of Metabolism: This is a group of genetic disorders that affect the body's ability to break down certain nutrients, leading to metabolic acidosis and other symptoms. The patient has in common: Metabolic acidosis. The patient does not have in common: Death in infancy, Tachycardia, Vomiting, Tachypnea, Hepatomegaly, Neonatal death.

Please note that this is not an exhaustive list, and a more detailed evaluation and testing would be necessary to confirm a diagnosis."
['Gyrate atrophy of choroid and retina'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include: blindness, anemia, hyperammonemia, malabsorption, hyperglycinemia, and death in childhood. The patient has in common: blindness, anemia, hyperammonemia, and hyperglycinemia. The patient does not have in common: malabsorption (patient has malabsorption, but it's not a primary symptom of MSUD).

\n\n+2. Hyperornithinemia-Hyperammonemia Syndrome (HHS): HHS is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include: hyperornithinemia, hyperammonemia, anemia, and death in childhood. The patient has in common: hyperammonemia and anemia. The patient does not have in common: blindness, malabsorption, hyperglycinemia, and severe short stature.

\n\n+3. Argininosuccinic Aciduria (ASA): ASA is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include: anemia, hyperammonemia, and death in childhood. The patient has in common: anemia and hyperammonemia. The patient does not have in common: blindness, malabsorption, hyperglycinemia, and severe short stature.

\n\n+4. Citrullinemia Type I (CTLN1): CTLN1 is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include: anemia, hyperammonemia, and death in childhood. The patient has in common: anemia and hyperammonemia. The patient does not have in common: blindness, malabsorption, hyperglycinemia, and severe short stature.

\n\n+5. Ornithine Transcarbamylase (OTC) Deficiency: OTC deficiency is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include: anemia, hyperammonemia, and death in childhood. The patient has in common: anemia and hyperammonemia. The patient does not have in common: blindness, malabsorption, hyperglycinemia, and severe short stature.

Note: The patient's symptoms are quite severe and suggest a genetic disorder affecting amino acid metabolism. Further testing and evaluation would be necessary to confirm a specific diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood'.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: 'Hypertyrosinemia'. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hyperphenylalaninemia'.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+4. Mucopolysaccharidosis (MPS): MPS is a group of genetic disorders that affect the breakdown of complex carbohydrates. Symptoms include intellectual disability, joint pain, and skin problems. The patient does not have in common: 'Abnormality of prenatal development or birth', 'Death in infancy', 'Neonatal death', 'Death in childhood', 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

\n\n+5. Congenital Hypothyroidism: Congenital hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. Symptoms include intellectual disability, short stature, and delayed development. The patient does not have in common: 'Hypertyrosinemia', 'Hyperphenylalaninemia'.

Note: The patient's symptoms are quite specific, and it's possible that the patient may have a rare or undiagnosed condition. Further testing and evaluation would be necessary to confirm a diagnosis."
['Carbamoyl-phosphate synthetase 1 deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has symptoms in common with this disease, such as hyperammonemia, cerebral edema, and neonatal death. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Methylmalonic Acidemia.

\n\n+2. Citrin Deficiency: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as hyperammonemia, cerebral edema, and neonatal death. However, the patient does not have symptoms such as liver dysfunction, jaundice, or failure to thrive, which are common in Citrin Deficiency.

\n\n+3. Organic Acidemia: This is a group of rare genetic disorders that affect the body's ability to break down certain organic compounds. The patient has symptoms in common with this disease, such as hyperammonemia, cerebral edema, and neonatal death. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in Organic Acidemia.

\n\n+4. Urea Cycle Disorders: This is a group of rare genetic disorders that affect the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as hyperammonemia, cerebral edema, and neonatal death. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Urea Cycle Disorders.

\n\n+5. Maple Syrup Urine Disease: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient does not have symptoms in common with this disease, such as sweet-smelling urine, developmental delays, or intellectual disability, which are common in Maple Syrup Urine Disease.

\n\n+6. Glutaric Acidemia Type I: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as hyperammonemia, cerebral edema, and neonatal death. However, the patient does not have symptoms such as seizures, developmental delays, or intellectual disability, which are common in Glutaric Acidemia Type I.

\n\n+7. Propionic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain amino acids. The patient has symptoms in common with this disease, such as hyperammonemia, cerebral edema, and neonatal death. However, the patient does not have symptoms such as vomiting, diarrhea, or abdominal pain, which are common in Propionic Acidemia.

Note: The above list is not exhaustive and is based on the symptoms provided. A definitive diagnosis can only be made after a thorough medical examination and laboratory tests."
['Canavan disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with each disease and which symptoms they do not have in common:

\n\n+1. Leber Congenital Amaurosis: This is a rare inherited disorder that causes blindness from birth. The patient has blindness in common with this disease, but does not have nystagmus, seizure, motor delay, generalized hypotonia, opisthotonus, neonatal death, abnormal circulating aspartate family amino acid concentration, abnormal myelination, or severe hearing impairment.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. The patient has abnormal circulating aspartate family amino acid concentration in common with this disease, but does not have blindness, nystagmus, seizure, motor delay, generalized hypotonia, opisthotonus, neonatal death, abnormal myelination, or severe hearing impairment.

\n\n+3. Pelizaeus-Merzbacher Disease: This is a rare genetic disorder that affects the development of the brain and spinal cord. The patient has abnormal myelination in common with this disease, but does not have blindness, nystagmus, seizure, motor delay, generalized hypotonia, opisthotonus, neonatal death, abnormal circulating aspartate family amino acid concentration, or severe hearing impairment.

\n\n+4. Congenital Muscular Dystrophy: This is a group of rare genetic disorders that affect the development and function of muscles. The patient has generalized hypotonia in common with this disease, but does not have blindness, nystagmus, seizure, motor delay, opisthotonus, neonatal death, abnormal circulating aspartate family amino acid concentration, abnormal myelination, or severe hearing impairment.

\n\n+5. Infantile Spasms: This is a rare seizure disorder that typically begins in infancy. The patient has seizure in common with this disease, but does not have blindness, nystagmus, motor delay, generalized hypotonia, opisthotonus, neonatal death, abnormal circulating aspartate family amino acid concentration, abnormal myelination, or severe hearing impairment.

\n\n+6. Rett Syndrome: This is a rare genetic disorder that affects the development of the brain and causes a range of symptoms including seizures, motor delay, and intellectual disability. The patient has seizure, motor delay, and generalized hypotonia in common with this disease, but does not have blindness, nystagmus, opisthotonus, neonatal death, abnormal circulating aspartate family amino acid concentration, abnormal myelination, or severe hearing impairment.

\n\n+7. Krabbe Disease: This is a rare genetic disorder that affects the development of the brain and spinal cord. The patient has abnormal myelination in common with this disease, but does not have blindness, nystagmus, seizure, motor delay, generalized hypotonia, opisthotonus, neonatal death, abnormal circulating aspartate family amino acid concentration, or severe hearing impairment.

\n\n+8. Meningitis: This is a serious infection that can cause inflammation of the membranes surrounding the brain and spinal cord. The patient does not have any symptoms in common with this disease.

\n\n+9. Encephalitis: This is a serious infection that can cause inflammation of the brain. The patient does not have any symptoms in common with this disease.

\n\n+10. Hypoxic-Ischemic Encephalopathy: This is a condition that occurs when the brain does not receive enough oxygen. The patient does not have any symptoms in common with this disease.

Note: This is not an exhaustive list and the patient may have a different diagnosis. A thorough medical examination and further testing would be necessary to determine the correct diagnosis."
"['Methylmalonic acidemia with homocystinuria, type cblC']","Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic aciduria: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include intellectual disability, developmental delays, and seizures. The patient has in common: Intellectual disability, Abnormal circulating carnitine concentration, Methylmalonic aciduria. The patient does not have in common: Hydrocephalus, Microcephaly, Strabismus, Nystagmus, Death in infancy, Premature birth, Respiratory insufficiency, Hyperhomocystinemia, Neonatal death, Death in childhood, Dyskinesia.

\n\n+2. Hyperhomocystinemia: This is a genetic disorder that affects the body's ability to break down the amino acid homocysteine. Symptoms include intellectual disability, developmental delays, and an increased risk of blood clots. The patient has in common: Hyperhomocystinemia. The patient does not have in common: Hydrocephalus, Microcephaly, Strabismus, Nystagmus, Intellectual disability, Death in infancy, Premature birth, Respiratory insufficiency, Methylmalonic aciduria, Abnormal circulating carnitine concentration, Neonatal death, Death in childhood, Dyskinesia.

\n\n+3. Carnitine deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms include intellectual disability, developmental delays, and muscle weakness. The patient has in common: Abnormal circulating carnitine concentration. The patient does not have in common: Hydrocephalus, Microcephaly, Strabismus, Nystagmus, Intellectual disability, Death in infancy, Premature birth, Respiratory insufficiency, Hyperhomocystinemia, Methylmalonic aciduria, Neonatal death, Death in childhood, Dyskinesia.

\n\n+4. Mitochondrial disorder: This is a group of genetic disorders that affect the mitochondria, the energy-producing structures within cells. Symptoms include intellectual disability, developmental delays, and muscle weakness. The patient has in common: Intellectual disability, Abnormal circulating carnitine concentration. The patient does not have in common: Hydrocephalus, Microcephaly, Strabismus, Nystagmus, Death in infancy, Premature birth, Respiratory insufficiency, Hyperhomocystinemia, Methylmalonic aciduria, Neonatal death, Death in childhood, Dyskinesia.

\n\n+5. Leukodystrophy: This is a group of genetic disorders that affect the white matter of the brain. Symptoms include intellectual disability, developmental delays, and muscle weakness. The patient has in common: Intellectual disability. The patient does not have in common: Hydrocephalus, Microcephaly, Strabismus, Nystagmus, Death in infancy, Premature birth, Respiratory insufficiency, Hyperhomocystinemia, Methylmalonic aciduria, Abnormal circulating carnitine concentration, Neonatal death, Death in childhood, Dyskinesia.

Please note that this is not an exhaustive list and a more detailed evaluation and testing would be necessary to confirm a diagnosis."
['Medium chain acyl-CoA dehydrogenase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Carnitine Deficiency Syndrome: This is a rare genetic disorder that affects the body's ability to use fat for energy. The patient has symptoms of abnormal circulating carnitine concentration and decreased 3-hydroxyacyl-CoA dehydrogenase level in common with this disease. However, the patient does not have symptoms of abnormality of prenatal development or birth, death in infancy, neonatal death, or gastrointestinal inflammation.

\n\n+2. Reye's Syndrome: This is a rare but potentially life-threatening condition that affects the brain and liver. The patient has symptoms of vomiting and gastrointestinal inflammation in common with this disease. However, the patient does not have symptoms of abnormal circulating carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, abnormality of prenatal development or birth, death in infancy, or neonatal death.

\n\n+3. Mitochondrial Myopathy: This is a group of disorders that affect the mitochondria, the energy-producing structures within cells. The patient has symptoms of abnormal circulating carnitine concentration and decreased 3-hydroxyacyl-CoA dehydrogenase level in common with this disease. However, the patient does not have symptoms of vomiting, gastrointestinal inflammation, abnormality of prenatal development or birth, death in infancy, or neonatal death.

\n\n+4. Inborn Errors of Metabolism: This is a broad term that refers to a group of genetic disorders that affect the body's ability to break down and use nutrients. The patient has symptoms of abnormal circulating carnitine concentration and decreased 3-hydroxyacyl-CoA dehydrogenase level in common with this disease. However, the patient does not have symptoms of vomiting, gastrointestinal inflammation, abnormality of prenatal development or birth, death in infancy, or neonatal death.

\n\n+5. Gastrointestinal Motility Disorder: This is a group of disorders that affect the movement of food through the digestive system. The patient has symptoms of vomiting and gastrointestinal inflammation in common with this disease. However, the patient does not have symptoms of abnormal circulating carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, abnormality of prenatal development or birth, death in infancy, or neonatal death.

It is important to note that these are just a few potential diseases that the patient may have, and a more thorough evaluation and testing would be necessary to make a definitive diagnosis."
['Biotinidase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Organic Acidemia: This is a group of genetic disorders that affect the breakdown of certain nutrients, leading to the accumulation of toxic compounds in the body. The patient has in common: Metabolic acidosis, Hyperammonemia. The patient does not have in common: Generalized hypotonia, Death in infancy, Leukopenia, Neonatal death.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder that affects the breakdown of certain nutrients, leading to the accumulation of toxic compounds in the body. The patient has in common: Metabolic acidosis, Hyperammonemia. The patient does not have in common: Generalized hypotonia, Death in infancy, Leukopenia, Neonatal death.

\n\n+3. Citrin Deficiency: This is a rare genetic disorder that affects the breakdown of certain nutrients, leading to the accumulation of toxic compounds in the body. The patient has in common: Metabolic acidosis, Hyperammonemia. The patient does not have in common: Generalized hypotonia, Death in infancy, Leukopenia, Neonatal death.

\n\n+4. Leukodystrophy: This is a group of genetic disorders that affect the breakdown of fatty substances in the brain and spinal cord, leading to damage and degeneration of these tissues. The patient does not have in common: Metabolic acidosis, Hyperammonemia, Generalized hypotonia, Death in infancy, Leukopenia, Neonatal death.

\n\n+5. Mitochondrial Disease: This is a group of genetic disorders that affect the function of the mitochondria, leading to a range of symptoms including muscle weakness, seizures, and developmental delays. The patient does not have in common: Metabolic acidosis, Hyperammonemia, Generalized hypotonia, Death in infancy, Leukopenia, Neonatal death.

\n\n+6. Congenital Disorders of Glycosylation: This is a group of genetic disorders that affect the breakdown of certain sugars in the body, leading to a range of symptoms including developmental delays, muscle weakness, and seizures. The patient does not have in common: Metabolic acidosis, Hyperammonemia, Generalized hypotonia, Death in infancy, Leukopenia, Neonatal death.

Please note that this is not an exhaustive list and further testing and evaluation would be necessary to confirm a diagnosis."
['Tyrosinemia type 2'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Albinism: Albinism is a group of genetic disorders that affect the production of melanin, leading to vision loss and sensitivity to light. The patient has photophobia in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

\n\n+2. Leber Congenital Amaurosis: This is a rare inherited disorder that causes severe visual impairment or blindness at birth. The patient has photophobia in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

\n\n+3. Chédiak-Higashi Syndrome: This is a rare genetic disorder that affects the production of lysosomes, leading to impaired immune function and increased risk of infections. The patient does not have any symptoms in common with this disease.

\n\n+4. Hyperkeratosis Lenticularis Oculi: This is a rare genetic disorder that causes thickening of the skin on the eyelids and surrounding areas, leading to vision loss and sensitivity to light. The patient has hyperkeratosis in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

\n\n+5. Mucopolysaccharidosis Type VII: This is a rare genetic disorder that affects the breakdown of mucopolysaccharides, leading to vision loss, intellectual disability, and other systemic symptoms. The patient has intellectual disability and hyperkeratosis in common with this disease, but does not have photophobia, seizure, or hypertyrosinemia.

\n\n+6. Oculocutaneous Albinism Type 1: This is a rare genetic disorder that affects the production of melanin, leading to vision loss, sensitivity to light, and skin and hair abnormalities. The patient has photophobia and hyperkeratosis in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

\n\n+7. Epidermolysis Bullosa Simplex: This is a rare genetic disorder that causes skin fragility and blistering, leading to increased risk of infections and scarring. The patient does not have any symptoms in common with this disease.

\n\n+8. Congenital Icthyosis: This is a rare genetic disorder that causes dry, scaly skin, leading to increased risk of infections and skin damage. The patient does not have any symptoms in common with this disease.

\n\n+9. Ichthyosis Vulgaris: This is a common skin condition that causes dry, scaly skin, leading to increased risk of infections and skin damage. The patient does not have any symptoms in common with this disease.

\n\n+10. Keratitis: This is a common eye condition that causes inflammation of the cornea, leading to vision loss and sensitivity to light. The patient has keratitis in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

\n\n+11. Conjunctivitis: This is a common eye condition that causes inflammation of the conjunctiva, leading to redness, discharge, and sensitivity to light. The patient has conjunctivitis in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

\n\n+12. Epiphora: This is a common eye condition that causes excessive tearing, leading to discomfort and vision loss. The patient has epiphora in common with this disease, but does not have intellectual disability, seizure, or hypertyrosinemia.

Note: The above list is not exhaustive, and further evaluation and testing may be necessary to confirm a diagnosis."
['Phenylketonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and behavioral problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in early adulthood.

\n\n+2. Tyrosinemia: Tyrosinemia is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in early adulthood.

\n\n+3. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of the amino acid branched-chain alpha-keto acids. Symptoms include intellectual disability, seizures, and a sweet, maple syrup-like odor in the urine. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in early adulthood.

\n\n+4. Alkaptonuria: Alkaptonuria is a rare genetic disorder that affects the breakdown of the amino acid homogentisic acid. Symptoms include dark urine, joint pain, and kidney stones. The patient does not have in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia, Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in early adulthood.

\n\n+5. Tyrosinemia type II: Tyrosinemia type II is a rare genetic disorder that affects the breakdown of the amino acid tyrosine. Symptoms include liver disease, kidney disease, and neurological problems. The patient has in common: Abnormal circulating tyrosine concentration, Hyperphenylalaninemia. The patient does not have in common: Abnormality of prenatal development or birth, Death in infancy, Neonatal death, Death in early adulthood.

Please note that this is not an exhaustive list, and further testing and evaluation would be necessary to confirm a diagnosis."
[],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include seizures, developmental delay, and a sweet, maple syrup-like odor in the urine. The patient has symptoms of seizure and hyperammonemia in common with MSUD, but does not have symptoms of cyanosis, death in infancy, or neonatal death.

\n\n+2. Methylmalonic Acidemia: This is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include seizures, developmental delay, and a buildup of toxic compounds in the blood. The patient has symptoms of seizure and hyperammonemia in common with Methylmalonic Acidemia, but does not have symptoms of cyanosis, death in infancy, or neonatal death.

\n\n+3. 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: This is a rare genetic disorder that affects the breakdown of certain fatty acids. Symptoms include seizures, developmental delay, and a buildup of toxic compounds in the blood. The patient has symptoms of seizure and 3-hydroxydicarboxylic aciduria in common with 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, but does not have symptoms of cyanosis, death in infancy, or neonatal death.

\n\n+4. Citrin Deficiency: This is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include seizures, developmental delay, and a buildup of toxic compounds in the blood. The patient has symptoms of seizure and hyperammonemia in common with Citrin Deficiency, but does not have symptoms of cyanosis, death in infancy, or neonatal death.

\n\n+5. Glutaric Acidemia Type I: This is a rare genetic disorder that affects the breakdown of certain amino acids. Symptoms include seizures, developmental delay, and a buildup of toxic compounds in the blood. The patient has symptoms of seizure and hyperammonemia in common with Glutaric Acidemia Type I, but does not have symptoms of cyanosis, death in infancy, or neonatal death.

Note: The patient's symptoms of cyanosis, death in infancy, and neonatal death are not typical of these diseases, and further evaluation and testing would be necessary to confirm a diagnosis."
['Alkaptonuria'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Congenital Bilary Atresia: This is a rare genetic disorder that affects the development of the bile ducts, leading to liver damage and jaundice. The patient has in common: 'Dark urine', does not have in common: 'Death in infancy', 'Vomiting'.

\n\n+2. Neonatal Sepsis: This is a serious infection that occurs in newborns, often caused by bacteria such as E. coli or Group B strep. The patient has in common: 'Vomiting', 'Death in infancy', does not have in common: 'Dark urine'.

\n\n+3. Biliary Atresia: This is a condition where the bile ducts are blocked or damaged, leading to liver damage and jaundice. The patient has in common: 'Dark urine', does not have in common: 'Death in infancy', 'Vomiting'.

\n\n+4. Inborn Errors of Metabolism: This is a group of genetic disorders that affect the body's ability to break down certain nutrients, leading to a buildup of toxic substances. The patient has in common: 'Death in infancy', 'Vomiting', does not have in common: 'Dark urine'.

\n\n+5. Neonatal Hyperbilirubinemia: This is a condition where the newborn's liver is unable to remove bilirubin from the blood, leading to jaundice. The patient has in common: 'Dark urine', does not have in common: 'Death in infancy', 'Vomiting'.

\n\n+6. Gastroesophageal Reflux Disease (GERD): This is a condition where stomach acid flows back up into the esophagus, causing symptoms such as vomiting and regurgitation. The patient has in common: 'Vomiting', does not have in common: 'Death in infancy', 'Dark urine'.

Please note that this is not an exhaustive list and a more detailed medical history and physical examination would be necessary to make a definitive diagnosis."
['Maple syrup urine disease'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Methylmalonic Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include growth delay, metabolic acidosis, and hyperammonemia, which the patient has in common. The patient also has seizures, lethargy, and drowsiness, which are not typical symptoms of this disease. The patient does not have severe hearing impairment or elevated urinary carboxylic acid, which are not common symptoms of Methylmalonic Acidemia.

\n\n+2. Propionic Acidemia: This is another rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include growth delay, metabolic acidosis, and hyperammonemia, which the patient has in common. The patient also has seizures, lethargy, and drowsiness, which are not typical symptoms of this disease. The patient does not have severe hearing impairment or elevated urinary carboxylic acid, which are not common symptoms of Propionic Acidemia.

\n\n+3. Isovaleric Acidemia: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include growth delay, metabolic acidosis, and hyperammonemia, which the patient has in common. The patient also has seizures, lethargy, and drowsiness, which are not typical symptoms of this disease. The patient does not have severe hearing impairment or elevated urinary carboxylic acid, which are not common symptoms of Isovaleric Acidemia.

\n\n+4. Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD): This is a rare genetic disorder that affects the body's ability to break down certain fats. Symptoms include growth delay, metabolic acidosis, and hyperammonemia, which the patient has in common. The patient also has seizures, lethargy, and drowsiness, which are not typical symptoms of this disease. The patient does not have severe hearing impairment or elevated urinary carboxylic acid, which are not common symptoms of MCADD.

\n\n+5. Glutaric Acidemia Type I: This is a rare genetic disorder that affects the body's ability to break down certain proteins and fats. Symptoms include growth delay, metabolic acidosis, and hyperammonemia, which the patient has in common. The patient also has seizures, lethargy, and drowsiness, which are not typical symptoms of this disease. The patient does not have severe hearing impairment or elevated urinary carboxylic acid, which are not common symptoms of Glutaric Acidemia Type I.

\n\n+6. Carnitine Deficiency: This is a rare genetic disorder that affects the body's ability to transport fatty acids into the mitochondria for energy production. Symptoms include growth delay, metabolic acidosis, and hyperammonemia, which the patient has in common. The patient also has seizures, lethargy, and drowsiness, which are not typical symptoms of this disease. The patient does not have severe hearing impairment or elevated urinary carboxylic acid, which are not common symptoms of Carnitine Deficiency.

Note: The patient's symptoms are consistent with a number of rare genetic disorders that affect the body's ability to break down certain proteins and fats. Further testing and evaluation would be necessary to determine the specific diagnosis."
['Ornithine transcarbamylase deficiency'],"Based on the symptoms provided, here are some potential diseases with a short description, indicating which symptoms the patient has in common with the proposed disease and which symptoms the patient does not have in common:

\n\n+1. Maple Syrup Urine Disease (MSUD): MSUD is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include hypoglycemia, vomiting, and seizures. The patient has symptoms in common with MSUD, such as hypoglycemia, vomiting, and hyperammonemia. However, the patient does not have symptoms such as seizures.

\n\n+2. Phenylketonuria (PKU): PKU is a genetic disorder that affects the breakdown of the amino acid phenylalanine. Symptoms include intellectual disability, seizures, and skin rash. The patient does not have symptoms such as intellectual disability or seizures. However, the patient has symptoms in common with PKU, such as skin rash and hyperammonemia.

\n\n+3. Citrullinemia: Citrullinemia is a rare genetic disorder that affects the breakdown of the amino acid citrulline. Symptoms include vomiting, lethargy, and seizures. The patient has symptoms in common with citrullinemia, such as vomiting and hyperammonemia. However, the patient does not have symptoms such as seizures.

\n\n+4. Argininosuccinic Aciduria (ASA): ASA is a rare genetic disorder that affects the breakdown of the amino acid arginine. Symptoms include vomiting, lethargy, and seizures. The patient has symptoms in common with ASA, such as vomiting and hyperammonemia. However, the patient does not have symptoms such as seizures.

\n\n+5. Orotic Aciduria: Orotic aciduria is a rare genetic disorder that affects the breakdown of the amino acid orotic acid. Symptoms include vomiting, diarrhea, and skin rash. The patient has symptoms in common with orotic aciduria, such as vomiting and skin rash. However, the patient does not have symptoms such as diarrhea.

\n\n+6. Aminoaciduria: Aminoaciduria is a rare genetic disorder that affects the breakdown of amino acids. Symptoms include vomiting, lethargy, and seizures. The patient has symptoms in common with aminoaciduria, such as vomiting and hyperammonemia. However, the patient does not have symptoms such as seizures.

\n\n+7. Hyperammonemia: Hyperammonemia is a condition characterized by elevated levels of ammonia in the blood. Symptoms include vomiting, lethargy, and seizures. The patient has symptoms in common with hyperammonemia, such as vomiting and hyperammonemia. However, the patient does not have symptoms such as seizures.

Note: The patient's symptoms are quite severe, and it is possible that they may have a combination of these diseases or other underlying conditions. Further testing and evaluation are necessary to determine the exact diagnosis."
